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ABSTRACT 
T cell antigen receptors (TCRs) on CD8
+
 T cells recognise endogenously processed 
peptides bound to major histocompatibility complex (pMHC) antigens presented on the 
cell surface on almost all types of cells in the body, including tumour cells.  The 
majority of tumour-associated peptide antigens (TAPAs) are derived from non-mutated 
self-proteins and are therefore subject to immunological tolerance, mainly through 
negative selection of high avidity T cells in the thymus.  In addition, there is low 
presentation of pMHC on the surface of cancer cells.  As a result, T cell responses tend 
to be weak and ineffective at killing tumour cells.  ImmTACs (Immune mobilising 
monoclonal T cell receptors Against Cancer) are bispecific soluble biologics 
comprising a soluble TCR with an enhanced affinity for tumour-associated pMHCI 
fused to a humanised anti-CD3 single-chain antibody fragment (scFv) which redirect 
and activate T cells to lyse tumour cells.  In this study, the potency, sensitivity, and 
specificity of ImmTACs was investigated for pMHCI epitopes derived from four 
tumour associated antigens (TAAs): (1) gp100, (2) MAGE-A3, (3) Melan-A/MART-1, 
and (4) NY-ESO-1/LAGE-1.  A comprehensive range of assays and methodologies 
have been established to characterise the ImmTAC reagents.  Cytokine release assays 
such as IFN-γ and Granzyme B ELISpot were used to evaluate the specificity and 
biological activity of ImmTACs.  In concentration-response experiments, all four 
ImmTACs produced EC50 values in the range of 100 picomolar or lower demonstrating 
a high degree of sensitivity despite low epitope numbers.  Killing assays, including 
LDH-release for assessing short-term lysis and IncuCyte technology to visualise long-
term killing kinetics in real time, show that redirected T cells potently kill their targets.  
Furthermore, in vitro screening against a panel of antigen negative, primary human cell 
lines have shown that ImmTACs are highly specific and only activate T cells against 
target cells presenting their cognate pMHC.  The potency of ImmTACs was also 
investigated using tumour infiltrating lymphocytes (TILs) extracted from tumour 
specimens and with tumour-derived cancer cells as targets.  An HLA-A2, gp100 
specific ImmTAC has received phase I clinical trial regulatory approval in the UK and 
in the US on the basis of this in vitro data, which has been used to determine minimal 
anticipated biological effect level (MABEL). The clinical trial is currently in progress. 
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CHAPTER 1 INTRODUCTION 
 
1.1 The immune system and cancer therapy: General introduction 
Cancer remains a largely intractable disease and is a leading cause of death worldwide 
(GLOBOCAN 2008 http://globocan.iarc.fr/).  Until recently, research into the nature of 
cancer has mainly focused on the cancer cell and on cancer as a genetic disease, as 
illustrated by the landmark review by Hanahan and Weinburg, published in 2000 
(Hanahan & Weinberg, 2000).  They proposed six characteristics (hallmarks) of cancer: 
the capacity to sustain proliferative signalling, to resist cell death, to induce 
angiogenesis, to enable replicative immortality, to activate invasion and metastasis, and 
to avoid growth suppressors.  However, a decade later it has become evident that cancer 
is not one disease, but many different diseases.  Thus, the focus of attention has shifted 
from the cancer cell to that of the host, and in particular, the microenvironment in which 
the cancer grows, a critical component of which is the immune system.  A new picture 
of cancer is now emerging and in 2011, four additional hallmarks were proposed.  Two 
of these hallmarks emphasise the newly recognised dual interaction between cancer and 
the immune system: firstly, the ability of cancer cells to avoid immune destruction, and 
secondly, tumour-associated inflammatory responses that promotes tumour growth 
rather than elimination (Hanahan & Weinberg, 2011). 
Standard therapies for cancer include small molecule drugs which are able to 
target exaggerated functions that allow cancer cells to grow in an uncontrolled manner, 
such as cell dividing components that are essential for cell cycle, or the evasive growth 
of cells.  Although these drugs have anti-cancer activity, in most cases they have limited 
efficacy and are associated with severe toxicity because such functions are also features 
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of normal cells, albeit for most types of cells to a lesser extent.  On the other hand, the 
immune system has the greatest potential for the specific eradication of tumours with no 
toxicity to normal tissue, as well as the development of immune memory that can 
prevent cancer recurrence.  The immune system can recognise and reject tumours 
through a process called immunosurveillance.  Tumour specificity of the immune 
response resides in the recognition of tumour antigens by cells of the adaptive immune 
system, principally, CD8
+
 cytotoxic T cells and CD4
+
 helper T cells.  However, most 
tumour antigens are ‘self-proteins’ to which the immune system has limited 
responsiveness, due to the development of tolerance by clonal deletion or anergy.  
Furthermore, in many cancers and particularly those forming solid tumours, malignant 
progression is accompanied by profound immune suppression that hinders an effective 
anti-tumour response and tumour destruction.   
The main premise of cancer immunotherapy is to stimulate or replenish the anti-
tumour elements of the patient’s immune system.  However, two important barriers 
must be overcome in order for a cancer immunotherapeutic to be effective: namely self-
tolerance and tumour subversion of the immune response.  The mainstay of 
immunotherapy has been the use of vaccines but they have had limited success, most 
likely because they are unable to effectively overcome the obstacles of tolerance and the 
immune-suppressive tumour microenvironment.  Anti-cancer monoclonal antibodies 
(mAbs), which target specific antigens expressed by cancer cells, are a well-established 
class of immunotherapeutic agent, apparently with higher therapeutic potential than 
vaccines.  Several Food and Drug Administration (FDA) approved mAbs are now 
standard treatment for some types of cancer, including trastuzumab for the treatment of 
breast cancer and rituximab for the treatment of B cell lymphoma.  Although transient 
remissions do occur in patients treated with these drugs, cure rates still remain low.  
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Some of the most exciting developments in cancer immunotherapy are those approaches 
that harness the most potent anti-tumour cells of the immune system i.e., CD8
+
 effector 
T cells, also known as cytotoxic T lymphocytes (CTLs).  Although CTLs have the 
potential to recognise and destroy malignant cells, there are a number of inhibitory 
pathways (immune check-points) hard-wired into the immune system that are crucial for 
the maintenance of self-tolerance in order to prevent autoimmunity.  Furthermore, 
tumours are able to adopt certain immune-checkpoint pathways as a major mechanism 
of immune resistance, particularly against T cells that are specific for tumour antigens.  
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a key immune check-point 
that attenuates T cell activation.  Ipilimumab is a monoclonal antibody to CTLA-4 and 
is the first agent to demonstrate a survival benefit in patients with advanced melanoma; 
Ipilimumab was approved by the FDA in March 2011 (Hodi et al., 2010).  By blocking 
CTLA-4, Ipilimumab dampens the inhibitory signals that curtail the full power of CTLs 
to destroy cancer cells.  Blockers of other immune-checkpoint proteins, such as 
programmed cell death protein-1 (PD-1) are also showing promising anti-tumour effects 
in early clinical trials. 
Another very effective approach for harnessing the anti-tumour potential of T 
cells is bispecific antibodies.  Bispecifics are a novel class of antibodies being 
developed to recruit pre-existing polyclonal T cell clones for the destruction of tumour 
cells.  Bispecific antibodies are equipped with two non-identical binding arms; one arm 
engages CD3, a potent signalling protein on the surface of T cells, whilst the other arm 
binds to an antigen on the tumour cell surface.  In B cell lymphoma and leukaemia, the 
bispecific T cell engager (BiTE) antibodies, developed by MicroMet, have 
demonstrated impressive clinical results (Nagorsen & Baeuerle, 2011).   
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Bispecifics as a way of re-directing T cell activity could make a significant 
contribution in the future to the immunotherapy of cancer.  However, the main 
disadvantage of antibody-based therapies is that they are limited in scope to membrane 
protein targets and therefore mainly restricted to tissue-specific or lineage-expressed 
antigens.  T cell receptors (TCRs) on the other hand specifically recognise 
endogenously processed peptides bound to major histocompatibility complex (pMHC) 
antigens presented on the cell surface.  These peptides are derived from proteins in all 
cellular compartments (Figure 1-1).  Thus, this class of antigen provides the most 
comprehensive range of therapeutic targets, particularly in cancer, as tumour-associated 
peptide antigens (TAPAs) often provide one of the few distinguishing features on the 
surface of malignantly transformed cells.  A major limitation to TCR-based therapeutic 
approaches is that TCRs have a natural affinity to pMHC that are several orders of 
magnitude weaker than mAb binding to protein antigens.  However, recent advances 
have enabled the engineering and production of soluble monoclonal TCRs (mTCRs) 
that target defined pMHC class I antigens with vastly improved affinities.  Furthermore, 
the improvement in affinity does not appear to have compromised the specificity of the 
TCR (Liddy et al., 2012).  Nevertheless, a significant challenge facing high affinity 
mTCR-anti-CD3 bispecifics is whether they can work against low numbers of TAPAs 
per cell which are frequently down-regulated as a mechanism of immune evasion by 
tumours. 
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Figure 1-1 T cell receptors (TCRs) as potential targeting molecules. 
 
TCRs bind to antigenic peptides derived from all proteins within a living cell and 
presented on the cell surface in the context of the major histocompatibility complex 
(peptide-MHC).  In this respect, TCRs have an advantage over antibodies, as the latter 
are unable to target intracellular proteins. 
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1.2 Cancer 
1.2.1 Cancer and cancer cells 
Cancer is a term broadly used to describe a spectrum of diseases in which abnormal 
cells divide without control and are able to invade other tissues.  The development of 
genomic instability is the most defining feature of cancer cells and lies at the core of 
neoplastic formation (Knudson, 2001; Maser & DePinho, 2002; Murga & Fernandez-
Capetillo, 2007).  Genomic destabilisation occurs early on in the evolution of a tumour 
and is a result of either increased rates of DNA damage, which overwhelm the ability of 
normal repair mechanisms to restore genomic integrity, or defective repair mechanisms 
that are unable to repair normal rates of DNA damage (Anderson et al., 2001).  
Disruption of genomic integrity is manifested as DNA defects, for example, in mitotic 
checkpoints, impaired non-homologous end joining and imprecise replication 
(Hoeijmakers, 2001; Lengauer et al., 1998).  It is the cumulative effect of all these 
factors which gives rise to the phenotype of cancer cells.  Genomic destabilisation and 
the high rate of mutations generate genetic diversity in malignant cell populations which 
drives tumour progression as certain mutant genotypes confer a selective advantage on 
sub-clones of cells.  This enables their outgrowth in the local tissue environment and, 
eventually, some sub-types acquire the characteristics necessary for invasive growth and 
for the cancer cells to spread, through the process of metatasis, to other tissues via the 
blood and lymph system (Hanahan & Weinberg, 2000). Recent evidence indicates that 
many types of tumours contain a particular sub-population, referred to as cancer stem 
cells (also called tumour-initiating cells), which, in contrast to the bulk of tumour cells, 
have the capacity for re-growth and, crucially, formation of new growth from a single 
cell, i.e., metastasis (reviewed in (Baccelli & Trumpp, 2012)).  The heterogeneity of 
tumours, which not only consist of the original clone and sub-clones, possibly including 
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cancer stem cells, means that these populations can differ in sensitivity to 
chemotherapy, radiotherapy, and other treatments, making clinical management 
challenging (Croce, 2008). 
 
1.2.2 Types of cancer 
Cancer includes many types of malignant disease, generally named by the organ or cell 
type from which the malignancy originates, such as, hepatomas, cancers of liver cells or 
melanomas, cancers of pigment-producing melanocytes.  There are more than one 
hundred types of cancer which are grouped into broader categories. The five main 
categories of cancer are: (1) Carcinoma, which begins in the skin or in tissues that line 
or cover internal organs; (2) Sarcoma, which originates in bone, cartilage, fat, muscle, 
blood vessels, or other connective or supportive tissue; (3) Leukemia, which starts in 
blood-forming tissue such as the bone marrow and causes large numbers of abnormal 
blood cells to be produced and enter the blood; (4) Lymphoma and myeloma, which are 
cancers that begin in the cells of the immune system; (5) Central nervous system 
cancers, which originate in the tissues of the brain and spinal cord (for classification of 
cancers, see National Cancer Institute website: http://www.cancer.gov).   
 
The experiments of this thesis have been particularly focused on malignant melanoma 
and multiple myeloma. 
 
1.2.2.1 Melanoma 
Melanoma is a form of skin cancer that accounts for less than 5% of cases but causes 
the vast majority of skin cancer deaths which currently affects approximately 120,000 
new patients per year in the western world.  It is more common in women than men, and 
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it is particularly common in Caucasians, especially of north-west European extraction 
living in sunny climates.  In 2010, 12,818 people in the UK were diagnosed with 
melanoma, and in the same year, there were 2,203 deaths from the disease.  Incidence 
rates for melanoma have increased in the last thirty years and, unlike other common 
cancers, melanoma has a wide age distribution.  (GLOBOCAN 2008 
http://globocan.iarc.fr/, Cancer Research UK, http://info.cancerresearchuk.org/).  Early 
stage melanoma is treatable with surgical resection, but the prognosis of advanced, 
metastatic melanoma remains very poor.  Advanced melanoma is still associated with 
an extremely poor median survival, ranging from 2 to 8 months, with only 5% of 
patients surviving more than five years, and remains one of the most treatment-
refractory malignancies.  Many agents have been investigated for anti-tumour activity in 
melanoma but the current treatment options for patients with metastatic disease are 
limited and do not offer a cure in the vast majority of cases. The chemotherapeutic 
agent dacarbazine (a DNA alkylating agent; also known as Imidazole) represents the 
most common option as the standard first-line treatment for metastatic melanoma.   
The importance of the immune system in controlling melanoma has been 
recognised for decades; there have even been case reports of spontaneous tumour 
regression in patients with metastatic melanoma (Bulkley et al., 1975).  This has led to 
intensive studies of immune-based treatment strategies with biologic response 
modifiers, i.e. cytokines such as interleukin-2 (IL-2) and interferon-α (IFN-α).  
However, the outcome of these studies showed that the results with systemically 
administered immunotherapy are not better than those with chemotherapy and there are 
associated problems with toxicity.  Studies combining immunotherapy and 
chemotherapy have also shown limited response rates (Mouawad et al., 2010).  
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Recently, targeted treatment approaches are looking more promising.  In March 
2011 the FDA approved the use of ipilimumab (Yervoy), a fully human monoclonal 
antibody against CTLA-4, for the treatment of unresectable, or metastatic, melanoma.  
Ipilimumab is designed to block the inhibitory molecule CTLA-4, which is expressed 
on T cells, thereby enhancing T cell activation, leading to increased anti-tumour 
responses.  Significantly, ipilimumab is the first agent that has demonstrated to improve 
overall survival in patients with metastatic melanoma in randomised Phase III clinical 
trials (Graziani et al., 2012).  This suggests that targeted immunotherapies could be the 
way forward in modulating anti-tumour immune responses that have the potential to 
produce durable clinical outcomes.   
Other targeted drugs that have shown positive outcomes include small molecule 
kinase inhibitors.  The discovery that melanomas in approximately 50% of patients 
harbour activating mutations in the serine-threonine BRAF kinase has prompted an 
intense search for compounds to inhibit BRAF activity.  Sarafenib (Nexavar®), a broad-
spectrum kinase inhibitor, was the first clinical drug candidate but results were 
disappointing (Vultur et al., 2010).  Greater success has been seen with more selective 
inhibitors.  The treatment of metastatic melanoma harbouring BRAF
V600 
mutation with 
the drug vemurafenib (Zelboraf) resulted in complete or partial tumour regression in the 
majority of patients.  Vemurafenib has recently been approved as a monotherapy for the 
treatment of patients with BRAF
V600
 mutation positive unresectable or metastatic 
melanoma.  However, there is a concern with the use of vemurafenib, which will 
probably apply to all other BRAF inhibitors, and that is the development of resistance 
by responsive tumours.  The heterogeneous nature of tumours means that not all cells 
within the same tumour may get killed, therefore allowing drug-resistant sub-
populations to eventually overtake non-drug resistant populations; alternatively, it could 
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be that all tumour cells respond to the compound but not to the same extent, allowing 
some cells to survive while they ‘rewire’ for growth (Flaherty et al., 2010).  
Although ipilimumab and vemurafenib have revolutionised the treatment of 
malignant melanoma, they have only produced modest improvements in overall survival 
and, for the majority of patients, neither constitutes a cure for advanced disease.  Thus, 
there remains a clear unmet medical need for new treatment options for malignant 
melanoma. 
 
1.2.2.2 Multiple myeloma 
Multiple myeloma is a cancer of the blood and occurs when plasma cells, which are 
produced in the bone marrow, become cancerous and proliferate uncontrollably.  
Healthy plasma cells eventually become crowded out which interferes with the 
production of other blood cells as well as those involved in regenerating bone.  The 
malignant plasma cells continue to produce antibodies but these are abnormal, 
monoclonal immunoglobulins and offer no protection against infection (Graham-Rowe, 
2011).  The bone marrow immune microenvironment is also known to play an 
important role in the pathobiology of myeloma.  Complex interactions between 
myeloma tumour cells and cells of the bone marrow, such as stromal cells, osteoclasts, 
osteoblasts, myeloid and lymphoid cells, leads to immune evasion and disease 
progression (Noonan & Borrello, 2011).  
Multiple myeloma is the second most frequent malignancy of the blood (after 
non-Hodgkins lymphoma), comprising around 1% of all cancers and approximately 
10% of haematological malignancies (Rajkumar, 2012).  The incidence of multiple 
myeloma worldwide is 1 to 5 individuals per 100,000 per year, with a higher incidence 
in the Western world (Parkin et al., 2005).  The disease is diagnosed in more men than 
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women with a prevalence rate in African Americans twice as high as that found in 
Caucasians (Landgren & Weiss, 2009).  The median age at diagnosis is between 63 and 
70 years old and the mortality rate is approximately 4 individuals per 100,000 per year 
(Dimopoulos & Terpos, 2010).  In the majority of cases, multiple myeloma is incurable; 
the best treatments available up until the late 1990s have been chemotherapies, 
including melphalan (a DNA alkylating agent) and prednisone (a prodrug form of 
corticosteroid), which gave a life expectancy of three to four years.  More recently, the 
availability of stem cell transplants and the introduction of lenalidomide (an analogue of 
thalidomide with a complex mode of actions, including direct tumour toxicity, 
inhibition of the tumour microenvironment, and immuno-modulation) and bortezomib 
(a proteasome inhibitor) have doubled life expectancy to 7-8 years.  However, despite a 
positive response seen to these new drugs, studies show that once patients relapse, the 
cancer becomes resistant to the drugs and the long term prognosis of patients remains 
poor (Graham-Rowe, 2011). 
One of the most effective treatments for multiple myeloma is Allogeneic Stem 
Cell Transplantation (Allo-SCT).  Although Allo-SCT is a risky procedure with a high 
treatment-related mortality, it can induce prolonged periods of disease free survival, and 
in some incidences, cure patients (Bensinger et al., 1996; Corradini et al., 1999; Gahrton 
et al., 1991; Gahrton et al., 1995).  Furthermore, the success of Allo-SCT suggests that 
multiple myeloma tumour cells are susceptible to immune recognition (Blade et al., 
2010).  More recently, autologous stem cell transplants (ASCT) have become the 
preferred treatment for multiple myeloma because, although slightly less potent against 
the cancer, it is not associated with the same level of risk for the patient.  The 
efficaciousness of both types of transplantation provides a good rationale for developing 
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further immunotherapies, possibly with curative potential, for patients diagnosed with 
multiple myeloma.  
 
1.3 T cell antigens in cancer 
The genomic instability of cancer cells gives rise to numerous mutated and aberrant 
proteins and peptides that deviate from self and therefore can be targets of the immune 
system.  Clinical observations such as the increased rate of tumour formation in 
immune-compromised individuals (Buell et al., 2005) and the spontaneous, albeit rare, 
regressions of tumours (Baldo et al., 1992) indicate the presence of anti-tumour activity 
in the human immune system.  Of the different cellular immune effectors involved in 
anti-tumour immunity, cytotoxic CD8
+
 T lymphocytes (CTLs) play a key role due to 
their ability to specifically and effectively kill tumour cells via the recognition of 
tumour antigens presented on the cell surface of malignant cells.  In the early 1990s, 
ground-breaking studies by Boon and colleagues, and Rosenberg and colleagues, 
established that T cells found in the peripheral blood of melanoma patients recognised 
defined antigens expressed by the tumours (Rosenberg, 1997; Van Pel et al., 1995) .  
MAGE-1 was the first gene reported to encode a human tumour antigen recognised by 
T cells (van der Bruggen et al., 1991) which subsequently led to the identification of the 
first CD8
+
 T cell epitope (Traversari et al., 1992).  This discovery heralded the 
beginning of a new era of antigen-specific T cell immunotherapy.  Since then numerous 
TAAs have been identified utilising both molecular and cellular immunological 
approaches.   
The classical approach employed to identify T cell epitopes involves isolating 
tumour-reactive T cells from the peripheral blood or tumour tissue of cancer patients 
which are co-cultured with autologous tumour cells for autologous epitope sensitisation 
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and induction of proliferation.  Subsequently, the stimulated T cells are screened against 
autologous target cells transfected with genes from a tumour-derived cDNA library.  
Specific killing of cells transfected with a particular cDNA identifies the protein 
encoded by this cDNA as a candidate tumour antigen.  In order to determine the 
epitope-containing region, the antigen-specific T cells are co-incubated with target cells 
expressing only truncated antigen fragments.  Then, in order to define the minimal T 
cell epitope, overlapping synthetic peptides covering the antigen fragment of interest are 
loaded on to target cells.  This approach has rapidly evolved, mainly due to the 
availability of new technology, and has been integrated with novel strategies such as (1) 
reverse immunology, (also known as epitope deduction) which predicts epitopes on the 
basis of known HLA-binding motifs and is performed using dedicated software.  
Several algorithms are publicly available such as BioInformatics and Molecular 
Analysis Section (BIMAS) (http://www-bimas.cit.nih.gov/molbio/hla_bind/) and 
SYFPEITHI (http://www.syfpeithi.de/) (2) biochemical methods which elute and 
fractionate TAA peptides naturally expressed on tumour cells in the context of MHC 
molecules by chromatography and mass spectrometry, and (3) DNA microarray 
technology which allows comparison of gene expression profiles in tumour tissues and 
normal counterparts (representational difference analysis [RDA], differential display 
[DD], and serial analysis of gene expression [SAGE]) (Gires & Selinger, 2009; Schultze 
& Vonderheide, 2001).  A useful database of described T cell antigens is maintained by 
the Cancer Research Institute (http://www.cancerimmunity.org/peptide/) (Van der 
Bruggen et al., 2013). 
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1.3.1 Classification of human tumour-associated T cell antigens 
Human tumour-associated T cell antigens have been classified into four major groups 
on the basis of their expression pattern: (1) unique antigens, which are often restricted to 
a tumour of an individual patient, and shared antigens which are present in many 
individual tumours and categorised as (2) Tumour-specific antigens (also referred to as 
cancer testis antigens); (3) differentiation antigens, and (4) overexpressed antigens. 
 
1.3.1.1 Unique Tumour Antigens 
These are antigens that are strictly tumour-specific and are not expressed by normal 
tissue.  They are commonly the result of somatic point mutations occurring in many 
different proteins expressed by tumour cells.  However, their expression is often unique 
to the tumour of an individual patient or restricted to very few patients.  The fact that 
they are not shared by tumours from different patients means that they are not attractive 
targets for immunotherapy.  An example of unique antigens includes abnormal forms of 
the proto-oncogene, p53. 
 
1.3.1.2 Tumour-specific Antigens (also known as Cancer/Testis (CT) Antigens) 
These antigens comprise a family of genes that are present in a wide variety of 
malignant tumours, but their expression in normal tissues is mostly restricted to MHC-
negative testicular germ cells and placental trophoblasts.  Epigenetic events, particularly 
DNA methylation, appear to be the primary mechanism regulating CTA expression in 
both normal and transformed cells.  However, little is known about their specific 
functions.  CT genes fall into two subsets; those encoded on the X-chromosome (CT-
X), which are highly expressed in spermatogonia and non-X CT genes, which are 
encoded on other chromomsomes and tend to be expressed during later stages of 
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spermatogenesis.  Non-X CT genes typically have a less restricted pattern of expression 
whereas most of the CT-X antigens are not expressed in normal somatic tissues.  
Examples of CT-X antigens include, NY-ESO and MAGE.  An example of a non-X CT 
antigen is BAGE. 
 
1.3.1.3 Differentiation Antigens 
These antigens are expressed by malignant cells but also by their normal counter-parts 
at a particular differentiation stage.  Differentiation antigens were originally identified 
when T cells from melanoma patients were found to recognise antigens encoded by 
normal melanocytic differentiation genes, such as those encoded by tyrosinase, Melan-
A/MART-1 and gp100/pmel17.  Many of these melanocyte lineage-related proteins are 
involved in the production of melanin.  Apart from melanocytes and pigmented retinal 
cells, these melanocyte differentiation antigens (MDAs) are not expressed on any other 
normal tissue.  In addition to melanoma, T cell differentiation antigens are known to be 
expressed in other malignancies, for example, carcinoembryonic antigen (CEA) in cases 
of gut carcinoma, and prostate specific antigen (PSA) in prostate carcinoma.  
Differentiation antigens are commonly selected as targets for immunotherapy.  
However, this can often result in autoimmunity towards the corresponding normal 
tissue.  In the case of melanocytes, which to an extent are dispensable, autoimmune 
toxicity is likely to be tolerable whereas more serious concerns about autoimmune side 
effects apply to CEA which is expressed in the colon. 
 
1.3.1.4 Overexpressed Antigens 
Aberrant over-expression of certain proteins has been found to occur at the mRNA or 
translational level in malignant cells.  The distribution of these antigens in normal 
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tissues is heterogeneous, with some antigens being expressed in a few normal tissues, 
while others can be detected ubiquitously.  The increased expression of these proteins in 
transformed cells contributes to their proliferation and survival.  Examples include 
survivin and hTERT  (Chaudhuri et al., 2009; Gires & Selinger, 2009). 
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Table 1-1 Mechanism for generating human tumour associated antigens with 
examples  
Classification of tumour 
antigen 
Cellular Mechanism Examples 
Unique antigens 
Point mutations 
Frameshift mutations 
Translocation mutations 
CDK4, BRAF, p53 
KRAS 
TGFβII, Bax 
Shared tumour-specific 
antigens (CT antigens) 
Reactivation of genes normally 
expressed in germ cells possibly 
through DNA demethylation 
MAGEs, NY-ESO-
1, SSX, CRT-2 
Differentiation antigens 
Aberrant post-translational 
modification  
Deamidation 
Differential protein splicing 
Translation of cryptic epitopes 
Translation from alternative ORF 
Tyrosinase 
Gp100, TRP-2 
MART-1, gp100 
Gp75 
Overexpressed antigens Gene amplifications 
Her2/neu, Akt-1, 
WT-1, c-Myc 
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1.3.2 Investigated tumour-associated antigens 
In this thesis, epitopes derived from four MHC class I-restricted tumour-associated 
antigens are investigated: NY-ESO-1 (and LAGE-1), gp100, Melan-A/MART-1 and 
MAGE-A3.   
 
1.3.2.1 NY-ESO-1 (and LAGE-1) 
NY-ESO-1 and LAGE-1 are classed as cancer/testis (CT) antigens and they form part of 
a subset of CT antigens encoded on the X chromosome (CT-X).  They are expressed in 
different types of cancer, and not in normal tissues except in male germ cells 
(spermatogonia) (Hofmann et al., 2008).  However, little is known about their functions.   
NY-ESO-1 was originally detected when screening an esophageal carcinoma sample by 
SEREX (serological analysis of tumour antigens by recombinant cDNA expression 
cloning), a technique for identifying tumour antigens that elicit an antibody response 
(Y. T. Chen et al., 1997).  The highly homologous antigen, LAGE-1, was subsequently 
isolated by a subtractive cDNA cloning approach (Lethe et al., 1998).  The close 
homology between NY-ESO-1 and LAGE-1 exists at both the mRNA and protein 
expression level (de Carvalho et al., 2011).  NY-ESO-1 and LAGE-1 are expressed by a 
wide range of tumours including myeloma (Andrade et al., 2008; van Rhee et al., 2005) 
and a variety of solid tumours such as ovarian (Odunsi et al., 2003), non-small cell lung 
cancer (NSCLC) (Gure et al., 2005; Konishi et al., 2004) and melanoma (Barrow et al., 
2006; Vaughan et al., 2004).  NY-ESO-1 has been an attractive target in clinical trials 
using a variety of immune-based therapies including vaccines and gene modified T cells 
(Nicholaou et al., 2006; Robbins et al., 2011).  Multiple studies have demonstrated that 
NY-ESO-1 is immunogenic in human patients (J. L. Chen et al., 2000; Jager et al., 
1999), although vaccination approaches alone rarely lead to a clinically significant 
Chapter 1 
 37 
response (Bioley et al., 2009; Caballero & Chen, 2009).  The epitope of interest in this 
study is for the immunogenic HLA-A*0201 presented peptide NY-ESO-1157-165 
(SLLMWITQC) (J. L. Chen et al., 2000; Jager et al., 1998; Liddy et al., 2012; Purbhoo 
et al., 2006).  This same epitope is also present and processed from the LAGE-1 
antigen, thus, representing a single therapeutic target (de Carvalho et al., 2011; Lethe et 
al., 1998).   
 
1.3.2.2 Gp100 and Melan-A/MART-1 
Gp100 and Melan-A/MART-1 (Melanoma Antigen Recognised by T-cells-1) are 
differentiation antigens of the melanocytic lineage which are involved in melanogenesis 
and cutaneous pigmentation (Gires & Selinger, 2009).  Both antigens are highly 
expressed at over 90% in metastatic melanoma (Boon et al., 2006).  Although these 
antigens represent normal ‘self-proteins’, T cell responses specific for epitopes derived 
from these molecules have been reported in melanoma patients (Chi et al., 1997; 
Hofbauer et al., 2004; Riker et al., 1999).  Indeed, immune responses to these antigens 
have been shown to correlate with clinical response (Engell-Noerregaard et al., 2009; 
Kawakami et al., 1995; Saleh et al., 2005).  However, various vaccination strategies to 
harness the immune response against these antigens in patients with metastatic 
melanoma has had limited success to date (reviewed in  (Lens, 2008)).   
Melan-A/MART-1 was originally isolated by cDNA expression cloning with 
HLA-A2 restricted melanoma reactive CTL from TIL (tumour-infiltrating lymphocytes) 
and PBMC (peripheral blood mononuclear cells) (Coulie et al., 1994; Kawakami, 
Eliyahu, Sakaguchi et al., 1994).  It was found to be an immunodominant antigen 
recognised by the majority of melanoma reactive TIL in HLA-A2
+
 patients (Kawakami 
et al., 2000; Kawakami, Eliyahu, Delgado et al., 1994; Kawakami et al., 1995) .  One of 
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the epitopes responsible for this immunodominance is the HLA-A*0201 restricted 
peptide Melan-A/MART-126-35 (EAAGIGILTV) (Kawakami, Eliyahu, Sakaguchi et al., 
1994; Romero et al., 1997; Valmori et al., 1998) and is the epitope targeted in this 
study. 
Gp100 was identified as a melanoma antigen recognised by T cells using three 
different methods; cDNA expression cloning, direct epitope identification using mass 
spectrometry and screening candidate molecules using melanoma reactive CTL (Bakker 
et al., 1994; Cox et al., 1994; Kawakami et al., 2000).  The HLA-A*0201 restricted 
peptide gp100280-288 (YLEPGPVTA) was found to be one of three immunodominant 
epitopes recognised by TIL (Cox et al., 1994; Kawakami et al., 1995) and is the focus of 
this study. 
 
1.3.2.3 MAGE-A3 
The melanoma antigen genes (MAGE) represent the largest gene family among the CT 
antigens.  Like NY-ESO-1 and LAGE-1, the MAGE-A, B, and –C family are localised 
in clusters on the X-chromosome and are referred to as CT-X-MAGE proteins.  MAGE-
A3 was identified when analysing CTL responses of a cancer patient to an autologous 
melanoma cell line (Gaugler et al., 1994).  MAGE-A3 is expressed in a range of solid 
tumours such as melanoma (Brasseur et al., 1995; van der Bruggen et al., 1991), head 
and neck squamous carcinoma (Atanackovic et al., 2006) and bladder carcinoma (Patard 
et al., 1995).  However, the richest antigen expression of MAGE-A3 is seen in multiple 
myeloma.  Interestingly, although the role of CT antigens in malignancy is poorly 
understood, MAGE-A3 is known to play an important part in promoting the survival of 
myeloma cells.  Indeed, tumour progression is closely correlated with the level of 
expression of MAGE-A3 (Atanackovic et al., 2010). 
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The epitope of interest in this study is for the immunogenic HLA-A*0101 
presented peptide MAGE-A3168-176 (EVDPIGHLY) (Celis et al., 1994) 
 
1.3.3 Cancer immune escape 
A key reason for the limited success of T cell based therapies to date is due to cancer 
immune escape mechanisms.  The inherent genetic instability of malignantly 
transformed cells results in a heterogeneous population of cells that are able to alter 
their antigenic profile and avoid immune destruction.  Indeed, immunological pressure 
exerted by immune cells allows for the Darwinian selection of the most fit tumour 
variants to survive which leads to the outgrowth of a tumour.  The cancer immuno-
editing theory postulates three phases that describe tumour progression in the context of 
its interaction with the immune system: elimination, equilibrium, and escape (Schreiber 
et al., 2011).  Elimination refers to the immunosurveillance phase whereby a strongly 
immunogenic tumour in a highly immunocompetent host induces optimal stimulation of 
cells from the innate and adaptive immune system (including natural killer (NK), αβ and 
γδ T cells) and immunoregulatory molecules (including IFN-γ, IL-12, perforin and 
TRAIL) which act together to detect and destroy the tumour cells.  Equilibrium phase 
occurs when the immune system is not able to completely eliminate the tumour due to 
low tumour immunogenicity and/or a less immunocompetent host.  However, at this 
stage, the subset of tumour cells, which have not been eliminated are still under 
immunosurveillance and do not progress or further metastasize. During the equilibrium 
phase the tumour is not a clinical disease and this phase could be life-long, thus 
mimicking elimination.  On the other hand, continuous pressure by the immune system 
on genetically unstable cells can lead to the generation of tumour subtypes or variants 
that are able to avoid immunosurveillance, or changes in the immune system are 
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induced that weaken its capacity for tumour surveillance.  The outcome of either change 
is tumour escape that leads to the development of clinically apparent tumours in an 
immunocompetent host (Dunn et al., 2004; Shankaran et al., 2001). 
 
A common mechanism by which tumours avoid immune detection is through down-
regulation of MHC molecules and TAAs.  Human tumours frequently lose expression of 
MHC class I antigen (Garrido & Algarra, 2001; Marincola et al., 2000).  A study has 
shown that the frequency of HLA class I antigen loss or down-regulation is as high as 
51% in melanomas, with total loss seen in 16% as assayed by immunohistochemical 
(IHC) techniques (Ferrone & Marincola, 1995).  Loss or down-regulation of MHC class 
I antigen expression abrogates the ability of CTLs to recognise and kill tumour cells 
(Buell et al., 2005).  Complete loss of MHC class I antigen expression is commonly 
caused by mutation of the β2 microglobulin (β2m) gene that results in the functional loss 
of β2m expression (Bicknell et al., 1994; Hicklin et al., 1998).  β2m is essential for 
expression of the HLA class I complex on the cell surface.  Loss of MHC class I is 
irreversible and can be restored only by wild-type β2m gene transfer (Hicklin et al., 
1998; Restifo et al., 1996).  However, a number of studies have shown that MHC class 
I-deficient cells are susceptible to lysis by NK cells (Ljunggren & Karre, 1985; Maio et 
al., 1991). 
Down-regulation of MHC class I can also result from defects in the peptide 
loading of HLA class I antigens which impairs the assembly and stability of MHC class 
I molecules.  This is caused by abnormalities in the expression and/or function of 
different component(s) of the MHC class I antigen-processing and –presentation 
pathway, such as the proteasomal subunits LMP2 and LMP7, the peptide transporters 
associated with antigen processing (TAP-1 and TAP-2), and the chaperone tapasin 
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(Seliger et al., 2000).  However, in many cases, the expression of these components can 
be restored by treatment of tumour cells with IFN-γ (Seliger et al., 1997).  MHC class I 
down-regulation can also involve the selective loss of HLA-haplotype, locus or allele 
(Rivoltini et al., 2002). 
In addition, genomic instability within tumour cells may result in the loss or 
down-regulation of TAA expression creating antigen loss variants that are able to 
escape T cell recognition.  For example, in melanoma, tumour progression is often 
associated with reduced expression of melanocyte differentiation antigens (MDA) 
(Cormier et al., 1998; Jager et al., 1997; Maeurer et al., 1996).  However, a recent study 
suggests that CTLs may indirectly eliminate these tumour variants when tumour cells 
express sufficient antigen to be effectively cross-presented by the tumour stroma 
(Spiotto et al., 2004).   
 
This section has described some of the cell-autonomous modifications at the level of the 
tumour cell that directly lead to evasion of immune detection.  Section 1.5.8 describes 
the modifications in immune cells, inflicted on these by tumour cells and which 
generate an immunosuppressive tumour microenvironment. 
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1.4 Cell surface antigen presentation 
1.4.1 Type of cell surface antigen recognised by antibodies and T cell receptor 
(TCR) 
The adaptive immune system consists of two kinds of lymphocyte; B cells and T cells, 
which have evolved to survey the host environment for abnormalities.  They recognise 
antigen by two distinct sets of highly variable receptor molecules; the immunoglobulins 
that function as antigen receptors on B cells and the antigen-specific T cell receptor 
(TCR) on T cells.  Immunoglobulins and TCRs differ in several ways: (1) 
immunoglobulins are tetramers, comprising four polypeptide chains (two heavy chains, 
two light chains) and possess two antigen recognition sites, while TCRs are dimers and 
possess only one binding site, (2) immunoglobulins can be synthesised as either 
transmembrane receptors or secreted antibodies, whereas TCRs are only expressed 
naturally as transmembrane receptors, and (3) while antibodies recognise cell surface 
protein antigens by their overall conformation, T cells recognise peptide (short protein) 
fragments which have been processed and become bound to MHC class I or II 
molecules.  These MHC-antigen complexes are presented at the cell surface of antigen 
presenting cells (APCs) (e.g., dendritic cells, B cells, macrophages, and monocytes).  
This phenomenon is known as MHC-restricted recognition, or MHC restriction (Lefranc 
& Lefranc, 2001). 
 
1.4.2 MHC class I antigen processing 
MHC class I molecules typically bind peptides which have originated from the 
degradation of the cells’ endogenous molecules and are presented to CD8+ cytotoxic T 
cells.  The degradation of peptides destined to be presented by MHC class I molecules 
begins in the cytosol of the cell in a process involving an organelle called a proteasome, 
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a multisubunit ATP-dependent protease.  Denatured or ubiquitinated (a tag for 
degradation) proteins are cleaved into peptides by the multicatalytic proteasome 
subunits.  Three subunits, called X (MB1), Y (δ), and Z, mediate its standard catalytic 
activity and in normal, untransformed cells, the production of MHC class I peptide 
ligands is an inefficient process.  However, in response to the cytokine IFN-γ, this 
subunit composition is altered, leading to the formation of an immunoproteasome which 
consists of the catalytic subunits LMP2, LMP7, and LMP10 (MECL-1).  The 
immunoproteasome is more efficient at generating antigenic peptide fragments suitable 
for binding MHC class I molecules.  This process is further enhanced by the proteasome 
activators, PA28α and β, the expression of which are also modulated by IFN-γ (Pamer 
& Cresswell, 1998)  The antigenic peptides are then transported into the endoplasmic 
reticulum (ER) by the peptide transporter associated with antigen processing (TAP).   
TAP, a member of the ATP-binding cassette (ABC) transporter family, consists 
of two subunits, TAP1 and TAP2, which form a heterodimer.  In the ER, newly 
synthesised MHC class I–β2m complexes associate with TAP which binds and 
translocates peptides of a specific sequence, with a preferential length of 8-16 amino 
acids (Momburg & Hammerling, 1998).  The chaperone molecule, tapasin acts as a 
bridge between TAP and MHC class I ensuring high peptide-loading efficiency, optimal 
ligand selection and stabilisation of the MHC class I-loading complex (Barnden et al., 
2000).  Other co-factors present in the ER, such as the chaperones calreticulin and 
ERp57, also associate with the TAP-tapasin-MHC class I complex to form a large 
complex called the peptide loading complex (PLC).  Components of the PLC facilitate 
peptide binding to MHC class I molecules.  Peptide occupancy triggers the release of 
MHC class I- β2m complex from the PLC which is then transported via the Golgi to the 
cell surface for presentation to CD8
+
 cytotoxic T cells (Raghavan et al., 2008). 
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MHC class I peptides are not exclusively generated from endogenous proteins, but can 
also be derived from endocytosed exogenous antigens, via different intracellular 
pathways, which are able to access the class I processing and presentation pathway.  
This phenomenon of cross-presentation (also referred to as cross-priming) is a key 
mechanistic step in the initiation of CD8
+
 T cell responses against tumour cells and 
many pathogens (Shen & Rock, 2006).  Cross-presentation was thought to be a specific 
feature of professional antigen presenting cells (pAPCs), such as dendritic cells.  
However, a recent study has demonstrated that CTLs from a melanoma patient 
recognised a cross-presented epitope on autologous tumour cells generated from an 
exogenous protein after receptor-mediated internalisation (Godefroy et al., 2005).  
Furthermore, studies have shown that T cells are able to eradicate or arrest growth of 
large established tumours, including antigen loss variants, by targeting non-malignant 
stromal cells that have internalised tumour antigens released from dead cancer cells and 
cross-presented the epitopes on their surface MHC molecules (Spiotto et al., 2004; 
Spiotto & Schreiber, 2005; B. Zhang et al., 2007).  This T cell destruction of stromal 
cells then leads to bystander killing of cancer cells (Spiotto et al., 2004; Spiotto & 
Schreiber, 2005; B. Zhang et al., 2008).   
 
1.4.3 MHC class I antigen presentation 
Almost, all nucleated cells present MHC class I molecules.  The function of MHC class 
I molecules is to present antigens which have originated inside the cell to cytotoxic 
CD8
+
 T cells.  There are approximately 10
5
 copies of MHC class I molecules expressed 
on the surface of most nucleated cells and, therefore, many different peptides are 
simultaneously presented.  These include self peptides such as leader signal peptides, 
enzymes, heat-shock proteins etc, as well as those derived from viruses or intracellular 
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pathogens which have infected the cell.  In contrast, MHC class II molecules are 
expressed only on B cells, dendritic cells, macrophages and thymic epithelium, and 
present antigen to CD4
+
 helper T cells. 
 
MHC class I molecules consist of a heavy polypeptide chain of 44 kDa non-covalently 
linked to a smaller 12 kDa polypeptide called β2-microglobulin (β2m).  The class I 
heavy chain consists of three extracellular domains, designated α1 (N-terminal), α2 and 
α3, a transmembrane region and a cytoplasmic tail.  The heavy chain is encoded by the 
highly polymorphic major histocompatibility (MHC) gene complex, in humans located 
on the short arm of chromosome 6.  In each individual there are three loci, called human 
leucocyte antigen (HLA)-A, -B and –C.  At each locus there are multiple heavy chain 
alleles which give rise to the extraordinary polymorphic nature of class I genes.  The 
paternal and maternal derived chromosome 6 combination results in the co-dominant 
expression of a maximum of six different MHC class I alleles.  Although several 
hundred human heavy chain alleles are known (listed at http://hla.alleles.org/ (Robinson 
et al., 2013)), specific alleles are preferentially expressed in certain population groups, 
for example the MHC class I molecule HLA-A*0201 is present in about 50% of 
Caucasians (New Allele Frequency Database: http://www.allelefrequencies.net/ 
(Gonzalez-Galarza et al., 2011).  
 
1.4.3.1 Structure and peptide binding of MHC class I molecules 
The first X-ray crystallographic structure of a human MHC class I molecule, HLA-A2 
(Bjorkman et al., 1987), revealed that both β2m and the α3 region resemble Ig domains 
in their folding pattern.  The non-polymorphic α3 domain also contains a site which 
interacts with the coreceptor, CD8, on cytotoxic T cells (Gao et al., 1997).  The highly 
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polymorphic α1 and α2 domains, which are most distal to the membrane, form two 
extended α-helices above a floor created by strands held together in a β-pleated sheet, 
forming a peptide binding cleft.  The extreme polymorphism concentrated in the α1 and 
α2 domains allows for the variation in the peptide-binding cleft enabling the binding of 
the many possible peptides and extends the range of antigens to which the immune 
system can respond. 
The binding cleft or groove is closed at both ends and restricts peptide length to 
8-11 residues (averaging 9 residues) and of a linear nature.  Antigenic peptides contain 
specific amino acids at their amino (N)- and carboxyl (C)-termini that bind to invariant 
sites at each end of all MHC class I molecule peptide binding clefts.  Moreover, 
particular amino acids with defined characteristics form ‘anchor residues’.  They 
represent the amino acid side-chains required to fit into allele-specific pockets in the 
MHC groove.  For class I –binding peptides there may be two or three anchor positions, 
one at the C-terminal end and the other typically at the second residue from the amino 
terminus of the peptide (termed position P2).  The anchor residues are typically 
hydrophobic residues; by contrast, the remaining amino acids in the sequence can vary 
almost infinitely (Rammensee et al., 1995).  Therefore, a given MHC class I molecule 
binds a distinct set of peptides sharing a common homologous binding motif, but is still 
able to present a wide array of peptides to the T cell receptor.  Peptide-binding motifs 
have been defined for numerous MHC class I alleles and this has made it possible to 
make predictions about the set of peptides with the ability to bind a given MHC class I 
allele by scanning the gene product sequence of interest with appropriate algorithms.  
This procedure has become known as reverse immunology and is a potentially useful 
tool for mining novel tumour antigens from the human genome (Schultze & 
Vonderheide, 2001).  
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1.5 T cells and the T cell receptor (TCR) 
T cell receptors (TCRs) are the clonotypic antigen-specific receptors presented on the 
surface of T cells, which recognise peptide antigen in the context of MHC molecules, 
and are critical to the adaptive immune response.  TCRs were first isolated using 
monoclonal antibodies directed against a clone-specific molecule on T cells (Haskins et 
al., 1983), and also independently at the same time, by the identification of genes that 
encode part of the same molecule (Hedrick et al., 1984).  The molecule was found to be 
a heterodimer comprising an α (40-50 kDa) and a β (35-47 kDa) polypeptide chain, 
linked by a disulfide bond.  The αβ heterodimers are very similar in structure to the 
antigen binding fragment (Fab) of an immunoglobulin (Ig) molecule.  They are present 
on the majority of T cells and recognise peptide antigens presented by MHC class I and 
II molecules.  A small proportion of T cells bear an alternative, although structurally 
similar, receptor made up of a different pair of polypeptide chains, γ and δ, whose 
function is less clearly defined at present.  The αβ and γδ forms of the TCR, which are 
structurally unique for each clone of T cells, are additionally both non-covalently 
associated with CD3, a membrane-bound signalling complex of non-polymorphic 
polypeptides which includes δ, γ, ε, and ζ chains.  
 
1.5.1 Structure of the T cell receptor 
As already eluded to, the αβ TCR framework structure resembles that of an Ig Fab 
fragment and this had been predicted for some time based on the sequence homology 
between the molecules (Chothia et al., 1988), before it was conclusively demonstrated 
in separate X-ray crystallography studies (Bentley et al., 1995; Fields et al., 1995; 
Garboczi et al., 1996; Garcia et al., 1996).  The α and β chains each comprises two 
extracellular domains, a variable (V) region with homology to the immunoglobulin V 
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domain, a constant (C) region with homology to the immunoglobulin C domain, and a 
short stalk segment containing a cysteine residue which forms the interchain disulfide 
bond.  Each chain is anchored into the plasma membrane by a transmembrane domain 
which has a short cytoplasmic tail.  Within the Vα and Vβ domains, there are regions of 
amino acid hypervariability, known as complementarity determining regions (CDRs) 1, 
2 and 3.  These are clustered together on the membrane distal part of the TCR to form 
an MHC-antigen binding site which is analogous to the antigen binding site on 
antibodies (Garcia, Teyton et al., 1999).    
 
1.5.2 Hypervariability 
Similar to B cell immunoglobulin receptors, the T cell receptor (TCR) germline DNA 
undergoes rearrangement, to produce the diversity of receptors required to recognise the 
universe of potential pathogens.  In αβ T cells, which recognise peptide antigens 
presented by MHC molecules, most of this receptor diversity is determined by the 
amino acid sequence encoded in the third complementarity determining region (CDR3) 
loop of the α and β chain variable domains.  The CDR3 regions are formed by 
rearrangement between variable (Vβ), diversity (Dβ), and joining (Jβ) gene segments in 
the β chain locus, and between analogous Vα and Jα gene segments in the α chain locus.  
The existence of multiple such gene segments in the β and α chain loci creates the 
potential for a large number of distinct CDR3 sequences to be encoded (Figure 1-2).  
Additional CDR3 sequence diversity is generated by template-independent addition, 
deletion and substitution of nucleotides at the junction of gene segments during 
rearrangement.  It has been estimated that TCR gene assembly and expression allows 
for a potential 10
13
-10
15
 variants of the αβ TCR heterodimer in the mouse (M. M. Davis 
& Bjorkman, 1988).  However, the theoretical number of possible TCRs in humans is 
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likely to be orders of magnitude larger, as humans possess 54 TCRβ variable genes as 
compared with the 35 genes in mice, with all other variables being comparable.  Thus, 
the potential number of unique αβ TCRs in human is > 1018  (Sewell, 2012). 
 
A key difference between antibodies and TCRs in the generation of diversity is that 
TCRs do not undergo somatic hypermutation.  Somatic hypermutation occurs in 
response to antigen and involves the introduction of non-templated point mutations in 
the recombined immunoglobulin variable region V(D)J genes.  It is a mechanism for 
increasing antibody diversity and affinity following antigen recognition (M. M. Davis & 
Bjorkman, 1988; Tonegawa, 1988).  By contrast, the T cell repertoire is shaped by 
selection processes that operate in the thymus and in the periphery to maintain lower 
affinities.  If hypermutation occurred, those mutations could lead to the emergence of 
high affinity autoreactive receptors and autoimmunity.  Thus, the affinity of TCR-
pMHC interaction is ‘locked’ after gene rearrangement and typically found to be in the 
low micromolar range (M. M. Davis et al., 1998) compared to antibody-antigen 
affinities which are in the nanomolar range (Braden et al., 1998). 
 
 
Chapter 1 
 50 
 
Figure 1-2 T cell receptor (TCR) α and β chain gene rearrangement and 
expression.   
 
The TCR α and β chain genes are composed of discrete segments that are joined by 
somatic recombination during T cell development in the thymus.  For the α chain (upper 
part of figure), a Vα gene segment rearranges to a Jα gene segment to create a 
functional V-region exon.  All V segments are preceded by a leader sequence (L).  
Transcription and splicing of the VJα exon to Cα generates mRNA that is translated to 
produce the TCR α chain protein.  For the TCR β chain (lower part of figure), the 
variable domain is encoded in three gene segments, Vβ, Dβ and Jβ.  Rearrangement of 
these gene segments generates a functional VDJβ V-region exon that is transcribed and 
spliced to join to Cβ; the resulting mRNA is translated to produce the TCR β chain.  
The α and β chains pair soon after synthesis to produce the αβ TCR heterodimer.  
Diversity is further increased through DNA nuclease activity and random N nucleotide 
addition at the gene segment junctions, providing almost limitless potential for the TCR 
repertoire.  This method of generating receptor diversity preserves germline-encoded 
information in the V regions that directly interact with MHC molecules (CDR1 and 
CDR2) while maximising diversity a the V(D)J junction (region marked by asterisks) 
that encodes the hypervariable CDR3 that contacts presented peptide antigens.  
Courtesy of Dr. Bent Jakobsen at Immunocore Ltd. 
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1.5.3 TCR antigen recognition 
The molecular recognition of the pMHC by the TCR is mediated by the three CDRs of 
each chain of the TCR at the interface with the pMHC complex (Garcia et al., 1996).  
Co-crystal structures of a number of TCR-pMHC complexes have demonstrated an 
approximately diagonal orientation of the TCR with respect to MHC, with the Vα 
domain poised above the N-terminal half of the peptide and the Vβ domain located over 
the C-terminal portion of the peptide.  The hypervariable CDR3 loops of the α chain and 
β chain are located over the central portion of the peptide (Rudolph et al., 2006).  One 
current model for TCR-pMHC association describe a two step approach, the first step 
being driven by the conserved, germline-encoded interactions made by the CDR1 and 
CDR2 loops of the TCR α and TCR β chains, which are largely peptide independent, 
thereby positioning the highly variable non-germline-encoded CDR3 loops over the 
peptide.  Specific recognition of the presented peptide by the TCR then occurs after the 
TCR has made the appropriate contacts with the MHC to orient itself correctly on the 
peptide-MHC complex.  T cell activation is triggered only when stable contacts are 
made with both HLA and peptide (Wu et al., 2002).  It is suggested that this paradigm 
explains how it may be possible for a TCR to efficiently scan the many thousands of 
peptides presented by MHC on the surface of an antigen presenting cell.  However, 
structural data from TCR-pMHC complexes appear to contradict this model, as the 
contributions of TCR-MHC and TCR-peptide contacts can vary considerably between 
different complexes. Also, it has been found that the orientation with which TCRs with 
the same germline CDRs are positioned over their respective pMHC ligands can vary 
with up to 60°, indicating that no fixed alignment and, therefore, set of contacts exist 
between the CDR1 and CDR2s to MHC (Gras et al., 2012).  Furthermore, it has been 
shown that a functional TCR repertoire can be thymically selected even if the CDR1 
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and CDR2 regions of the TCR β chain were changed to those from a TCR γ chain, 
which does not recognise MHC class I.  Thus, the TCR CDR1 and CDR2s are not 
obligatory for pMHC recognition and it therefore appears more likely that the TCR 
adopts a flexible, rather than an ordered, step-wise docking mode when engaging with 
pMHC (Holland et al., 2012).   
Regardless of the various models for the initiation of TCR-pHLA contacts, 
paired structures of unbound TCRs and TCR-pMHC complexes have revealed 
considerable flexibility within the CDR loops of the TCR molecule, with stabilisation 
occurring upon binding to pMHC (Willcox et al., 1999).  Hence, a flexible binding 
mechanism has been proposed for TCR-pMHC docking (Garcia et al., 1998; Garcia, 
Teyton et al., 1999; Reiser et al., 2003).  This TCR ‘plasticity’ is thought to be an 
important determinant of the ligand degeneracy that has been reported for both MHC 
class I- and class II-restricted TCRs (Ishizuka et al., 2008; Wilson et al., 2004). 
 
1.5.4 TCR degeneracy 
TCR recognition of peptide-MHC is ‘polyspecific’, i.e., a particular TCR is not limited 
to the specific recognition of a single ligand.  Indeed, it has been estimated that one 
TCR can respond to over million different peptides when presented in the context of a 
single MHC type (Wooldridge et al., 2012).  Despite this apparently high level of cross-
reactivity, TCRs are still functionally specific because they will recognise only a small 
fraction (<0.01%) of the peptides that can be presented by a particular MHC molecule 
(Mason, 1998).  T cell cross-reactivity permits effective T cell responses to a vast 
number of potential peptide sequences bound to MHC molecules with specificity 
sufficient to distinguish between self and foreign peptides (Sewell, 2012).   
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TCR-pMHC interactions typically comprise fast kinetics and weak affinity with 
dissociation constants (KD), defined at equilibrium as the rate of dissociation divided by 
the rate of association (KD = Koff/Kon), ranging from 1-100 μM (Cole et al., 2007; M. M. 
Davis et al., 1998; Garcia, Degano et al., 1999; van der Merwe & Davis, 2003).  These 
binding properties, shaped during thymic selection, are necessary to enable TCR to 
effectively trigger the T cell once a rare antigenic complex has been encountered but 
also to avoid autoreactive responses against self-pMHC (Krogsgaard & Davis, 2005; 
Rudolph et al., 2006). 
 
1.5.5 TCR thymic selection 
The T cell repertoire is generated during thymic development in preparation for the 
response to pathogenic antigens and also involves strict quality control mechanisms to 
prevent autoimmunity.  Immature thymocytes (thymic T cells) that undergo V(D)J 
recombination of the TCR genes and express the unselected T cell repertoire are 
generated in the thymic cortex.  The processes of positive and negative selection shape 
the functional repertoire of CD8
+
 cytotoxic T cells (Starr et al., 2003).   
Positive selection occurs in the thymic cortex and requires that immature, 
double-positive (DP: CD4
+
CD8
+
) thymocytes be able to recognise self-pMHC 
molecules on thymic cortical epithelial cells (cTECs).  cTECs present a spectrum of 
peptides that bind weakly to MHC molecules.  The presented peptides, which have been 
generated by a thymoproteasome, are different from the peptides presented in the 
periphery or in the thymic medulla (Nitta et al., 2010).  The low affinity recognition of 
the cTEC self-pMHC complexes promotes survival of the immature thymocytes; in the 
absence of recognition, DP thymocytes will undergo apoptotic death through lack of 
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stimulation.  Recognition of the cTEC self-pMHC complexes also determines the 
commitment of the DP thymocytes to either the CD4 or CD8 lineage.   
Negative selection mainly occurs in the medulla, where single-positive 
thymocytes (SP: CD4
+
CD8
-
 or CD4
-
CD8
+
) encounter thymic epithelial cells (mTECs), 
and dendritic cells (DCs) that have migrated from the periphery to the thymus.  Both 
mTECs and medullary DCs process peptides through the constitutive proteasome and 
the more efficient immunoproteasome, and therefore possess the capability to present a 
vast repertoire of self-pMHC to mirror that presented in the periphery (Groettrup et al., 
2010).  mTECs also specialise in promiscuous gene expression (pGE), induced by the 
autoimmune regulator (Aire) (reviewed in (Taniguchi & Anderson, 2011)) which acts as 
a master switch directing the transcriptional activation of genes for a number of organ-
specific antigens.  Negative selection results in the clonal deletion of T cells from the 
repertoire that possess high affinity TCR to self-pMHC thereby conferring immune 
tolerance to the host and preventing autoimmunity. 
Thymic selection generates a TCR repertoire with low affinity for self-pMHC 
but potentially high affinity for foreign antigens.  The result is that, while CTLs can 
respond vigorously to pathogen-derived antigens, tumour cells appear to evade the CTL 
response.  Most tumour associated peptide antigens (TAPAs) are derived from self and 
it has been shown that the affinity of TCRs for cancer-associated antigens are of 
approximately one order of magnitude lower affinity than TCRs recognising viral 
peptides (Aleksic et al., 2012). 
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1.5.6 T cell activation in the periphery 
1.5.6.1 The immunological synapse 
T cell immune responses are initiated by the engagement of the αβ TCR and coreceptor, 
CD8 or CD4, with its cognate peptide-MHC.  The TCR itself has no intrinsic signalling 
activity and is associated non-covalently on the cell surface with the non-variable CD3 
complex (van der Merwe & Davis, 2003).  The main role of the CD3 complex is to 
propagate signals into the interior of the cell (Salmond et al., 2009).  T cell activation 
also involves various antigen independent cell-cell interactions including CD2 (LFA-2), 
CD40L, LFA-1, and CD28 located on the surface of T cells, which bind CD58 (LFA-3), 
CD40, ICAM-1, and CD80 (B7.1)/CD86 (B7.2) on the surface of APCs, respectively.  
Together, these interactions serve to strengthen T cell-APC contact and regulate T cell 
activation (Bennett et al., 1998; M. K. Jenkins et al., 1991).  Costimulatory signals such 
as the CD28-CD80/CD86 interaction are critical for the activation of naïve T cells that 
have never encountered antigen (Chai et al., 1999). 
Given that the affinity of the interaction between an individual TCR for its 
specific peptide-MHC complex is relatively low, the successful docking of T cells and 
targets depends on various pairs of accessory molecules in order for a stable association 
to be formed.  The most important of these is the engagement of the integrin LFA-1 on 
the T cell with its cognate molecule ICAM-1 on antigen presenting cells (APCs).  
Antigen-induced up-regulation of LFA-1 binding to ICAM-1 is one of the first critical 
steps to the formation of a specialised structure at the T cell: APC interface called an 
immunological synapse or ‘supramolecular activation clusters’ (SMAC) (Grakoui et al., 
1999; Monks et al., 1998).   
Pioneering fixed-cell imaging studies by Kupfer and colleagues (Monks et al., 
1998) revealed that the immunological synapse forms a ‘bull’s eye’ pattern with its 
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target cell, which may be important for the polarised delivery of cytolytic granules into 
the immunological synapse space.  For example, the bull’s eye immunological synapse 
of cytolytic CD8
+
 T cells is characterised by a central area known as the cSMAC in 
which the TCR-CD3 complex, its coreceptors CD8/CD4, and the costimulatory 
molecule CD28 are positioned for optimal interaction with pMHC, CD80 and CD86 on 
the APC.  This, in turn, is surrounded by a peripheral ring (pSMAC) of molecules such 
as ICAM-1/LFA-1.  The pSMAC may act as a sealing ring, preventing the leakage of 
cytolytic granule contents to bystander cells (M. R. Jenkins & Griffiths, 2010; 
Stinchcombe et al., 2001). Furthermore, the ring of integrins is also surrounded by a 
more distal ring (dSMAC) of membrane proteins like CD43 and CD45 with large 
ectodomains.   
Dynamic studies with planar bilayers have shown that during the formation of 
the immunological synapse, TCR microclusters initially created in the dSMAC, move 
centripetally towards the cSMAC region in an actin dependent process (Grakoui et al., 
1999).  Moreover, there is evidence to suggest that the TCR microclusters are the site 
where TCR signalling is initiated, and that signalling is sustained by the movement of 
the TCR microclusters into the cSMAC (Campi et al., 2005; Yokosuka et al., 2005).  
The TCR microclusters also serve as sites for the initiation of costimulation.  The most 
of important of these costimulatory molecules is CD28 which binds to its ligands CD80 
(B7.1) and CD86 (B7.2); these interactions are highly enriched in TCR microclusters.  
However, T cell activation and immunological synapse formation can also be 
constrained by the action of inhibitory receptors.  For example, the expression of 
cytotoxic T lymphocyte antigen-4 (CTLA-4) on T cells after activation suppresses T 
cell signalling by out-competing CD28 for the binding of CD80 and CD86.  
Programmed-death 1 receptor (PD-1) is another example of an inhibitory molecule 
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involved in co-signalling in T cells.  PD-1 has two ligands, PD-L1 and PD-L2 
frequently expressed on tumour cells (Fooksman et al., 2010). 
Although studies of the immunological synapse throws light on how T cells 
function, formation of the mature synapse does not appear to be a pre-requisite for full 
T cell activation (D. M. Davis & Dustin, 2004; Purbhoo et al., 2004; Thauland & 
Parker, 2010).  Thus, in looser terms, the immunological synapse can be considered to 
be any structure formed at the interface of functional T cell:APC contacts, whereas the 
cSMAC and pSMACs are structures restricted to certain conditions (Alarcon et al., 
2011).  Thus, T cell activation does not always follow a clearly recognisable pattern, 
probably reflecting that the kinetics and degree of order in the T cell:APC contacts can 
vary considerably. 
 
T cell activation requires signal transduction by the CD3 complex following 
engagement of the TCR by its ligand.  CD3 contains CD3γ, CD3δ, CD3ε and CD3ζ 
subunits which have been found to associate with one another to form CD3ζζ 
homodimers and CD3εδ or CD3εγ heterodimers.  Each of the CD3 complex subunits 
contain immunoreceptor tyrosine-based activation motifs (ITAMS) in their cytoplasmic 
domains; these are present as single copies in the CD3γ, CD3δ and CD3ε subunits and 
as three copies in the CD3ζ subunit (Koning et al., 1990; Manolios et al., 1994).   
Protein phosphorylation is one of the main forms of chemical modification that 
controls TCR signalling, and is mediated by a number of protein tyrosine kinases 
(PTKs).  After cognate pMHC molecule binding, TCRs cross-link (cluster) during the 
formation of an immunological synapse, and the Src family kinase, Lck, is activated 
leading to the phosphorylation of the CD3 chains and ζ-chain homodimer ITAMS of the 
TCR complex.  These, in turn, provide docking sites for the Syk family kinase, ζ-chain-
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associated 70 kD protein called ZAP-70.  ZAP-70 becomes activated by Lck-mediated 
phosphorylation and propagates the TCR signal by phosphorylating downstream 
signalling molecules, including the adaptor molecules SH2 domain-containing 
leucocyte protein of 76 kDa (SLP-76) and the linker for activation of T cells (LAT) 
(Wange & Samelson, 1996; Weiss & Littman, 1994).  In addition, the stable recruitment 
of the coreceptors CD4 or CD8 to the TCR plays a key role in early phosphorylation 
events during T cell signalling.  The cytoplasmic tails of CD4 and CD8 are 
constitutively associated with Lck which can phosphorylate the ITAMS of the CD3 
complex leading to the precipitation of signal transduction within the cell (Smith-Garvin 
et al., 2009). 
 
1.5.6.2 TCR triggering and considerations for designing bispecific activator 
molecules 
The TCR is able to detect as little as a single agonist peptide MHC on the surface of an 
antigen-presenting cell (APC).  However, it appears that around 3-10 specific pMHC 
complexes are required for the T cell to embark on the signalling pathways that lead to 
full activation and deployment of its effector functions (Irvine et al., 2002; Purbhoo et 
al., 2004).  Furthermore, sustained signalling over a period of a few hours has been 
shown to be essential for cytokine production and proliferation in effector T cells, while 
naïve T cells require an even longer signalling period (approximately 20 hours) to be 
activated (Iezzi et al., 1998; Schrum & Turka, 2002; Valitutti, Dessing et al., 1995; 
Weiss et al., 1987).  This raised the question of how relatively low affinity TCRs could 
remain bound to the same pMHC for long enough to achieve sustained signalling.  The 
serial triggering model addresses this issue by proposing that each cognate pMHC 
serially engages many TCRs, one after the other.  This model is supported by evidence 
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that, during a 5 hour T cell:APC interaction ~ 100 specific pMHC induced the down-
regulation of up to 18,000 TCRs (Valitutti, Muller et al., 1995).  The serial triggering 
model is consistent with the typically short-lived nature of TCR-pMHC interactions and 
dictates a requirement for an optimal dwell-time range for a given TCR-pMHC 
complex.  Therefore, interactions with half-lives below or exceeding this optimum are 
predicted to be less effective.  This notion is supported by evidence that T cell 
activation can be impaired by mutations that either decrease or increase the binding 
half-life of the TCR-pMHC interaction (Kalergis et al., 2001).  Of particular relevance 
here, the serial triggering model could have implications for designing an effective 
bispecific T cell activator molecule and suggests that the potency of the molecule could 
be critically dependent on its affinity for the TCR-CD3 complex. 
Although it has been known for some time that CD3 transduces signals from the 
engaged receptor via its ITAMs, exactly how ligation of the TCR is translated into the 
first signal, in a process referred to as TCR triggering, is still not fully understood.  
Several models have been proposed to explain how spatio-temporal organisation and 
interaction of molecules on the cell surface of a T cell enable effective signal 
transduction within the T cell (reviewed in (van der Merwe & Dushek, 2011)).   
One of the mechanisms proposed for TCR triggering is binding-induced 
segregation or distribution of the TCR-CD3 complex relative to other cell membrane-
associated proteins.  The kinetic-segregation model proposes that TCR binding to 
pMHC ligand traps the TCR-CD3 complex in close-contact zones (~15 nm apart), 
thereby segregating it from the large ectodomain inhibitory tyrosine phosphatases, 
CD45 and CD148, resulting in the constitutive phosphorylation of TCR-CD3 ITAMs by 
Lck.  The model is supported by a number of key observations; first, inhibitory tyrosine 
phosphatases are excluded from areas of TCR triggering (J. Lin & Weiss, 2003; Varma 
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et al., 2006); second, truncation of the large phosphatase ectodomains inhibits TCR 
triggering (Irles et al., 2003; J. Lin & Weiss, 2003); third, elongation of the pMHC 
complex inhibits TCR triggering (Choudhuri et al., 2009; Choudhuri et al., 2005); 
fourth, surface-associated TCR ligands induce TCR triggering more effectively than 
their soluble counterparts (Geppert & Lipsky, 1987; Ma et al., 2008).  Finally, and of 
particular relevance when considering bispecific T cell activators, is that recognition by 
engineered TCRs is optimal when the epitope is positioned close to the plasma 
membrane of the target cell (Bluemel et al., 2010; James et al., 2008).  Moreover, the 
kinetic-segregation model is thought to account for the activating effects of certain 
antibodies.  The best known T cell stimulatory antibodies are anti-CD28 and anti-CD3.  
Analyses of conventional and superagonist antibodies to CD28, for example, have 
shown that the triggering of CD28 is sensitive to size-dependent effects.  The 
superagonist antibodies formed a more compact complex which more effectively 
excluded the large proteins (CD45 and CD148), thus favouring more intense 
phosphorylation of CD28, leading to more potent signalling (S. J. Davis & van der 
Merwe, 2006). 
 
1.5.7 T cell effector functions 
Prior to the first encounter of cognate antigen, naïve CD8
+
 T cells are not capable of 
exerting effector functions such as killing.  Naïve CD8
+
 T cells must be ‘primed’ or 
activated in the peripheral lymphoid organs before acquiring cytotoxic effector 
functions.  T cell priming is typically mediated by a specialist type of antigen presenting 
cells (APC) called dendritic cells (DCs).  Naïve CD8
+
 T cells reach maximal activity 
after 1-3 days of persistent stimulation of the TCR by its cognate antigen in the context 
of MHC class I, and a CD28 co-stimulus.  This promotes the clonal expansion and 
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differentiation of the CD8
+
 T cells into cytotoxic T lymphocytes (CTLs) that kill 
antigen expressing target cells (through granzymes and perforin), and secrete cytokines 
such as interferon-γ (IFN-γ) and tumour necrosis factor (TNF).  CTLs that exert effector 
functions following secondary antigen encounter are referred to as effector memory 
cells (Tem).  A distinguishing feature of effector memory CD8
+
 T cells is their ability to 
rapidly deploy their arsenal of effector functions.  CD4
+
 T cells recognise peptide 
presented in the context of MHC class II on the surface of APCs; CD4
+
 T cells 
differentiate into T helper (Th1) cells that produce IFN-γ, TNF and interleukin-2 (IL-2).  
They also possess some cytotoxic activity but one of their key roles is maintenance of 
antigen-specific CD8
+
 T cell responses. 
 
1.5.7.1 T cell-mediated killing 
CTLs employ two distinct effector pathways to kill infected or malignantly transformed 
cells: death receptor-mediated and granule-mediated killing.  In the death receptor-
mediated pathway, CTLs expressing ligands of the tumour necrosis factor (TNF) 
superfamily on their cell surface can kill target cells expressing the corresponding 
receptors.  Examples of these ligand/receptor pairings include FasL/FasR, TNF-
α/TNFR1, Apo3L/DR3, Apo2L/DR4, and Apo2L/DR5 (Ashkenazi & Dixit, 1998; 
Chicheportiche et al., 1997; Peter & Krammer, 1998; Rubio-Moscardo et al., 2005; 
Suliman et al., 2001).  Engagement between a ligand and its receptor initiates a 
signalling pathway within the target cell that results in the recruitment and activation of 
caspases.  Caspases, a family of cysteine proteases, are the main effectors of apoptotic 
cell death by cleaving cellular substrates on the carboxy-terminal side of an aspartate 
residue (Launay et al., 2005). 
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However, the granule-exocytosis pathway of cytotoxicity is the dominant 
mechanism by which CD8
+
 cytotoxic T cells destroy target cells (de Vries et al., 2007; 
Yasukawa et al., 2000).  CTLs contain modified lysosomes filled with cytotoxic 
proteins, collectively called cytotoxic granules.  The granules are synthesized only after 
the CTL has encountered its specific peptide-MHC and has become activated.  The 
major granule components include the pore-forming protein, perforin, and granzymes.  
Recognition of a target cell by a CTL triggers the rapid migration of the granules inside 
the effector cell towards the site of contact i.e. immunological synapse.  At this site, the 
granules fuse with the effector cell plasma membrane and are then secreted into the 
tight intercellular junction (Cullen & Martin, 2008).  Following this ‘kiss of death’, 
which can be as short as 20 mins, the CTL can disengage, unharmed, to kill again; thus, 
CTL can perform serial target cell killing (Cullen & Martin, 2008; Rothstein et al., 
1978). 
By a mechanism still not fully understood, the cytotoxic granule protein perforin 
is thought to polymerise within the target cell membrane forming pores that permit 
passage of other granule constituents, such as granzyme B, into the target cell.  An 
alternative mechanism that has been proposed involves the endocytosis of granzyme B 
via a specific target cell surface receptor, the mannose-6-phosphate receptor.  The 
internalised granzyme B is retained in an endosome-like vesicle which is then 
perforated by the perforin, releasing the granzyme B molecules into the cytosol of the 
target cell (Barry & Bleackley, 2002). 
 
1.5.7.2 The role of granzyme B in T cell-mediated cell death 
Granzymes are a subclass of serine proteases displaying the chymotrypsin fold (Smyth 
et al., 1996).  In humans there are a total of five granzymes; A, B, H, K and M.  
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Granzymes A and B are generally the most abundant, and are the most extensively 
studied.  However, all of the granzymes appear to play a role in the lysis of malignant 
cells, albeit via different pathways (D. Chowdhury & Lieberman, 2008).  Granzyme B 
is a major constituent of CD8
+
 CTL granules, promoting target cell death (apoptosis) 
through proteolysis of a number of cellular substrates.  Knockout mouse studies have 
demonstrated a vital role for granzyme B in target cell DNA fragmentation and 
apoptosis, with granzyme B-deficient CTLs exhibiting delayed killing, suggesting that 
this granzyme is required for the rapid and efficient killing of the target cell (Heusel et 
al., 1994; Pardo et al., 2004). 
Once in the target cell cytosol, granzyme B initiates apoptosis primarily through 
the proteolysis of the BH3-only protein BID (Pinkoski et al., 2001; Waterhouse et al., 
2006).  Cleavage product truncated BID (tBID) translocates to the mitochondria where 
it induces the oligomerisation of the BCL-2 family members, BAX and/or BAK in the 
outer mitochondrial membrane (J. B. Alimonti et al., 2001; Barry et al., 2000; Heibein 
et al., 2000).  This promotes mitochondrial permeabilisation that permits the release of 
cytochrome c in to the cytosol, which leads to the formation of a complex known as the 
apoptosome, between Apaf-1 and pro-caspase-9 (Jiang & Wang, 2000; P. Li et al., 
1997).  Assembly of the apoptosome results in caspase-9 activation followed by the 
activation of down-stream caspases, such as caspase-3 and -7 (Slee et al., 1999).  
Granzyme B can also bypass the mitochondrial pathway and initiate caspase activation 
directly and/or cleave caspase substrates such as the inhibitor of caspase-activated 
deoxyribonuclease (ICAD), thereby allowing CAD to translocate to the nucleus to 
fragment DNA (Cullen & Martin, 2008) (Figure 1-3).   
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Figure 1-3 Mechanisms of granzyme B mediated cell death.   
 
See section 1.5.7.2 for detailed description (Barry & Bleackley, 2002). 
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1.5.8 The failure of the immune system against cancer 
The main reason for the lack of a robust immune response by T cells against tumour-
associated antigens presented on tumour cells is because these antigens are usually 
derived from ‘self’ (as described in section 1.3.1).  The process of central tolerance i.e., 
the deletion of high affinity TCRs to self pMHC during thymic development results in 
low affinity TCRs to self antigens.  Direct biophysical measurements show that TCRs 
specific for tumour antigens bind to their cognate pMHC with affinities that lie 
approximately one order of magnititude below corresponding affinities of TCRs 
specific for non-self antigens (Aleksic et al., 2012).  The low affinity of anti-cancer 
TCRs is thought to impair the ability of T cells to mount a full response to tumour cells.  
 
Tolerance to self-antigens impedes an effective immune response against tumours.  
Even so, it has been shown that T cells do in fact home to tumour sites, at least in some 
patients.  Tumour infiltrating lymphocytes (TILs) have been observed in patients with 
melanoma (Elder, 1999; Lyle et al., 2000) , colon cancer (Prall et al., 2004) and ovarian 
cancer (L. Zhang et al., 2003), amongst others, and these studies suggest the presence of 
TILs correlate with more positive clinical prognosis.  However, even when an immune 
response is mounted, tumours can evolve active mechanisms to avoid detection and 
destruction by the immune system.  In a process described as ‘cancer immuno-editing’, 
the immune system can promote the growth of tumour cells by selecting for tumour 
escape variants with reduced immunogenicity (Dunn et al., 2004).  Commonly, immune 
escape mechanisms involve the loss of tumour-associated antigens or down-regulated 
MHC antigen expression, described in more detail in section 1.2.3.  However, tumours 
can evade T cell responses by a plethora of complex mechanisms which can lead to an 
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immunosuppressive tumour microenvironment (reviewed in (Rabinovich et al., 2007)); 
some of these mechanisms are described below.   
Tumours can upregulate suppressive ligands such as PD-LI or PD-L2 that 
engage PD-1 on the surface of activated T cells, causing T cell anergy or exhaustion 
(Hamanishi et al., 2007).  The release immunosuppressive molecules by tumours such 
as indoleamine 2,3-dioxygenase (IDO), limits T cell function by depleting the amino 
acid tryptophan (Mellor & Munn, 2004; Munn & Mellor, 2004).  Dendritic cells (DCs) 
are the most efficient APCs and an effective anti-tumour response depends on the 
presentation of tumour antigens by DCs; to inhibit this, tumour cells can secrete agents 
which affect the differentiation and function of DCs.  For example, tumour cells can 
produce large amounts of the angiogenic factor vascular endothelial growth factor 
(VEGF) which has been shown to suppress the differentiation and maturation of 
dendritic cells (Gabrilovich et al., 1996).  Expression by tumours or non-tumour stromal 
cells of the immunoregulatory cytokines TGF-β and IL-10 also exert suppressive effects 
on the immune system (Rabinovich et al., 2007).  Transforming growth factor-β (TGF-
β) is a pleiotrophic immunosuppressive cytokine that inhibits T cell function (M. O. Li 
et al., 2006).  Indeed, elevated levels of TGF-β levels have been shown to be associated 
with poor prognosis in a number of different cancers (reviewed in (Drake et al., 2006)).  
Furthermore, it has been demonstrated that TGF-β acts on CTLs to suppress their 
cytolytic activity by repressing the expression of perforin, granzyme B, Fas ligand 
(FasL) and IFN-γ (Thomas & Massague, 2005).  IL-10 has been shown to impair DC 
functionality (Gerlini et al., 2004) and to protect tumour cells from CTL-mediated 
cytotoxicity by down-regulating TAP1 and TAP2 (Kurte et al., 2004). 
Regulatory T cells (Tregs) are a specialised subset of CD4
+
 T cells that can 
suppress immune responses.  They play an important role in preventing autoimmunity 
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but can also hamper a robust effector T cell response against tumours through multiple 
mechanisms, including expression of CTLA-4.  Furthermore, the infiltration of Tregs 
has been shown to correlate with poor prognosis in a number of tumour types (Curiel et 
al., 2004; Kono et al., 2006).  In addition to Tregs, other cell types can promote immune 
suppression in tumours.  Myeloid-derived suppressor cells (MDSCs), a heterogeneous 
population that includes direct progenitors of DCs, macrophages and granulocytes, can 
also be recruited into the tumour site and have been shown to inhibit tumour-specific T 
cell responses by a variety of mechanisms, including nitric oxide, reactive oxidative 
species and arginase (reviewed in (Gabrilovich et al., 2012)).  Finally, tumour stroma 
cells, which comprise non-malignant host cells and extracellular matrix, exert tumour-
promoting and immunosuppressive effects.  For example, mesenchymal stem cells 
block proliferation and function of effector T cells (Aggarwal & Pittenger, 2005). 
 
1.6 Targeted immunotherapy 
Recent advances in our understanding of how tolerance, immunity and 
immunosuppression regulate anti-tumour immune responses have led to the 
development of more targeted cancer immunotherapeutics that are beginning to show 
durable therapeutic benefit in the treatment of cancer.  To date, the most significant 
development in cancer immunotherapy was the readout of the ipilimumab phase III 
trials in late-stage metastatic melanoma in which a clear survival benefit was observed.  
Furthermore, the survival benefit was still durable after 2.5 years and included a 
complete response in some patients (Hodi et al., 2010).  Ipilimumab, a monoclonal 
antibody specific to CTLA-4, blocks an important inhibitory signal for activated T cells 
allowing enhanced T cell stimulation and a more potent anti-tumour response.  In 
March 2011 ipilimumab was approved by the US Food and Drug Administration (FDA) 
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for the treatment of unresectable or metastatic melanoma.  The clinical results with 
ipilimumab highlight the anti-tumour potential of endogenous T cell responses and 
therefore support the concept of immune-based therapies as a pathway to achieving 
durable and long-lasting responses in cancer patients. 
 
1.6.1 Cancer T cell vaccines 
There are two kinds of cancer vaccine; prophylactic and therapeutic (Palucka et al., 
2010).  Prophylactic (preventive) vaccines are used for the prevention of cancers of 
viral origin, such as human papillomavirus (HPV) which is associated with cervical 
cancer, and have proved to be very successful (Medeiros et al., 2009) (Munoz et al., 
2010).  However, in contrast, the development of therapeutic vaccines to treat existing 
disease has posed a considerable challenge even in patients with minimal residual 
disease where the goal has been to prevent relapse rather than induce the host to 
eliminate a solid tumour (Okur & Brenner, 2010). 
Therapeutic cancer vaccines developed from the discovery that patients can 
harbour T cells specific for tumour-associated antigens expressed on their tumours 
(Boon et al., 2006).  The principal objective of cancer vaccination is to amplify the 
frequency and strength of these pre-existing anti-tumour T cell responses.  Early 
attempts at vaccination met with limited success due to the failure to identify suitable 
target antigens to mitigate the immunosuppressive tumour microenvironment and 
generate an effective immune response.  However, advances in our understanding of the 
immune system and in particular that of tumour immunity has led to more sophisticated 
vaccine strategies which are beginning to show more promise.  Various cancer 
vaccination strategies have been investigated including the use of whole-tumour cells or 
lysates, dendritic cells, peptide-based approaches, recombinant proteins, and viral and 
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DNA delivery vectors.  The first therapeutic cancer vaccine to be approved by the FDA 
was Sipuleucel-T (Trade name: Provenge) in April 2010 for the treatment of metastatic 
hormone-refractory prostate cancer.  Sipuleucel-T comprises a complex mixture of 
autologous peripheral blood mononuclear cells including antigen-presenting cells 
(APCs) that have been activated in ex vivo with a recombinant protein composed of 
prostatic acid phosphatase (PAP, a tumour-associated differentiation antigen) and the 
cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).  In phase III 
clinical trials, Sipuleucel-T was found to improve median survival of patients by 4.1 
months which was deemed significant even though there was little evidence of actual 
tumour shrinkage or delay in disease progression (Mellman et al., 2011; Pandolfi et al., 
2011). 
Despite the huge number of patients that have been treated with cancer vaccines, 
the overall objective response rate remains low.  For example, in 2004, 541 different 
cancer vaccines had been tested in a total population of 440 patients with metastatic 
melanoma at the National Cancer Institute (NCI), Bethesda; the overall objective 
response rate was found to be 2.6% and this is consistent with many other such trials 
(Rosenberg et al., 2004).  Although there have been some promising developments, 
cancer vaccines are still failing to successfully conquer the barriers of immune tolerance 
and immune suppression, and more effective strategies are needed. 
 
1.6.2 Adoptive T cell therapy 
Adoptive cellular therapy (ACT) presents a promising approach to breaking down the 
barriers of immune tolerance that has hampered conventional vaccination strategies.  
ACT involves the administration of autologous or allogeneic T cells which have been 
manipulated and expanded ex vivo to exhibit high specificity for TAA (Rosenberg et al., 
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2008).  The major break-through for this technology occurred in 1988 with the 
treatment of patients with metastatic melanoma with autologous tumour-infiltrating 
lymphocytes (TILs) following host lymphodepletion (Dudley et al., 2005; Rosenberg et 
al., 1988).  However, despite cases of successful treatment of malignant melanoma, the 
approach did not translate so well for other cancers where TILs could not be easily 
identified and expanded (R. A. Morgan et al., 2006).  In addition, TILs often became 
tolerant to TAA and are difficult to re-activate into an effective state.  Genetically 
engineering antigen-specifically into T cells offers a powerful way to combat tolerance 
and can be achieved in a number of ways, as outlined in the following. 
 
1.6.2.1 TCR gene transfer 
TCRαβ chains derived from a T cell with a high affinity for a defined MHC-restricted 
TAA, or a TCR which has been genetically engineered for high affinity for a particular 
TAA, are transduced into a new T cell using an integrating vector.  A T cell is created 
that possesses both the endogenous (natural) and exogenous (introduced) TAA-specific 
TCR (Rosenberg et al., 2008).  Clinical trials using TCR gene transfer against various 
tumours expressing distinct TAAs have been carried out and have shown encouraging 
signs of efficacy.  For example, in a recent clinical trial using T cells engrafted with a 
NY-ESO-1-specific TCR against NY-ESO-1 expressing cancers, metastatic melanoma 
and synovial cell sarcoma, five of 11 melanoma and four of six synovial cell sarcoma 
patients showed objective clinical responses.  Two of 11 melanoma patients showed 
complete tumour regression which persisted after one year (Robbins et al., 2011). 
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1.6.2.2 Chimeric antigen receptors (CARs) 
CARs combine the antigen-binding domains from the variable regions of a TAA-
specific monoclonal antibody (scFv) linked to the signalling domain of the T cell 
receptor-ζ (TCR-ζ) and are capable of triggering T cell activation in much the same way 
as that of the endogenous TCR (Eshhar et al., 1993; Irving & Weiss, 1991).  The main 
advantage CARs have over TCR gene therapy is that they are not MHC-restricted and 
do not need to be HLA-matched to the patient.  This also means that an anti-tumour 
response can be generated even when MHC molecules have been down-regulated (Okur 
& Brenner, 2010).  First generation CARs, T cells showed limited efficacy in the clinic 
due to poor in vivo persistence (Kershaw et al., 2006; Park et al., 2007).  However, 
successive generations of CARs have incorporated additional signalling domains such 
as CD28 to harness both TCR activation and costimulation mechanisms (Finney et al., 
1998; Friedmann-Morvinski et al., 2005; Maher et al., 2002).  To improve persistence, 
the introduction of 4-1BB (CD137) domains has been shown to enhance CAR-
transduced T cell survival and function by inducing production of the anti-apoptotic 
protein Bcl-x (Zhao et al., 2009).  The therapeutic potential of CARs has recently been 
demonstrated in the clinic when three patients with chronic lymphocytic leukaemia 
treated with CD19/4-1BB/CD3ζ CAR T cells exhibited strong anti-tumour responses.  
Two of the three patients went into complete remission and the CAR+ T cells showed 
encouraging levels of in vivo expansion and persistence (Kalos et al., 2011). 
 
1.6.3 Bispecific T cell Activators 
Bispecifics are a class of antibodies which are being developed to harness the most 
potent effector cells of the immune system i.e., cytotoxic T lymphocytes (CTLs), for the 
elimination of tumour cells.  The recruitment of T cells is the major advantage 
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bispecific antibodies have over conventional monoclonal antibodies which cannot 
engage T cells.  Bispecific antibodies are constructed using cell-fusion or recombinant 
DNA technology to possess dual non-identical binding arms.  One arm binds the 
monomorphic CD3 complex expressed on the surface of T cells.  CD3 is a potent signal 
transducer associated with the polymorphic TCR.  Thus, engagement of CD3 by 
bispecific antibodies can trigger TCR signalling regardless of the clonotypic antigen 
specificity of the T cell.  The second arm binds to a tumour-associated antigen on the 
target cell.  Bispecific antibodies bind to the tumour thereby decorating it with a matrix 
of binding sites for T cells.  A passing T cell can then engage with the tumour cell via 
the bispecific antibody and become activated to kill the bound partner.  A variety of 
bispecific antibody formats for recruiting T cells have been developed including 
diabodies, tandem diabodies, quadroma, F(ab)2 and single-chain antibody (scFv)-based 
constructs (reviewed in (Carter, 2001; Kufer et al., 2004; von Mehren et al., 2003)).  
However, most bispecific antibodies are not very efficient at triggering T cell redirected 
killing against target cells and typically require additional costimulation with anti-CD28 
or pre-stimulation of the T cells as well as a high effector to target (E:T) ratio.  There 
have also been issues with Fc-mediated effects and immunogenicity resulting in severe 
adverse effects such as cytokine release syndrome.  To date, the only approved 
bispecific antibody is catumaxomab (Removab), developed by Fresenius Biotech, which 
targets CD3 and EpCAM (epithelial cell adhesion molecule), a pan-epithelial 
differentiation antigen expressed on nearly all carcinomas.  Catumaxomab is also 
termed trispecific because the mode of manufacture ensures that the antibodies retain 
their natural Fc effector function thus providing a third binding site for cells with an Fc 
receptor.  It is used for the intraperitoneal treatment of malignant ascites (a common 
manifestation of advanced cancer) in patients with EpCAM-positive carcinomas 
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(Sebastian et al., 2009).  Recently though, one particular format of bispecific antibody 
has attracted special attention.  These molecules are called BiTE (bispecific T-cell 
engager) antibodies. 
BiTE antibodies, developed by Micromet Inc., represent a new class of 
bispecific T cell activator antibodies that have overcome many of the previous 
limitations.  BiTE antibodies are recombinant protein constructs composed of two 
binding domains (variable heavy (VH) and variable light (VL) chain domains) of two 
different human IgG antibodies flexibly linked by a short non-immunogenic peptide.  
The two single-chain Fvs are arranged in tandem on a single non-glycosylated 
polypeptide chain of approximately 55 kDa molecular weight.  One scFv is specific for 
a tumour-associated surface antigen on target cells and the second scFv is specific for 
CD3, present on all mature T cells.  The small size and short flexible linker of BiTEs 
facilitate close proximity between T cell and target cell membranes when both cell 
populations are bound to the respective binding arm.  By binding to CD3, BiTE 
antibodies are able to recruit T cells regardless of their TCR specificity and typically 
recruit CD8
+
 cytotoxic T cells of the memory phenotype rather than naïve T cells, 
resulting in a polyclonal T cell response.  The main advantage BiTE antibodies have 
over other bispecific antibodies is that they do not require a costimulatory signal by 
CD28 or engagement by CD4 or CD8 coreceptor to induce T cell activation.  This 
feature might be explained by the ability of BiTE antibodies to induce an 
immunological cytolytic synapse between target cell and cytotoxic T cell which has 
been shown to bear all the hallmarks of the synapse induced by the interaction of 
specific TCR and pMHC.  The transient nature of the interaction also permits serial 
killing of many targets by single cytotoxic T cells which results in the lysis of targets at 
low E:T ratios (Baeuerle et al., 2003).     
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In vitro, BiTE antibodies have been demonstrated to potently mediate redirected 
tumour cell killing in culture assays at half maximal concentrations (EC50 values) in the 
low pg/ml range.  Furthermore, their potency far exceeds that of some conventional 
mAb therapies (Dreier et al., 2002).  In vivo, anti-tumour effects were shown in 
xenograft and syngeneic mouse models, and in a non-human primate model.  There are 
several BiTE antibodies currently in clinical trials, the furthest developed of these is 
blinatumomab which targets CD19 on lymphoma and leukemia cells and CD3 on T 
cells.  In a Phase I clinical study in patients with relapsed B cell non-Hodgkin’s 
lymphoma (NHL), treatment with blinatumomab resulted in a 100% response rate with 
2 complete and 5 partial responses; furthermore efficacy was seen at very low dose 
levels (Bargou et al., 2008).  In a Phase II trial in patients positive for minimal residual 
disease of acute B-cell lymphoblastic leukemia (B-ALL) following conventional 
treatment, blinatumomab induced a complete response in 80% of patients (16 out of 20) 
(Topp et al.).  However, CD19 is not a tumour-specific antigen but is also present on 
normal B cells.  Therefore, adverse events (AEs) of varying severity have been 
observed with blinatumomab (Nagorsen & Baeuerle, 2011).  Furthermore, 
unexpectedly, in some patients symptoms related to the central nervous system were 
also observed. 
 
1.6.4 TCR-directed therapeutics 
1.6.4.1 The T cell receptor (TCR) as a targeting molecule 
The main advantage of using TCRs as a targeting molecule is that they can target 
intracellular antigens, which are presented on the cell surface as peptides in the context 
of MHC molecules, whereas mAbs cannot.  Notwithstanding the extremely broad range 
of uses for which they can be applied, mAb are limited to cell-surface TAA, which 
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represent only a small fraction of the total antigen repertoire.  For the treatment of 
cancer, this is a significant limitation because secreted or cell surface-bound proteins 
represent a relatively small proportion, probably 10-15%, of malignant state-associated 
antigens.  However, the potential applicability of a TCR-directed therapeutic is 
governed by the prevalence of both the presenting MHC allele and of the antigen from 
which the peptide antigen is derived.  Although HLA type limits the proportion of 
patients that could potentially benefit from TCR-mediated cancer therapies, the 
availability of a large choice of intracellular antigens compared to other cell surface 
antigens means that pMHC antigens can offer better patient coverage than some 
antibodies.  For example, Her2-neu as an antibody target in breast cancer is present in 
approximately 22% of the population (Nagai et al., 1993; Slamon et al., 1987), whereas 
an intracellular antigen such as gp100 is expressed in up to 95% of malignant 
melanomas (Barrow et al., 2006; Hofbauer et al., 2004; Mocellin et al., 2001; Spagnoli 
et al., 1995; Wagner et al., 1997).  Given that the prevalence of HLA-A2 is 
approximately 50% in European and North American populations, a TCR specific for 
gp100 presented by HLA-A2 would therefore give approximately 47% coverage of that 
patient population. 
 
1.6.4.2 Soluble TCRs 
Unlike antibodies, TCRs do not exist naturally in a soluble form.  Naturally occurring 
αβ TCRs are disulphide-linked heterodimers, with each chain comprising the N-
terminal variable domain and the constant domain, followed by a transmembrane region 
and a short C-terminal intracellular signal-transducing tail.  In order to engineer a 
soluble form of monoclonal TCR, a truncated version was designed whereby the native 
disulphide bond was removed and a new interchain disulphide link was introduced 
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between TRAC threonine 48 and TRBC serine 57, which were mutated to cysteines, to 
produce a highly stable TCR framework (Boulter et al., 2003) (Figure 1-4).  This 
resulted in the generation of a highly stable, fully human soluble protein, designated as 
monoclonal TCR (mTCR). 
 
1.6.4.3 High affinity TCRs 
The wild-type affinities (KDs) of TCRs for their pMHC are between 1 – 100 μM (M. M. 
Davis et al., 1998), with binding half-lives of only a few seconds.  The low affinity of 
native TCRs, a result of selection processes in the thymus, means that a monovalent 
soluble TCR would not be able to bind its target with sufficient affinity to be of 
therapeutic benefit.  However, it has been demonstrated that no inherent genetic or 
structural limitations exist on TCR affinity (Holler et al., 2000).  Utilising phage display 
technology, native TCR affinity has been improved almost a million-fold to produce 
TCRs with affinities in the picomolar range, similar to that of antibodies (Y. Li et al., 
2005).  The process of mTCR affinity maturation using phage display involves PCR 
mutagenesis to introduce variability into the targeted CDR regions of the α- and β-
chains of the TCR.  The CDR mutant libraries are then expressed on phage and panned 
against the specific peptide-MHC.  At this stage, the affinity typically increases from 
micromolar to nanomolar.  Creation of second generation phage TCR libraries, and 
repeated selections against decreasing concentrations of antigen, result in the isolation 
of TCRs with further incremental improvements in affinity.  Optimum affinity mutants 
are made by combining mutations in several CDRs and making soluble mTCRs through 
Escherichia coli expression and in vitro refolding.  The affinities of the resultant 
mTCRs are measured using surface plasmon resonance microchip-based detectors 
(BIAcore™); by this stage the TCRs are typically in the picomolar affinity range.   
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Figure 1-4 The monoclonal TCR (mTCR) 
 
(a) Natural αβ TCRs (left) are disulphide-linked heterodimers, each chain comprising 
the N-terminal variable domain and the constant domain, followed by a transmembrane 
region and a short C-terminal intracellular signal-transducing tail.  In the mTCR (right), 
the chains are truncated and the native interchain disulphide bond replaced by an 
engineered disulphide bond.  Based on molecular modelling studies, an optimal site was 
selected that links the two constant domains producing highly stable and fully human 
soluble TCR molecules.  (b) Crystal structure-based model of 1G4 mTCR bound to NY-
ESO peptide-MHC.  The ligand consists of MHC class I heavy chain (green) with the 
9aa-long antigenic peptide (grey tube) buried within the groove formed between the two 
helices of the apical α3 domain and the non-covalently associated invariant β2m 
(yellow).  The mTCR, a heterodimer of an α-chain (red) and a β-chain (blue), contacts 
the antigenic surface through its CDRs (highlighted by light cyan and light magenta 
colours).  The centrally positioned CDR3 loops of both chains predominantly contact 
the peptide, while the CDR1 and CDR2 loops (appearing furthest from the groove) 
contribute mostly to the contacts with the relatively conserved HLA α3 domain.  The 
locations of the N- and C-termini of both TCR chains (encircled), can potentially serve 
as fusion points for the attachment of effector function moieties. 
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Phage display is highly efficient as it can be used to screen libraries of up to 10
10
 
variants and the technology can be applied to any mTCR.  Notably, crystal structures of 
high affinity human TCRs bound to pMHC have shown that the docking mode of 
enhanced affinity TCRs is identical to that of the parental wild-type TCR, and they 
exhibit only slight structural alterations in the mutated complementarity determining 
regions (CDRs) (Sami et al., 2007) (Figure 1-5) . 
Fluorescently labelled high affinity mTCRs for TAPAs have permitted the 
detection of single antigens on tumour cell lines and shown that, as monovalent 
molecules, they do not cross-react to any detectable extent with self-pMHC (Purbhoo et 
al., 2006).   
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Figure 1-5 Structural alterations in CDR3α and CDR3β loops between wild-type 
and affinity enhanced mTCR. 
 
CDR3 loops shown as sticks.  Wildtype 1G4 TCR specific for NY-ESO-1157-165 peptide, 
binding T1/2 = 7 seconds (red), and affinity enhanced 1G4 TCR, binding T1/2 = 19 hours 
(blue), on top of NY-ESO peptide van der Waals surface (light blue) (Sami et al., 2007). 
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1.6.4.4 Immune-mobilising monoclonal TCRs against cancer (ImmTAC) 
Although high affinity mTCRs offer potential as diagnostic tools (Purbhoo et al., 2007; 
Purbhoo et al., 2006), to be of therapeutic use they require an effector function which 
can enable the potent killing of target cells.  BiTEs have successfully demonstrated the 
potent cytotoxic potential of the T cell-activating anti-CD3 scFv antibody.  
Conceptually similar, ImmTACs which are approximately 77 kDa molecular weight, 
comprise a humanised CD3-specific scFv fused to the high affinity mTCR β chain by a 
flexible linker; the mTCR part of the fusion binds to an antigenic peptide-MHC on the 
target cell whilst the other end of the molecule, by binding the ε-chain of the CD3 
glycoprotein, is capable of activating any CD8
+
 CTL, regardless of its intrinsic TCR 
specificity (Figure 1-6).  As is the case for BiTE antibodies, T cell activation induced by 
ImmTAC molecules does not require a costimulatory signal by CD28 or, CD4 or CD8 
coreceptors.  Also, the recruited T cells are mostly effector memory or central memory 
T cells that have encountered antigen previously, rather than naïve T cells.  
Mechanistically, the main difference between the two reagents is that BiTEs target 
thousands of antigens per cell whereas ImmTACs will, in most cases, be targeting only 
a few tens of the cognate HLA-peptide complex.  Therefore, ImmTACs have to be 
highly efficient at initiating optimal contacts for the formation of an immunological 
synapse. 
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Figure 1-6 Redirection of T cells against cancer with ImmTAC. 
 
(a) ImmTAC molecules comprise a picomolar affinity mTCR, specific for a selected 
cancer-related peptide-MHC, and an anti-CD3 scFv.  (b) The mTCR component 
engages strongly to its ligand on a cancer cell, while the anti-CD3 scFv component 
activates a proximal T cell, independently of its native specificity.  This results in the 
redirected killing of the bound cancer cell. 
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1.7 Aims of this thesis 
ImmTACs are novel bispecific agents intended for targeted cancer therapy.  These 
molecules have been designed to overcome the limitations of natural TCR-mediated 
recognition and redirect T cells of the host immune system to kill tumours expressing 
even very low epitope numbers on their cell surfaces.  ImmTACs comprise a soluble 
TCR with an enhanced affinity for tumour associated pMHC class I fused to a 
humanised anti-CD3 scFv, thereby combining enhanced epitope targeting with potent T 
cell activation. 
The four ImmTAC reagents investigated in this study comprise a high affinity 
mTCR specific for the following tumour-associated epitopes: (1) gp100280-288, 
YLEPGPVTA-HLA-A*0201 (Cox et al., 1994); (2) MAGE-A3168-176, EVDPIGHLY-
HLA-A*0101 (Celis et al., 1994); (3) Melan-A/MART-126-35, EAAGIGILTV-HLA-
A0201 (Kawakami, Eliyahu, Sakaguchi et al., 1994); (4) NY-ESO-1157-165, 
SLLMWITQC-HLA-A*0201 (Jager et al., 1998). 
 
The first objective of this study was to investigate the potency, antigen sensitivity, and 
specificity of the ImmTAC reagents in in vitro cellular assays and assess their suitability 
for, and potential as, clinical immunotherapies for cancer. Secondly, a further aim was 
to employ in vitro T cell assays to define a safe clinical starting dose, and maximum 
dose, for the selected first-in-human ImmTAC, which targets the metastatic melanoma 
epitope gp100280-288 presented by HLA-A*0201. 
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CHAPTER 2 MATERIALS AND METHODS 
 
2.1 TCR-based reagents 
TCR isolation and engineering to produce soluble mTCR, mTCR-anti-CD3 scFv and 
ImmTAC fusions has been described previously (Y. Li et al., 2005; Liddy et al., 2012).  
Briefly, TCR genes were isolated from T cell clones by PCR, then modified by deletion 
of the gene segments encoding the transmembrane and cytoplasmic domains and by a 
single mutation to introduce a cysteine residue in each of the constant domains of the  
and  chains. For production of mTCR protein, the modified  and  chain genes were 
expressed separately in E.coli and harvested from the bacteria in the form of inclusion 
bodies.  The protein chains were denatured in buffer containing guanidine, then refolded 
by dilution into buffer enabling the native conformation.  Refolded TCR was purified 
using anion exchange and size exclusion chromatography.  Finally, the TCR reagents 
were formulated in phosphate buffered saline, typically at a concentration of 1 mg/ml. 
 High affinity TCR variants were identified from TCR phage display libraries. 
The TCR  chain was fused to gene III, whereas the  chain was expressed in soluble 
form; this enabled the formation on the surface of phage particles of TCR proteins 
corresponding to the extracellular part of the receptor. Libraries with extensive 
mutations in each CDR region were generated by directed PCR mutagenesis; several 
individual phage libraries were generated for each CDR.  Mutants with increased 
affinity were isolated by, typically, three rounds of panning with the cognate pHLA 
complex and the affinity effects of individual and combined sets of mutations were 
assessed by producing, as described above, soluble mTCR proteins for which the 
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affinities for pHLA were determined by BIAcore™ surface plasmon resonance binding 
analysis to immobilised pHLA complexes. 
 
2.2 General Cell Culture 
Tissue culture reagents were purchased from Life technologies™ Corporation, and 
Corning Costar® Tissue culture plasticware was used, except where otherwise 
indicated. 
 
2.2.1 Human cell lines  
A list of cell lines used in this study is presented in Table 2-1.  HLA genotype and/or 
phenotype and expression of various cancer-associated antigens were confirmed by 
DNA sequencing, RT-PCR, and antibody staining, either by co-workers in-house or by 
external collaborators. 
 
2.2.2 Human primary cells 
2.2.2.1 Primary cells grown in culture 
A list of the normal human primary cells used in this study is presented in Table 2-2.  
Primary cells were grown in custom made tissue culture media purchased from the 
supplier and cultured as per the manufacturer’s instructions.   
2.2.2.2 Primary tumour tissue 
Primary tumour tissue from a lung cancer patient (NSCLC#29) was kindly provided by 
Dr. Michael Kalos, University of Pennsylvania.  The tumour biopsy was supplied as a 
frozen aliquot which had been processed to obtain single-cell suspension.  For use in 
cellular assays, the vial was thawed and the cells used immediately. 
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Table 2-1 Cell lines; cell type and source 
Cell lines Cell type Source 
A375 Human melanoma 
American Type Culture 
Collection (ATCC) 
Colo205 
Human colorectal 
adenocarcinoma 
American Type Culture 
Collection (ATCC) 
EJM Human multiple myeloma 
Deutsche Sammlung von 
Mikroorganismen und 
Zellkulturen (DSMZ) 
HCT116 
Human colorectal 
carcinoma 
American Type Culture 
Collection (ATCC) 
IM9 
Human EBV-transformed 
B cell line 
American Type Culture 
Collection (ATCC) 
Mel526 Human melanoma Thymed 
Mel624 Human melanoma Thymed 
SK-Mel-37 Human melanoma 
Ludwig Institute for Cancer 
Research (LICR) 
T2 
Human hybrid B and T cell 
lymphoblast 
American Type Culture 
Collection (ATCC) 
U266 Human multiple myeloma 
American Type Culture 
Collection (ATCC) 
 
Table 2-2 Primary cell grown in culture; cell type and source 
Primary cell lot number Cell type Source 
CM12 Cardiac myocyte ScienCell 
HA2 Astrocyte ScienCell 
HEP2 Hepatocyte ScienCell 
NHEM10 Epithelial melanocyte PromoCell 
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2.2.2.3 Frozen peripheral blood mononuclear cells (PBMC) derived from multiple 
myeloma patients 
PBMC derived from multiple myeloma patients were purchased from AllCells as frozen 
aliquots, and were thawed and used on the day of the assay. 
 
2.2.3 Tissue culture media 
Cell lines were grown at 37°C with 5% CO2, in RPMI 1640 (with phenol red) medium 
supplemented with 10% heat-inactivated foetal bovine serum (HI FBS) (Sera 
Laboratories International), 2 mM L-glutamine, 50 U/ml penicillin and 50 μg/ml 
streptomycin (R10 medium).  Cell lines were regularly screened for mycoplasma 
infection, carried out by Mycoplasma Experience Ltd, UK. 
 
2.2.4 Thawing cell lines 
Vials of cryopreserved cells were removed from liquid nitrogen storage and thawed in 
37°C water bath while being constantly agitated.  Immediately upon thawing cells were 
transferred into a 15 ml centrifuge tube containing 10 ml pre-warmed R10 medium.  
Cells were centrifuged at 300 g for 5 mins and the supernatant discarded.  The cell 
pellet was resuspended in 15 ml R10 media and transferred to a T75 flask. 
 
2.2.5 Maintenance and sub-culturing of cell lines 
Every 2 to 3 days, cells were split and a portion thereof seeded into fresh media.  Care 
was taken to ensure the cells did not exceed 80-90 % confluency and/or turned the 
media yellow, indicating a decrease in pH level due to the build up of waste products.  
For adherent cell lines, the whole content of the tissue culture flask was transferred into 
a 50 ml centrifuge tube and the flask rinsed with PBS to remove all remains of the 
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media.  Three ml trypsin-0.25% EDTA was added to detach the cells from the inner 
surface of the flask.  The flask was then incubated at 37°C for 2-4 mins and then rinsed 
with an equal volume of R10 media to inhibit further trypsinisation.  The bulk cell 
suspension was transferred to the 50 ml centrifuge tube and the flask was then rinsed 
with 10 ml PBS to maximise the number of cells harvested and added to the tube.  The 
tube was then centrifuged at 300 x g for 5 mins and resuspended in R10 medium for 
counting.  Cells were plated into a new flask at the recommended seeding density 
(between 5,000 and 10,000 cells per cm
2
).  For suspension cultures, cells were 
resuspended thoroughly and counted if required.  Cells were then split into fresh R10 
medium in a new flask. 
 
2.2.6 Counting cells 
Cells were thoroughly resuspended, 25 μl of cell suspension was removed and mixed 
with equal volume of trypan blue 0.4% solution (Sigma-Aldrich) in a single well of a 
96-well round bottomed plate.  Twenty μl was loaded onto a disposable counting 
chamber (Nexcelom Bioscience) and inserted into an automated cell counting machine 
(Cellometer™ Auto T4, Nexcelom Bioscience).  The machine automatically calculated 
the cell concentration and the percentage viability, based on trypan blue exclusion. 
 
2.2.7 Cryopreservation of cells 
Cells were centrifuged at 300 x g for 5 mins to remove culture media, and resuspended 
in freezing mix (90% HI FBS, 10% DMSO (Sigma-Aldrich)).  One ml aliquots were 
frozen down in internal thread cryovials (Nunc) at -70°C using a Mr. Frosty® freezing 
container (Nalgene).  Typically, each aliquot contained 2-5 x 10
6
 cells.  Once frozen, 
the cells were stored short- or long-term in liquid nitrogen at -196°C. 
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2.3 Donor blood samples 
2.3.1 Fresh donors 
Fresh blood from healthy donors was obtained in-house (donor code with prefix FB) 
and from the National Blood Service (NBS, Bristol) as buffy coats (donor code with 
prefix Buf).  Fresh blood from melanoma patients (donor code with prefix IC) was 
obtained from Dr. Neil Steven, University of Birmingham.  Donors were HLA typed by 
single strand conformational polymorphism (Tissue Typing Laboratory, Churchill 
Hospital, Oxford).  Peripheral vein blood was collected into 50 ml centrifuge tubes 
containing 20 μl of 2000 U/ml of the anti-coagulant heparin (Sigma-Aldrich).   
 
2.3.2 Isolation of peripheral blood mononuclear cells (PBMC) 
PBMC were isolated by Lymphoprep™ (Axis shield PoC, Norway) density gradient 
centrifugation.  Peripheral blood was diluted at a ratio of 1.4:1 with Ca
2+
 and Mg
2+
 free 
Hanks Buffered Saline Solution (HBSS).  To a 50 ml conical leucosep® tube (Greiner 
Bio-One) containing 15 ml Lymphoprep™, which had been centrifuged at 800 x g for 1 
minute to force the Lymphoprep™ below the porous membrane, 35 ml of the diluted 
blood was carefully poured onto the top of the porous membrane.  After checking that 
the caps of the tubes were properly secured, the tubes were centrifuged at 800 x g for 15 
minutes (Sorvall Legend T™) at room temperature in a swinging bucket rotor with the 
brake off.  A 10 ml serological pipette was used to remove as much of the plasma layer 
as possible without disturbing the cloudy white band of cells at the interface, and 
discarded.  The interface layer, which contained the mononuclear cells, was drawn off 
using a 5 ml serological pipette and transferred to a fresh 50 ml centrifuge tube for 
washing.  The tube was topped up to 50 ml with HBSS medium and centrifuged at 350 
x g for 8 minutes (brake set to maximum).  The supernatant was discarded and two 
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further washes were performed at 200 x g for 10 minutes to remove platelets.  After the 
final wash, PBMC were either frozen down in 1 ml aliquots of between 5 x 10
6
 and 2 x 
10
7
 PBMC following the procedure described in section 2.2.7, or resuspended in R10 
medium and kept in the incubator at 37°C/5% CO2 for further processing.   
 
2.3.3 Isolation of mononuclear cells from bone marrow aspirates of multiple 
myeloma patients 
Fresh bone marrow aspirates from multiple myeloma patients were obtained from Dr. 
Chris Hatton, Churchill Hospital, Oxford.  Typically ~10 ml of bone marrow aspirate 
diluted in R10 medium was received.  The sample was passed through a 30 μm filter 
(Miltenyi Biotech) to remove bone fragments.  The filtered bone marrow aspirate 
sample was then gently layered onto an equal volume of Lymphoprep™ in a 50 ml 
centrifuge tube and centrifuged at 445 x g for 35 minutes at room temperature in a 
swinging bucket rotor without application of the brake.  The bone marrow mononuclear 
cells (BM MNC) at the interface were carefully removed and transferred to a new 50 ml 
centrifuge tube for washing.  The tube was topped up to 40 ml with buffer (Ca
2+
 and 
Mg
2+
 free PBS, 2 mM EDTA (Sigma-Aldrich)) and centrifuged at 300 x g for 10 
minutes at room temperature with the brake set to maximum.  The supernatant was then 
discarded and a final wash was performed at 200 x g for 10 minutes to remove platelets.  
After the final wash, BM MNC were either frozen down in 1 ml aliquots of between 2 x 
10
6
 to 2 x 10
7
 BM MNC following the procedure described in section 2.2.7 or 
resuspended in R10 medium and kept in the incubator at 37°C/5% CO2 for further 
processing as described in section 2.3.6). 
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2.3.4 Isolation of CD8
+
 or CD4
+
 T cells from PBMC 
CD8
+
 T cells were isolated from PBMC by depletion of non-CD8 T cells using 
Dynabeads® Untouched™ human CD8 T cell kit as per manufacturer’s instructions.  
Fresh PBMC were centrifuged at 300 x g for 10 minutes and the pellet resuspended in 
500 μl Isolation Buffer (Ca2+ and Mg2+ free PBS, 2% HI FBS, 2 mM EDTA) per 5 x 107 
PBMC.  Added 100 μl heat-inactivated FBS and 100 μl Antibody Mix per 5 x 107 
PBMC and mixed thoroughly.  The Antibody Mix contained biotinylated mouse IgG 
antibodies for CD4, CD14, CD16 (specific for CD16a and CD16b), CD19, CD36, 
CD56, CDw123 and CD325 (Glycophorin A).  The CD8
-
 T cells were labelled for 20 
mins at 4°C.  The cells were washed by adding 10 ml Isolation Buffer per 5 x 10
7 
PBMC, inverting the tube several times to mix, and centrifuged at 350 x g for 8 mins.  
The cell pellet was resuspended in 500 μl Isolation Buffer per 5 x 107 PBMC and 500 μl 
pre-washed Dynabeads®, which are streptavidin coated superparamagnetic polystyrene 
beads of 1 μm diameter, were added.  Gentle tilting and rotation for 15 minutes at room 
temperature enabled stable binding between the Dynabeads® and the antibody-labelled 
cells to occur.  The bead-bound cells were then vigorously resuspended using a 1 ml 
pipette tip and 5 ml Isolation Buffer per 5 x 10
7 
PBMC was added.  The tube was placed 
in the magnet for 2 minutes where the bead-bound CD8
-
 T cells were separated to the 
side of the tube due to magnetic attraction, while the untouched CD8
+
 T cells remained 
in the supernatant.  The supernatant containing the CD8
+
 T cells was pipetted off and 
transferred to a fresh tube.  The tube containing the Dynabeads® was removed from the 
magnet, and the bead-bound CD8
-
 T cells vigorously resuspended in 5 ml Isolation 
Buffer, and placed in the magnet again for 2 minutes.  This supernatant was also 
removed and the two supernatants were combined. 
Chapter 2 
 91 
The same procedure applied to the isolation of CD4
+
 T cells from PBMC by 
depletion of CD4
-
 T cells using Dynabeads® Untouched™ human CD4 T cell kit.  The 
purity of the enriched CD8
+
 and CD4
+
 T cells was typically between 85-90%, as 
determined by FACS staining.  
 
2.3.5 Generation of CD8
+
 T cell clones 
The HLA-A*0201-restricted MEL187.c5 and EBV176.c4.1 CD8
+
 T cells, specific for 
Melan-A/MART-126-35 and EBV BRLF1259-267 respectively, were generated as 
previously described (Adams, 2004). 
 
2.3.5.1 Expansion and culture of CD8+ T cell clones 
T cell clones were expanded from cryopreserved stocks.  A restimulation mix was 
prepared as follows: vials of frozen PBMC (2 x 10
7
 cells per vial) from three different 
donors were thawed and combined in the same tube containing 20 ml R10 medium.  
The cells were washed by centrifuging at 250 x g for 8 minutes.  The supernatant was 
discarded and the PBMC resuspended in 10 ml R10 medium containing 5 μg/ml 
Phytohaemagglutinin (Sigma-Aldrich).  The cell mixture was incubated at 37°C/5% 
CO2 for 1 hour and then subjected to γ-radiation (Gammacell, Nordion) at 33 Gy.  For 
cell culture: a vial of CD8
+
 T cell clone (approximately 4 x 10
6
 cells) was thawed and 
washed as above.  Cells were resuspended in 4 ml of restimulation mix and seeded into 
2 wells of a 24-well tissue culture plate.  The plate was incubated at 37°C/5% CO2 and 
left until the wells were confluent.  Once the wells were confluent (no gaps between 
cells), cells were split 1:1 into a new well and topped up to 2 ml with R10 culture 
medium containing 25 μg/ml recombinant human IL-15 (Peprotech).  T cell clones 
could be maintained for up to 10 weeks by replacing half the media with fresh R10 
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medium containing 25 μg/ml recombinant human IL-15, or cryopreserved according to 
the method described in section 2.2.7. 
 
2.3.6 Isolation of CD138
+
 plasma cells and marrow infiltrating lymphocytes (MILs) 
from BM MNC 
MACS beads were used to positively select for CD138
+
 plasma cells from fresh and 
frozen BM MNC samples (described in section 2.3.3).  Following the manufacturer’s 
instructions, 2 x 10
7
 BM MNC were resuspended in 80 μl of chilled MACS buffer (Ca2+ 
and Mg
2+
 free PBS, 0.5% HI FBS, 2 mM EDTA), to which 20 μl anti-CD138 antibody 
coated microbeads (Miltenyi Biotec) was added.  The cells and beads were mixed 
thoroughly and incubated for 15 minutes at 4°C.  The cells were washed by adding 1-2 
ml MACS buffer per 2 x 10
7
 cells and centrifuged at 300 x g for 10 minutes.  The 
supernatant was completely removed and the cell pellet resuspended in 500 μl MACS 
buffer and applied to a LS MACS positive selection column (Miltenyi Biotec), which 
had been equilibrated with 3 ml MACS buffer, held in a QuadroMACS magnetic 
separator (Miltenyi Biotec).  The CD138 negative cells passed through the column and 
were collected in the flow through.  This fraction contained the marrow infiltrating 
lymphocytes (MILs) and was used in in vitro cellular assays the same day.  The 
percentage of CD4
+
/CD8
+
 T cells, within the CD138
-
 sample, was 12% as determined 
by FACS staining performed by a co-worker (Dr. Giovanna Bossi).  The column was 
washed with 3 x 3 ml MACS buffer, and the CD138
+
 cells were eluted by removing the 
column from the magnetic separator and placing it on a 15 ml centrifuge tube.  Then 5 
ml of MACS buffer was applied to the column and the plunger was used to flush out the 
magnetically labelled cells.  The CD138
+ 
cells were isolated with 99% purity, as 
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determined by FACS staining.  Following their isolation, the CD138
+ 
cells were used 
immediately in the in vitro cellular assays of this study. 
 
2.4 T cell Activation Assays 
2.4.1 Enzyme linked immunosorbent assay (ELISA) for interferon-γ (IFN-γ)  
T2 cells were resuspended in R10 medium and peptide-pulsed with Melan-A/MART-
126-35 heteroclitic peptide ELAGIGILTV at the stated concentrations for 90 minutes at 
37°C/5% CO2.  The cells were washed three times in unsupplemented RPMI 1640 
medium by centrifuging at 300 x g for 5 minutes.  After the final wash, the peptide-
pulsed T2 cells were resuspended in R10 medium at a concentration of 2 x 10
6
 cells per 
ml.  50 μl of peptide-pulsed T2 cells (1 x 105 cells) were added to each well of a 96-well 
round bottomed plate (Nunc).  CD8
+
 T cells which had previously been isolated from a 
buffy coat and stored in liquid N2, were thawed on the day of the assay, counted, and 
plated at 1 x 10
5
 cells per well in 50 μl R10 medium.  A two times concentrated stock of 
each mTCR-anti-CD3 scFv test reagent was made up in R10 medium and 100 μl added 
to the wells to give the final indicated concentration.  Each condition was assayed in 
triplicate in a final well volume of 200 μl.  The plate was incubated overnight at 
37°C/5% CO2.  The plate was centrifuged at 300 x g for 5 minutes, the supernatants 
removed, and assayed for IFN-γ using Diaclone ELI-Pair ELISA kit (Gen-Probe).  The 
plate was read on plate reader (VERSAmax, Molecular Devices) using SoftMax Pro 4.6 
software.  Data was plotted using Prism 4.0 software (GraphPad Software).   
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2.4.2 Enzyme linked immunospot (ELISpot) assay for interferon-γ (IFN-γ) and 
granzyme B 
The ELISpot assay, derived from the sandwich enzyme-linked immunosorbent assay 
(ELISA), was originally described by Lalvani et al (1997).  This was one of the key 
assays used in this thesis for measuring ImmTAC redirected T cell responses.  The main 
advantage of the ELISpot assay compared to the ELISA is its exquisite sensitivity with 
which it can measure very low frequencies of analyte-producing cells (Helms et al., 
2000).  This was particularly important for detecting any potential ImmTAC cross-
reactivity against antigen negative target cells.  ELISpot kits were used for measuring 
IFN-γ and granzyme B (BD BioSciences).  Each kit included polyvinylidene difluoride 
(PVDF) membrane-coated 96-well mircowell plates, unlabeled capture antibody, 
biotinylated detection antibody and enzyme conjugate (streptavidin-HRP).  The PVDF-
backed plate was pre-coated with 100 μl per well of capture antibody as per the 
manufacturer’s instructions, and the plate incubated overnight at 4°C.  The coating 
antibody was discarded and the wells washed once with 200 μl per well of R10 medium, 
then blocked with 200 μl per well of R10 medium for 2 hours at room temperature.  The 
blocking medium was discarded, and the required volume of R10 medium was added to 
the sample wells to result in a final well volume of 200 μl.  Target cells were prepared 
to a cell density of 1 x 10
6
 cells per ml in R10 medium and plated at 50 μl (5 x 104 cells) 
per well.  A 4 times concentrated stock of ImmTAC test reagent was prepared at the 
highest test concentration, which was serially diluted 1 in 10 in R10 medium in a 
separate plate to obtain the other test concentrations.  ImmTAC was then added to the 
ELISpot plate at 50 μl per well to give the final indicated titrated amounts.  Effector 
cells were added at 50 μl per well at a pre-determined cell concentration in R10 
medium.  Each condition was assayed in triplicate.  For untested effector cells it was 
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necessary to determine the optimal cell concentration in the first ELISpot experiment.  
This was carried out by testing a range of effector cell concentrations (typically 1 x 10
3
-
1 x 10
5
 cells per well) and incubating with the target cell of interest in the presence of 
top experimental concentration of the relevant ImmTAC reagent.  The plate was then 
left disturbed overnight at 37°C/5%CO2.  During this period, the immobilised capture 
antibody specifically captures proteins secreted or released from the effector cells.  The 
following day the cells were discarded and the wells washed three times with PBS 
containing 0.05% Tween-20 (Sigma) using an automated plate washer (Ultrawash Plus, 
Dynex Magellan Biosciences).  The captured protein was specifically detected by the 
addition of 100 μl per well biotin-conjugated antibody diluted in PBS containing 10% 
FBS, and left to incubate for 2 hours at room temperature.  After three further washes, 
horseradish peroxidise (HRP)-conjugated streptavidin diluted in PBS/10% FBS was 
added at 200 μl per well for 1 hour at room temperature.  After this, the sample wells 
were washed three times with PBS/0.05% Tween-20 followed by two washes with PBS, 
3-amino-9-ethyl-carbazole (AEC) substrate reagent set (BD BioSciences) was added for 
2-5 minutes for IFN-γ and up to 30 minutes for granzyme B.  The resulting appearance 
of dark spots represented individual IFN-γ or granzyme B producing T cells.  The 
colour reaction was terminated by washing the plate under running tap water.  After 
leaving the plate to dry at room temperature for several hours, the spots were 
enumerated using an automated ELISpot reader (Immunospot Series 5 Analyser, 
Cellular Technology Ltd.).  Data was analysed using Prism 4.0 software (GraphPad 
Software).   
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2.5 Cytotoxicity assays 
A number of different cytotoxicity assays were employed to investigate ImmTAC 
redirected target cell killing, as described in the following. 
 
2.5.1 Analysis of caspase-3/7 activation at an early time point 
To assess early manifestations of ImmTAC redirected target cell killing, activity of 
caspases 3 and 7 was measured using the Apo-ONE® Homogeneous Caspase-3/7 Assay 
(Promega).  Caspases are proteolytic enzymes that become activated during the process 
of apoptosis.  The Promega Apo-ONE® Homogeneous Caspase-3/7 Assay detects 
caspase-3/7 activity based on the cleavage of a profluorescent DEVD peptide-
Rhodamine 110 substrate [(Z-DEVD)2-R110] to create the fluorescent Rhodamine 110.  
The amount of fluorescent product generated is proportional to the amount of caspase-
3/7 cleavage activity present in the sample.  
Target cells and effector cells were washed, counted and resuspended in R10 
medium without phenol red.  Target cells were adjusted to a cell density of 4 x 10
5
 cells 
per ml and the effector cells at a cell density of 2 x 10
6 
cells per ml.  A 2 times 
concentrated stock of ImmTAC was prepared at 2, 0.2, 0.02, 0.002 nM in R10 without 
phenol red.  In a 96-well round bottomed plate, 25 µl (1 x 10
4
 cells) target cells were 
mixed with 25 µl effector cells (5 x 10
4
 cells) in each well resulting in an effector to 
target (E:T) ratio of 5:1, followed by 50 μl of ImmTAC to give the final indicated 
titrated amounts.  All wells were prepared in triplicate in a final volume of 100 μl.  The 
plate was centrifuged (Heraeus Megafuge 1.0R) at 250 x g for 4 minutes and then 
incubated at 37°C/5%CO2 for 4 hours.  Following the incubation period, the plate was 
centrifuged at 250 x g for 4 minutes, and 50 μl of supernatant was removed and 
discarded.  As per the manufacturer’s instructions, the caspase-3/7 substrate Z-DEVD-
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R110 was diluted in the Apo-ONE® buffer, which contains a cell lysis compound and 
an activity buffer for caspase-3/7, and added 50 μl per well (constituting a 1:1 ratio with 
sample volume in each well).  The samples were then mixed by placing the plate on a 
shaker at 300-500 rpm for 30 minutes and then placed in the freezer at -20°C overnight.  
The next day, the plate was thawed and put on the shaker for 2 hours at 300-500 rpm.  
80 μl was transferred from each well to the corresponding well on a white 96-well flat 
bottomed plate and the fluorescence of each well was measured using a 
spectrophotometer (Wallac VICTOR
2™, Perkin Elmer).  Data was analysed using 
Prism 4.0 software (GraphPad Software).   
 
2.5.2 
51
Cr-release assay 
Mel526 target cells were prepared in R10 medium and labelled with sodium chromate-
51 (3.7 MBq (100 μCi) per 1 x 106 cells) (Perkin Elmer) and incubated for 1 hour at 
37°C/5%CO2.  The cells were washed four times in R10 medium and adjusted to 5 x 10
4 
cells per ml.  Unstimulated purified CD8
+
 effector cells were prepared in R10 medium 
at a cell density of 5 x 10
5
 cells per ml and EBV-specific CD8
+
 T cell clone 
(EBV176c4.1) at a cell density of 2.5 x 10
5
 cells per ml.  Two times concentrated stocks 
of the ImmTAC-gp100 were prepared at 20, 2, 0.2, 0.02, 0.002, 0.0002 nM in R10 
medium.  In a 96-well round bottomed plate, 50 µl (2,500 cells) target cells was mixed 
with 50 µl effector cells in each well resulting in an effector to target (E:T) ratio of 10:1 
for the unstimulated CD8
+
 T cells (2.5 x 10
4
 cells), and an E:T ratio of 5:1 for the EBV-
specific T cell clone (1.25 x 10
4
 cells), followed by 50 μl of ImmTAC to give the final 
indicated titrated amounts.  Control wells were set up with target cells alone to calculate 
spontaneous release; target cells were set up with 1% Triton X 100 (v/v) to calculate 
maximum release.  Each condition was assayed in triplicate in a final volume of 200 μl.  
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The plate was incubated at 37°C/5%CO2 for 4 hours.  Following incubation, 40 μl were 
transferred from each well to the corresponding well in a solid scintillant white opaque 
96-well microplate LumaPlate (Perkin Elmer).  The LumaPlate was sealed with an 
adhesive cover and read on a TopCount scintillation counter (Perkin Elmer).  
Percentage cytotoxicity was then calculated using the following equation: Specific lysis 
= [(experimental lysis – spontaneous lysis)/(maximum lysis – spontaneous lysis)] x 100.  
Data was analysed using Prism 4.0 software (GraphPad Software).   
 
2.5.3 LDH-release assay 
ImmTAC redirected target cell killing was measured in a non-radioactive radioactive 
cytotoxicity assay using CytoTox96® (Promega).  This assay is a colorimetric 
alternative to the 
51
Cr-release cytotoxicity assays and quantitatively measures lactate 
dehydrogenase (LDH); this is an enzyme that is released upon cell lysis.  Released LDH 
in culture supernatants is measured with a 30 minute coupled enzymatic assay, which 
results in the conversion of a tetrazolium salt (INT) into a red formazan product.  The 
amount of colour formed is proportional to the number of cell lysed. 
Target cells and effector cells were washed, counted and resuspended in R10 
medium without phenol red.  It should be noted that primary cell targets (described in 
section 2.2.2.1) were washed three times to remove culture media which can contain 
components that are inhibitory to T cells.  Target cells were adjusted to a cell density of 
2 x 10
5
 cells per ml and the effector cells at a cell density of 2 x 10
6 
cells per ml.  In a 
96-well round bottomed plate, 50 µl (1 x 10
4
 cells) target cells were mixed with 50 µl 
effector cells (1 x 10
5
 cells) in each well resulting in an effector to target (E:T) ratio of 
10:1.  When other E:T ratios were used, the target cell number was kept the same, while 
the number (concentration) of effector cells was adjusted accordingly.  A 3 times 
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concentrated stock of ImmTAC test reagent was prepared at the highest test 
concentration, which was serially diluted 1 in 10 in R10 medium without phenol red in 
a separate plate to obtain other test concentrations.  ImmTAC was then added to the 
assay plate at 50 μl per well to give the final indicated titrated amounts.  Control wells 
were set up with effector cells alone to calculate effector spontaneous release, target 
cells alone to calculate target spontaneous release, and target cells with 80 μg/ml 
digitonin final to calculate maximum release.  Each condition was assayed in triplicate 
in a final volume of 150 μl.  The plate was centrifuged (Heraeus Megafuge 1.0R) at 250 
x g for 4 minutes and then incubated at 37°C/5%CO2 for 4 or 24 hours.  Following the 
incubation period, the plate was centrifuged at 250 x g for 4 minutes and 50 μl 
transferred from each well to the corresponding well in a 96-well flat bottomed 
Maxisorb plate (Nunc).  The CytoTox96® substrate mix was reconstituted using 
CytoTox96® assay buffer, as per manufacturer’s instructions, and 50 μl added to each 
well of the plate.  The plate was covered with aluminium foil and incubated at room 
temperature for 30 minutes.  Then 50 μl of CytoTox96 stop solution was added to each 
well and absorbance recorded at 490 nm on a plate reader (VERSAmax, Molecular 
Devices) using SoftMax Pro 4.6 software.  Percentage cytotoxicity was then calculated 
using the following equation: Specific lysis = [(Experimental – Effector Spontaneous – 
Target Spontaneous)/(Target Maximum – Target Spontaneous)] x 100.  Data was 
analysed using Prism 4.0 software (GraphPad Software).   
 
2.5.4 IncuCyte and real-time quantification of cell killing 
IncuCyte™ FLR technology (Essen Biosciences) enables direct visualisation of 
caspase-3/7 dependent apoptosis by microscopy at 37°C in real time.  This technology 
is relatively new and has been optimised in our laboratory to monitor the long-term 
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killing kinetics of ImmTAC redirected T cells in vitro.  Kinetic measurement of 
apoptosis is made using CellPlayer 96-well Kinetic Caspase-3/7 reagent (Essen 
Biosciences) which couples the activated caspase-3/7 recognition motif (DEVD) to 
Nucview™ 488, a DNA intercalating dye.  When added to tissue culture medium, this 
inert and non-fluorescent substrate crosses the cell membrane where it is cleaved by 
activated caspase-3/7 resulting in the release of the DNA dye and green fluorescent 
staining of nuclear DNA.  Kinetic activation of caspase-3/7 can be monitored 
morphologically using live cell imaging, and quantified using the IncuCyte object 
counting algorithm. 
The day before the assay, target cells were prepared in R10 medium without 
phenol red at a cell density of 2 x 10
5
 cells per ml and 100 μl (2 x 104 cells) added per 
well of a 96-well flat bottomed microwell plate.  The plate was incubated at 
37°C/5%CO2 overnight to allow the cells to settle/adhere to the bottom of the plate.  
The following day, 50 μl of the supernatant was carefully removed from each well, 
leaving the cells undisturbed.  A six times stock of ImmTAC reagent was prepared in 
R10 medium without phenol red and 25 μl was added to the relevant cells to give the 
final indicated concentration.  A 30 μM stock of the CellPlayer 96-well Kinetic 
Caspase-3/7 reagent was prepared in R10 medium without phenol red and 25 μl added 
to all wells to give a final concentration of 5 μM.  Effector cells were prepared in R10 
medium without phenol red at a cell density of 2 x 10
6
 cells per ml and 50 μl (1 x 105 
cells) added per well to give an E:T ratio of 5:1.  Each condition was assayed in 
triplicate in a final volume of 100 μl.  Images were taken at intervals of 2 hours and the 
number of apoptotic cells was quantified using IncuCyte object counting algorithm. 
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CHAPTER 3 OPTIMISATION AND EVALUATION OF HIGH AFFINITY TCR-
ANTI-CD3 FUSIONS FOR TUMOUR CELL RECOGNITION  
 
3.1 Introduction 
Epitope counting using fluorochrome-labelled high affinity monoclonal TCRs in single 
molecule fluorescence microscopy experiments showed that the density of tumour-
associated peptide-MHC at the tumour cell surface is as low as 10-50 epitopes per cell 
on both cell lines and fresh tumour samples (Purbhoo et al., 2006).  The low epitope 
number on tumour cells poses a significant challenge when considering a suitable 
effector function that could successfully convert the high affinity mTCR from simply a 
research tool (Purbhoo et al., 2007; Purbhoo et al., 2006) into one that can deliver 
therapeutic potential. 
Unlike antibodies, mTCRs do not possess an Fc fragment or any other effector 
function.  Therefore, targeted cell killing requires conjugation or fusion to a suitable 
cytotoxic agent or biological modulator.  There are two modes of action that can be 
utilised; first, is a direct mechanism delivering a payload, for example a radioisotope or 
cytotoxin, to the cancer surface, or second, an indirect mechanism whereby immune 
activity is redirected against the cancer cell. 
 
3.1.1 Direct mechanisms 
Successful use of a radioisotope as a conjugate to kill tumour cells would require the 
delivery of several thousand molecules per cell.  Previous tumour staining experiments 
(Purbhoo et al., 2007; Purbhoo et al., 2006) indicated that the density of peptide antigen 
at the tumour cell surface was considerably lower than this level so such an approach 
was ruled out. 
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A more promising option was the use of the very potent cell toxin, Pseudomonas 
exotoxin A-derived PE38, where a single molecule is capable of killing a eukaryotic 
cell.  However, although PE38-fused mTCRs were shown to kill peptide-pulsed targets 
(which can present non-physiologically high numbers of epitope per cell) they were not 
potent enough to efficiently kill naturally presenting tumour cells (unpublished data).  
This is probably because the toxin requires internalisation to kill the cell and the use of 
fluorochrome-labelled high affinity monoclonal TCRs in single molecule fluorescence 
experiments showed that mTCRs remain bound on the cell surface for over 24 hours 
with no internalisation detectable (Purbhoo et al., 2007; Purbhoo et al., 2006).  This 
observation pointed strongly to an indirect mechanism of action being the most suitable 
option for mTCRs. 
 
3.1.2 Indirect mechanisms 
Indirect mechanisms for delivering an effector function involve fusing the mTCR to a 
protein capable of eliciting a potent activation signal to the immune system within the 
vicinity of the tumour.  Such a protein moiety could be a cytokine, a receptor, a 
bacterial superantigen or an antibody fragment.  In order to be effective any such 
mechanism would need to be capable of delivering an immune system recognisable 
function to a target cell presenting only 10-50 copies of the relevant peptide target. 
 
The first protein moiety of this kind to be evaluated with the mTCR was the cytokine 
interleukin-2 (IL-2).  A low level of T cell stimulatory effect was demonstrated in vitro 
with high affinity NY-ESO mTCR fused to IL-2 when CD8
+
 CTLs were stimulated to 
exhibit activity against NY-ESO peptide-pulsed targets.  A small effect was also seen in 
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an animal model but it was concluded that IL-2 was not a suitable therapeutic candidate 
based on the toxicity of IL-2 versus the anticipated efficacy that could be achieved.  
mTCR fused to bacterial superantigen was capable of redirecting T cell activity, 
producing a low level of target cell killing, and although inadequate, it pointed to a T 
cell stimulator as the most promising solution. 
Cytotoxic T cells (CTL) are considered to be the most potent killer cells of the 
immune system.  They have evolved to eliminate pathogenic cells such as virus-infected 
and, to a lesser extent, malignant cells.  As described in section 1.5.6.2 CTL triggering 
can be induced with as few as 3 cognate ligands.  Therefore, the recruitment of 
cytotoxic T cells is a highly compelling therapeutic strategy for targeting cancer as these 
cells offer potent cytotoxicity with exquisite sensitivity.  It is long established that T cell 
triggering can be achieved by monoclonal antibodies specific for the CD3/TCR 
complex.  This has led to the development of a number of bispecific T cell activating 
antibodies, comprised of a fusion between a monoclonal anti-CD3 antibody and a 
monoclonal antibody specific for a tumour-associated antigen.  Probably the most 
potent bispecific T cell activator antibodies reported to date are the so-called BiTE 
(bispecific T-cell engager) antibodies which are a tandem scFv molecule where one 
scFv has specificity for CD3 whilst the other targets a tumour antigen (Baeuerle & 
Reinhardt, 2009; Dreier et al., 2002; Topp et al., 2011). 
Normally, the activity of T cells is a tightly controlled process involving various 
cell surface receptors including a specific TCR, the CD3 signalling complex, co-
receptors, cell adhesion and costimulatory molecules; ultimately, these interactions can 
lead to the formation of an immunological synapse with the target cell (Dustin et al., 
2010).  This high level of control is required to ensure the cytotoxic T cell response is 
highly specific and that the wrong cells/tissues are not attacked.  With bispecific 
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therapeutics, the anti-CD3 antibody activates T cells by short-circuiting normal T cell 
activation, bypassing the need for specific TCR, pMHC complex and costimulatory 
molecules.  Therefore, when considering anti-CD3 as an effector function for the mTCR 
it is vitally important to ensure that specificity is maintained.  In particular, it is essential 
that the anti-CD3 antibody does not activate T cells without the mTCR having bound its 
target; T cell activation should only be triggered upon concomitant binding to the target 
cell. 
 
The reagents evaluated in this thesis are called ImmTACs (Immune-mobilising 
monoclonal TCRs against cancer).  These comprise a high affinity mTCR fused to a 
humanised CD3-specific scFv, resulting in a fusion protein of approximately 76 kDa 
molecular weight.  ImmTACs are designed to redirect and activate both cancer-specific 
and non cancer-specific T cells to lyse tumour cells.  This chapter describes the cellular 
testing which guided the optimisation of the ImmTAC reagents.  I was not involved in 
the design, engineering or the manufacture of the ImmTAC reagents. My own studies 
involved in vitro testing of ImmTACs in order to assess which reagents might prove to 
be most potent for therapeutic applications. 
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3.2 Results 
3.2.1 Overview of the testing of different prototype mTCR-anti-CD3 scFv 
(ImmTACs) for the elimination of tumour cells 
As described above, my work involved cellular testing of mTCR-anti-CD3 scFv 
molecules in order to assess what would be optimal for tumour cell killing with these 
reagents.  At the outset there were a number of questions that I aimed to answer.  The 
first of these was to establish which of the many anti-CD3 antibodies might provide 
greatest potency.  Second, I aimed to examine the optimal way to fuse these bispecifics 
by examining the potency of both N-terminal and C-terminal fusion molecules and 
various linkers between the two molecules. Third, I assessed whether addition of a 
second, tandem anti-CD3 scFv moiety could increase the potency of cellular activation.  
Access to a range of enhanced TCRs also allowed me to assess the role of TCR binding 
affinity in the potency of mTCR-anti-CD3 scFv molecules. 
 
3.2.2 Comparison of different anti-CD3 scFv antibodies as fusion partners for 
mTCR 
There are a number of widely used anti-CD3 antibodies available.  The humanised 
monoclonal anti-CD3 antibodies called OKT3 (Xu et al., 2000), 12F6 (B. Li et al., 
2005) and UCHT1 (Shalaby et al., 1992) were selected as potential effector function 
binding partners for the mTCR.  These antibodies recognise epitopes on CD3ε found in 
heterodimers with CD3δ and with CD3γ but not CD3ε expressed in isolation (Salmeron 
et al., 1991). 
The antigen sensitivity mediated by three humanised anti-human CD3 scFv 
antibodies, OKT3, 12F6 and UCHT1 was evaluated by fusing them to the C-terminus of 
the TCR beta chain of a high affinity mTCR specific for Melan-A/MART-126-35, 
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EAAGIGILTV-HLA-A*0201 (ImmTAC-MEL).  This mTCR binds to its cognate 
antigen with a KD of 39 pM and half-life interaction of 37 hours.  The three reagents, 
ImmTAC-MEL/OKT3, ImmTAC-MEL/12F6 and ImmTAC-MEL/UCHT1 were tested 
using and interferon-γ (IFN-γ) enzyme-linked immunosorbent assay (ELISA) to 
measure the activation of unstimulated purified CD8
+
 T cells in the presence of T2 cells 
pulsed with varying concentrations of the HLA-A*0201 restricted Melan-A/MART-126-
35 heteroclitic peptide ELAGIGILTV (10
-11
-10
-5 
M)  (Figure 3-1a-c).   
ImmTAC-MEL/OKT3 shows the least antigen sensitivity of the three anti-CD3 
scFv antibodies (Figure 3-1a), activating CD8
+
 T cells at a peptide concentration of 10
-7 
M.  Activation with ImmTAC-MEL/OKT3 did not reach saturation.  ImmTAC-
MEL/12F6 (Figure 3-1b), is able to activate CD8
+
 T cells at a 10-fold lower peptide 
concentration than ImmTAC-MEL/OKT3 with full activation achieved with 1 μM 
cognate peptide.  ImmTAC-MEL/UCHT1 (Figure 3-1c) shows the greatest antigen 
sensitivity of the three anti-CD3 scFv antibodies; 1 pM ImmTAC-MEL/UCHT1 gave 
comparable activity to ImmTAC-MEL/12F6 used at a concentration of 10 nM which 
equates to a 10,000-fold difference in antigen sensitivity (Figure 3-1b,c).  In all cases, 
no activation of CD8
+
 T cells is seen in the presence of ImmTAC-MEL without targets.  
This illustrates that the ImmTAC only activates when a multivalent contact is made 
between the target cell and the T cell. 
 
The huge difference in potency between mTCR fusions with these 3 anti-human CD3 
scFv antibodies ensured that UCHT1 was selected as the anti-CD3 scFv antibody 
effector fusion partner for future ImmTAC reagents and experiments. 
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Figure 3-1 The antigen sensitivity of ImmTAC-MEL when fused to different anti-
CD3 scFv antibodies.  
 
IFN-γ ELISA assay showing the activation of unstimulated purified CD8+ T cells 
mediated by ImmTAC-MEL fused at the C-terminus to humanised anti-CD3 scFv 
antibodies in the presence of T2 cells pulsed with various concentrations of the Melan-
A/MART-126-35 heteroclitic peptide ELAGIGILTV (closed circles).  Controls are 
represented by T2 cells pulsed with 10
-5 
M ELAGIGILTV peptide in the presence of 
CD8
+
 T cells, without ImmTAC-MEL (open circles) and CD8
+
 T cells in the presence 
of ImmTAC-MEL, without targets (open triangles). (a) ImmTAC-MEL fused to OKT3, 
used at a 10 nM. (b) ImmTAC-MEL fused to 12F6, used at 10 nM. (c) ImmTAC-MEL 
fused to UCHT1, used at 1 pM (light purple) and 10 pM (dark purple).  Data are means 
± s.e.m.  The data shown are representative of two experiments. 
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3.2.3 Potency of different anti-CD3 scFv fusion designs 
My work described above established that fusions with the UCHT1 scFv were >1000 
times more antigen sensitive than those with the other activating anti-CD3 antibodies 
tested.  Next, I aimed to test for the optimal design of ImmTAC-UCHT1 reagents to 
increase stability, reduce immunogenicity and improve yield and potency so that they 
would be suitable for manufacture and potential use in the clinic. 
 
3.2.3.1 Fusion of the anti-CD3 scFv to the N-terminus of the TCR beta chain to 
improve potency 
In the first generation ImmTAC constructs the anti-CD3 scFv antibody was fused to the 
C-terminus of the TCR beta chain via an inter-linker, as molecular modelling based on 
crystal structures indicated that fusion to the N-terminus of the TCR might interfere 
with binding to the HLA-peptide complex.  However, the presence of anti-CD3 scFv at 
the C-terminus of the mTCR increases the overall length of the molecule which could 
impact on its ability to efficiency activate T cells due to the increased distance between 
the target cell and T cell.  To investigate this further, ImmTACs were produced with the 
anti-CD3 scFv antibody fused to the N-terminus of the TCR beta chain via an inter-
linker (Figure 3-3a).  This modification makes the ImmTAC reagent more compact and, 
if functional, could permit closer contact to be made between the target cell and the 
recruited cytotoxic T cell, potentially resulting in more potent T cell activation.  
However, there were concerns that the position of the anti-CD3 scFv antibody on the N-
terminus could sterically interfere with the binding of the TCR to its target. 
I examined the biological activity of an anti-CD3-mTCR N-terminus ImmTAC 
construct versus the anti-CD3-mTCR C-terminus ImmTAC construct. These 
experiments were conducted using a different TCR specific for an HLA A*0201-
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specific epitope from the cancer/testis antigen NY-ESO-1 (residues 157-165; 
SLLMWITQC). This TCR binds with a KD of 18 pM and a half-life interaction of 17 
hours. 
 
The NY-ESO-specific ImmTAC (ImmTAC-NYE) with UCHT1 scFv fused either on 
the C-terminus or N-terminus of the TCR beta chain, were used to activate CTL against 
T2 target cells pulsed with 10
-9 
M NY-ESO-1157-165 heteroclitic peptide SLLMWITQV.  
The 9V mutaion in the peptide improves binding to HLA A*0201 compared to the 
wildtype SLLMWITQC sequence (J. L. Chen et al., 2000). 
 
IFN-γ activity measured from redirected unstimulated purified CD8+ T cells in an 
enzyme-linked immunospot (ELISpot) assay showed that the N-terminus ImmTAC-
NYE construct produced approximately a 4-fold improvement in redirected CD8
+
 T cell 
activity compared to the C-terminus ImmTAC-NYE (EC50 values of 12 pM versus 45 
pM) (Figure 3-2).  
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Figure 3-2 The biological activity of N-terminus versus C-terminus ImmTAC-
NYE.  
 
IFN-γ ELISpot assay showing the activation of unstimulated purified CD8+ T cells 
mediated by titrated amounts of N-terminus ImmTAC-NYE (closed grey squares) 
compared with C-terminus ImmTAC-NYE (closed blue circles) in the presence of T2 
cells pulsed with 10
-9 
M NY-ESO157-165 heteroclitic peptide SLLMWITQV.  Controls 
(open symbols) represent the relevant ImmTAC-NYE at 1 nM in the presence of T2 
cells pulsed with 10
-9 
M irrelevant peptide (P450 CYP1B1190-198 FLDPRPLTV) and 
CD8
+
 T cells.  Data are means ± s.e.m.  The data shown are representative of three 
experiments. 
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3.2.3.2 Testing for the optimal ImmTAC intra- and inter-linkers 
The intra-linker, which links the light chain and the heavy chain variable domains of the 
anti-CD3 scFv, and the inter-linker, which links the TCR to the anti-CD3 scFv, were 
both modified to a GS motif (Figure 3-3a), which is often used in fusion proteins in 
order to ensure flexibility between the fusion partner polypeptides.  Further purposes of 
these modifications were to increase the stability of the ImmTAC and reduce potential 
immunogenicity.  The linker modifications were not expected to affect the biological 
activity of the ImmTAC.   
Experiments examining the role of linker sequences were performed with a TCR 
specific for and HLA A*0201 epitope in the gp100 protein (YLEPGPVTV). This TCR 
binds with a KD of 15 pM  and a half-life of 33 hours. 
 
To verify that the modification of the intra- and inter- linkers did not significantly affect 
the biological activity of the ImmTAC, titrated amounts of the lead therapeutic 
candidate ImmTAC-gp100, expressed with the first generation linkers or the second 
generation GS linkers, were compared.  The melanoma cell line, Mel526, expressing 
natural levels of wild-type gp100280-288 presented by HLA-A*0201 was used as target.  
IFN-γ activity was measured from the redirected unstimulated purified CD8+ T cells 
(Figure 3-3b).  There was no significant difference in biological activity between 
ImmTAC-gp100 with the first generation linkers and ImmTAC-gp100 with the second 
generation GS motif linkers.  However, the second generation linkers are considered 
more suitable for a therapeutic product and have therefore been used for all subsequent 
ImmTAC reagents. 
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Figure 3-3 The effect of GS motif linkers on the biological activity of ImmTAC-
gp100.  
 
(a) A schematic representation of ImmTAC-gp100 showing the difference in the amino 
acid sequence between the 1
st
 and 2
nd
 generation inter- and intra- linkers. (b) IFN-γ 
ELISpot assay showing the activation of unstimulated purified CD8
+
 T cells mediated 
by titrated amounts of ImmTAC-gp100 with the 1
st
 generation intra- and inter-linker 
(closed red circles) compared to ImmTAC-gp100 with the 2
nd
 generation GS motif 
intra- and inter-linker (closed grey squares) in the presence of the HLA-
A*0201
+
/gp100
+
 melanoma cell line Mel526.  Controls (open symbols) represent the 
corresponding ImmTAC-gp100 at 10 nM in the presence of the HLA-A*0201
+
/gp100
-
 
cell line, A375, and CD8
+
 T cells.  Data are means ± s.e.m.  The data shown are 
representative of three experiments. 
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3.2.3.3 Other modifications 
Further modifications were made to the lead therapeutic candidate, ImmTAC-gp100, to 
make it suitable for clinical testing.  These modifications included: (1) truncation of the 
TCR α-chain as this was found to be chemically unstable, (2) removal of an acetylation 
site from the N-terminus of the gp100 TCR alpha chain to reduce levels heterogeneity 
in manufacturing, and (3) removal of a methionine residue from the N-terminus of the 
gp100 TCR β-chain anti-CD3 fusion to reduce potential immunogenicity.   
All of the modified ImmTAC-gp100 reagents were tested in IFN-γ release 
assays to verify biological activity.  None of the modifications significantly affected the 
potency of ImmTAC-gp100 compared to the non-modified control (Figure 3-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 114 
-13 -12 -11 -10 -9 -8
0
10,000
20,000
30,000
40,000 Non-modified
Truncated
C
o
n
tr
o
ls
a
Log10[ImmTAC-gp100](M)
IF
N
-
 S
F
C
p
e
r 
1
0
6
C
D
8
+
c
e
ll
s
-13 -12 -11 -10 -9 -8
0
10,000
20,000
30,000 Non-modified
-Acetylation site
C
o
n
tr
o
ls
b
Log10[ImmTAC-gp100](M)
IF
N
-
 S
F
C
p
e
r 
1
0
6
C
D
8
+
c
e
ll
s
-13 -12 -11 -10 -9 -8
0
10,000
20,000
30,000 Non-modified
-Methionine
C
o
n
tr
o
ls
c
Log10[ImmTAC-gp100](M)
IF
N
-
 S
F
C
p
e
r 
1
0
6
C
D
8
+
c
e
ll
s
 
Figure 3-4 The effect of various modifications on the biological activity of the lead 
therapeutic candidate ImmTAC-gp100. 
 
IFN-γ ELISpot assay showing the activation of unstimulated purified CD8+ T cells 
mediated by titrated amounts non-modified ImmTAC-gp100 (closed red circles) 
compared to modified ImmTAC-g100 (closed grey squares) in the presence of the 
HLA-A*0201
+
/gp100
+
 melanoma cell line Mel526.  Controls (open symbols) represent 
the corresponding ImmTAC-gp100 at 10 nM in the presence of the HLA-
A*0201
+
/gp100
-
 cell line, A375, and CD8
+
 T cells. (a) Truncation of TCR α-chain. (b) 
Removal of acetylation site from N-terminus of TCR α-chain. (c) Removal of 
methionine residue from the N-terminus of the TCR β-chain.  Data are means ± s.e.m.  
The data shown are representative of three experiments. 
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3.2.4 Testing of mTCR-tandem anti-CD3 scFv fusions 
An alternative approach to enhancing effector function potency would be through 
increasing the payload, i.e., the number of effector function moieties conjugated to each 
mTCR molecule.  An antibody tandem scFv-based lidamycin fusion protein targeting 
gelatinases, which play important roles in tumour invasion and metastasis, has been 
shown to enhance therapeutic efficacy in mouse models (Zhong et al., 2010)  
To investigate whether a tandem effector function could improve the biological 
activity of the ImmTAC reagents, a tandem anti-CD3 (UCHT1) scFv version of the 
ImmTAC was generated and compared with single anti-CD3 (UCHT1) scFv ImmTAC.  
These experiments were performed with the gp100-specific TCR. 
 
The tandem anti-CD3 scFv ImmTAC-gp100 was constructed with an extra UCHT1 
molecule linked via a GS inter-linker to the existing UCHT1 molecule which is fused to 
the N-terminus of the TCR beta chain via a GS inter-linker (Figure 3-5a).  The 
biophysical properties of the tandem anti-CD3 scFv ImmTAC-gp100 were evaluated by 
surface plasmon resonance (SPR) technology (BIAcore™) to measure binding to CD3 
and HLA-A*0201 presenting gp100280-288 heteroclitic peptide YLEPGPVTV (Figure 3-
5a-c).  To examine whether tandem anti-CD3 scFv ImmTAC-gp100 binds to CD3 with 
higher affinity than single anti-CD3 scFv ImmTAC-gp100, CD3εγ was immobilised on 
the chip and single and tandem anti-CD3 scFv ImmTAC-gp100 fusions were injected 
over the surface.  The single anti-CD3 scFv ImmTAC-gp100 dissociated from the 
bound CD3 with a half-life (T1/2) of 16 minutes, whereas tandem anti-CD3 scFv 
ImmTAC-gp100 had not dissociated substantially even after 20 hours indicating that the 
avidity of the interaction of the tandem UCHT1 molecules to the surface with 
immobilised CD3 is very high (Figure 3-5b).  To show that the tandem anti-CD3 scFv 
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ImmTAC-gp100 can bind both CD3 and its cognate pMHC, a bi-functional assay also 
was performed.  HLA-A*0201 presenting gp100280-288 heteroclitic peptide 
YLEPGPVTV was immobilised on the chip followed by tandem anti-CD3 scFv 
ImmTAC-gp100 or single anti-CD3 scFv ImmTAC-gp100 to saturate the immobilised 
pHLAs.  CD3 was then injected over the sensor surface.  Both anti-CD3 scFv-gp100 
fusions, bound through their TCR part to the immobilised pHLA, were able to capture 
soluble CD3 complex, thus demonstrating that both type of subunit of the bispecific 
molecules are functional (Figure 3-5c). 
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C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5 The biophysical characteristics of ImmTAC-gp100 with tandem anti-
CD3 scFv.  
 
Surface plasmon resonance (SPR) technology was used to characterise the binding of 
tandem anti-CD3 scFv ImmTAC-gp100 to HLA-A2/gp100 complex and CD3-εγ. (a) A 
schematic representation of the single and tandem anti-CD3 ImmTAC-gp100 
molecules. (b) CD3 was immobilised to the chip and tandem anti-CD3 scFv ImmTAC-
gp100 was injected over the sensor surface.  The same procedure was repeated for the 
single anti-CD3 scFv ImmTAC-gp100. (c) Bi-functional assay to show functionality of 
anti-CD3 scFv and mTCR components of the tandem anti-CD3 scFv ImmTAC-gp100.  
HLA-A*0201 presenting gp100280-288 heteroclitic peptide YLEPGPVTV was 
immobilised to the chip followed by tandem anti-CD3 scFv ImmTAC-gp100 or single 
anti-CD3 scFv ImmTAC-gp100 to saturate the immobilised pHLA (upper graph).  CD3 
was then injected over the sensor surface (lower graph).  The data shown are courtesy of 
Dr. Milos Aleksic at Immunocore Ltd. 
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The biological activity of the tandem anti-CD3 scFv and the single anti-CD3 scFv 
ImmTAC-gp100 were compared in T cell activation assays.  The melanoma cell line, 
Mel526, expressing natural levels of wild-type gp100280-288 complexed to HLA-A*0201 
was used as targets.  IFN-γ activity was measured from the redirected unstimulated 
purified CD8
+
 T cells (Figure 3-6).  The data shows that, at all concentrations from 10
-13
 
to 10
-8
 M of the two reagents, the tandem anti-CD3 scFv fusion is inferior to the single 
anti-CD3 scFv fusion at activating the T cells.   
The close proximity of the two anti-CD3 scFv subunits ensures that they would 
not be able to cross-link two T cells by binding to the cell-surface CD3 on different 
cells.  Indeed, no activation of T cells was seen in the presence of tandem anti-CD3 
scFv ImmTAC-gp100 or single anti-CD3 scFv ImmTAC-gp100 without targets. 
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Figure 3-6 The biological activity of tandem anti-CD3 (UCHT1) scFv ImmTAC-
gp100 versus single anti-CD3 (UCHT1) scFv ImmTAC-gp100.  
 
IFN-γ ELISpot assay showing the activation of unstimulated purified CD8+ T cells 
mediated by titrated amounts of tandem anti-CD3 (UCHT1) scFv ImmTAC-gp100 
(closed grey squares) compared to single anti-CD3 (UCHT1) scFv ImmTAC-gp100 
(closed red circles) in the presence of the HLA-A*0201
+
/gp100
+
 melanoma cell line, 
Mel526.  Controls (open symbols) represent the corresponding ImmTAC-gp100 at 1 
nM with CD8
+
 T cells in the presence of the HLA-A*0201
+
/gp100
-
 target cell line, 
A375 (coloured open symbols) and in the absence of target cells (black open symbols).  
Data are means ± s.e.m.  The data shown are representative of two experiments. 
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Next, it was investigated whether the tandem anti-CD3 scFv fusion would be more 
efficient at recruiting low numbers of CD8
+
 T cells compared to the single anti-CD3 
scFv fusion.  The melanoma cell line, Mel526, which naturally presents the wild-type 
gp100280-288 complexed to HLA-A*0201, was used as a target.  IFN-γ activity was 
measured from the titrating numbers of unstimulated purified CD8
+
 T cells in the 
presence of 1 nM tandem or single anti-CD3 scFv fusion (Figure 3-7).  The data shows 
that the tandem anti-CD3 scFv fusion is inferior to the single anti-CD3 scFv fusion at 
activating the T cells at all the cell concentrations tested (312.5 to 10,000 CD8
+
 T cells 
per well).  It should be noted that the data shown is representative of one experiment 
only.   
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Figure 3-7 Recruitment of CD8
+
 T cells by tandem anti-CD3 (UCHT1) scFv 
ImmTAC-gp100 versus single anti-CD3 (UCHT1) scFv ImmTAC-gp100.  
 
IFN-γ ELISpot assay showing the activation of titrating numbers of unstimulated 
purified CD8
+
 T cells mediated by 1 nM tandem anti-CD3 (UCHT1) scFv ImmTAC-
gp100 (closed grey squares) compared with 1 nM single anti-CD3 (UCHT1) scFv 
ImmTAC-gp100 (closed red circles) in the presence of the HLA-A*0201
+
/gp100
+
 
melanoma cell line, Mel526.  Data are means ± s.e.m. 
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3.2.5 The relationship between mTCR affinity and ImmTAC potency 
The relationship between mTCR affinity and the biological potency of ImmTAC 
molecules was investigated next.  To examine the relationship between biological 
activity and ImmTAC-pMHCI affinity, as determined by surface plasmon resonance 
(SPR) equilibrium measurements, titrating amounts of a panel of seven variants of 
ImmTAC-gp100 with KD values spanning over six orders of magnitude (Table 3-1) 
were investigated.  The melanoma cell line, Mel526, presenting natural levels of wild-
type gp100280-288 complexed to HLA-A*0201 (< 70 epitopes per cell) (Liddy et al., 
2012) was used as the target.  IFN-γ activity was measured from the redirected 
unstimulated purified CD8
+
 T cells (Figure 3-8).  All the ImmTAC variants respond in a 
concentration-dependent manner but are active in different concentration ranges.  The 
two ImmTACs with the highest affinities for pMHCI (KD values of 0.32 nM and 0.03 
nM) are the most potent, activating CD8
+
 T cells at concentrations as low as 10
-11 
M, 
with cellular EC50 values around 40 pM.  Progressive increases in EC50 are seen as the 
affinities of the ImmTAC/pMHCI interactions decrease, with the wildtype and 
minimally modified ImmTACs showing only limited activation even at the highest test 
concentration of 10
-8 
M.   
To summarise, the data shows the potency of ImmTAC reagents is dependent on 
the affinity of the interaction with cognate pMHCI antigen.  This serves to highlight the 
significance of the affinity engineering process and the potential of the high affinity 
mTCR as a targeting reagent. 
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Figure 3-8 The biological activity of a panel of ImmTAC-gp100 affinity variants. 
 
IFN-γ ELISpot assay showing the activation of unstimulated purified CD8+ T cells in 
the presence of the HLA-A*0201
+
/gp100
+
 melanoma cell line Mel526 and titrated 
amounts of a panel of seven ImmTAC-gp100 affinity variants, colour coded by affinity 
according to the inset key.  Data are means ± s.e.m.  The data shown are representative 
of three experiments. 
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Table 3-1 Binding kinetics of a panel of seven different ImmTAC-gp100 variants 
ImmTAC-gp100 Clone ID 
Ka 
(M
-1
s
-1
) 
Kd 
(s
-1
) 
T ½ (s) KD (nM) 
ImmTAC-gp100-(30000nM) awtbwt n.d n.d n.d 30000 
ImmTAC-gp100-(8000nM) a20bwt n.d n.d n.d 8000 
ImmTAC-gp100-(61nM) awtb5 1.6x10
5
 9.6x10
-3
 72 61 
ImmTAC-gp100-(43nM) awtb9 1.3x10
5
 5.5x10
-3
 126 43 
ImmTAC-gp100-(3.9nM) awtb17 1.4x10
5
 5.3x10
-4
 1000 3.9 
ImmTAC-gp100-(0.32nM) awtb23 1.7x10
5
 5.6x10
-5
 10000 0.32 
ImmTAC-gp100 a20b24 5.3x10
5
 6.7x10
-6
 104400 0.03 
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3.3 Summary 
In the experiments described in this Chapter I tested a number of different of mTCR-
anti-CD3 scFV fusion molecules to identify the optimal design for their ability to 
redirect primary CD8
+
 T cells to recognise tumour cells.  I used mTCRs specific for 
three different HLA A*0201-restricted epitopes: Melan-A/MART-1, NY-ESO-1 and 
gp100.  First, I compared different anti-CD3 scFv molecules and concluded that the 
UCHT1 antibody was by far the most potent as a mTCR effector fusion partner for 
activation of CD8
+
 T cells.  All subsequent experiments, therefore, used UCHT1 
fusions.  I next examined whether fusing the UCHT1 to the C-terminus or the N-
terminus of the mTCR produced a more potent T cell activator.  From these experiments 
I concluded that fusing the UCHT1 to the mTCR N-terminal end, which generates a 
more compact molecule and therefore probably generates closer proximity between the 
target cell and the T cell, enabled approximately 4-fold more potent T cell engagement.  
Fusion with two in-line anti-CD3 domains to the mTCR displayed higher affinity for 
CD3 immobilised on a 2-dimensional surface, but did not produce an improvement in 
potency; rather this design reduced the potency of the fusion molecule compared to the 
mTCR fused to a single UCHT1 scFv molecule. 
Overall, I conclude that the most potent ImmTACs use a single anti-CD3 scFv 
domain from the UCHT1 antibody fused to the N-terminus of an mTCR with the 
highest possible affinity for the pHLA target. 
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CHAPTER 4 IN VITRO CHARACTERISATION OF REDIRECTED T CELL 
ACTIVATION BY IMMTACS 
 
4.1 Introduction 
Studies have shown that CD8
+
 cytotoxic T cells (CTLs) are the major effector cells 
involved in the eradication of tumour cells (Celluzzi et al., 1996; Mackensen et al., 
2006; Rosenberg et al., 2011).  Activation of CTLs is normally initiated through 
engagement of their TCR with a specific peptide-HLA on the surface of target cells.  
After triggering through the TCR, CTLs secrete cytokines with cytotoxic and antiviral 
function, and exocytose lytic granules which deliver cytotoxic molecules directly into 
the target cell, resulting in apoptosis.  Several of these activation markers can be 
measured in cellular assays to study T cell responses and are therefore also useful for 
understanding redirected activation of CD8
+
 T cells with ImmTAC molecules.  Many of 
the T cell activation markers are also of pivotal importance for understanding the 
therapeutic potential of T cell activation: whilst lytic granule secretion is mainly 
responsible for direct target cell killing, activated CTLs are also thought to mediate 
indirect anti-tumour activity by the production of pro-inflammatory cytokines, such as 
interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α) and interleukin-2 (IL-2).  
Indirect stimulation of the immune system through cytokines can have profound anti-
tumour effects; for example, a fraction of patients with metastatic melanoma or kidney 
cancer have responded to treatments with IL-2 and IFN (Dutcher, 2002).  
 
Cytotoxic CD8
+
 T cells represent a major source of IFN-γ and its secretion is one of the 
earliest markers of T cell activation.  IFN-γ production is induced following antigen or 
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mitogen stimulation of the T cell receptor.  Its release has both immunostimulatory and 
immunomodulatory effects and has been associated with anti-viral, immunoregulatory, 
and anti-tumour responses (Schroder et al., 2004).  A major anti-tumour effect of IFN-γ 
is to enhance MHC class I expression on the surface of tumour cells, thus rendering 
them more susceptible to recognition by tumour-specific CD8
+
 T cells (J. Alimonti et 
al., 2000; Shankaran et al., 2001).  There have been a number of studies demonstrating a 
critical role for endogenously produced IFN-γ in promoting host anti-tumour responses 
(reviewed in (Ikeda et al., 2002)).  An example is a study by Schreiber and co-workers 
(Kaplan et al., 1998) which examined the effects of IFN-γ on the development of both 
chemically induced and spontaneously arising tumours in mice.  Essentially, mice 
lacking sensitivity to either IFN-γ (i.e., IFN-γ receptor deficient mice) or all IFN family 
members (i.e., Stat1-deficient mice) developed tumours more rapidly and with greater 
frequency when challenged with different doses of the chemical carcinogen 
methylcholanthrene (MCA) compared to wild-type mice.  To address the role of IFN-γ 
in preventing the incidence of spontaneous tumours, the authors monitored the 
development of tumours in IFN-γ-sensitive and IFN-γ-insensitive (IFN-γ receptor 
negative) mice that lack the p53 tumour-suppressor gene.  They found that IFN-γ-
insensitive mice developed tumours more quickly than wild-type mice when bred onto a 
background deficient in p53.  Furthermore, IFN-γ-insensitive p53-/- mice also developed 
a broader range of tumours compared with mice lacking p53 alone (Kaplan et al., 1998).   
 
In addition to cytokine release, activated CD8
+
 T cells are capable of inducing lysis of 
tumour cells via the granule-exocytosis pathway.  Cytolytic granules are exocytoxic 
vesicles stored within CTLs, but they are also found in other cell types such as natural 
killer (NK) cells.  They contain various proteins including the pore-forming protein 
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perforin and the proteolytic enzyme granzyme B, which upon antigen encounter, release 
these molecules towards the target cell.  Once inside the target cell, granzyme B elicits 
programmed cell death (apoptosis) via proteolytic activation of pro-caspases and direct 
cleavage of caspase substrates (D. Chowdhury & Lieberman, 2008; Elgert, 2009).  
Granzyme B release, therefore, represents an important early marker of T cell 
activation. 
 
In this chapter, I aimed to assess the potency, antigen sensitivity, and specificity of 
ImmTAC molecules by measuring the release of two early markers of T cell activation: 
IFN-γ and granzyme B.  A functional T cell assay, the enzyme-linked immunospot 
(ELISpot) assay, was the tool selected to quantitate these responses.  ELISpot, a 
modified version of the sandwich enzyme-linked immunosorbent assay (ELISA), is a 
highly sensitive assay and allows detection of cytokine release from T cells at the single 
cell level (Helms et al., 2000).  I have also sought to investigate the ability of ImmTAC 
reagents to redirect different T cell populations derived from healthy donors as well as 
T cells derived from cancer patients, including T cells isolated directly from the tumour 
microenvironment.  Finally, the ability of ImmTACs to redirect T cell activity against 
ex vivo primary tumour was investigated as this will be crucial in determining whether 
ImmTACs could be effective as potential cancer therapeutics. 
 
4.2 Results 
4.2.1 The potency and specificity of different ImmTACs to target tumour cell lines 
and activate CD8
+
 T cells 
In this section, four ImmTAC reagents are investigated for biological activity and 
specificity.  The ImmTACs were engineered on the basis of TCRs isolated from T cell 
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clones specific for the following tumour-associated epitopes: (1) gp100280-288, 
YLEPGPVTA-HLA-A*0201 (Cox et al., 1994); (2) Melan-A/MART-126-35, 
EAAGIGILTV-HLA-A*0201 (Kawakami, Eliyahu, Sakaguchi et al., 1994); (3) NY-
ESO-1/LAGE-1157-165, SLLMWITQC-HLA-A*0201 (Jager et al., 1998); and (4) 
MAGE-A3168-176, EVDPIGHLY-HLA-A*0101 (Celis et al., 1994). 
 
High-affinity mTCRs were generated from the isolated wild-type TCRs using directed 
molecular evolution and phage display selection (Y. Li et al., 2005).  The binding of 
each ImmTAC to its cognate pMHCI complex has been biophysically characterised by 
surface plasmon resonance (SPR) equilibrium-binding measurements (Table 4-1).  For 
all four ImmTACs, the antigen binding properties were similar to that of the 
corresponding unfused mTCR indicating that the integrity of the mTCR binding surface 
has not been compromised by the process of fusing the anti-CD3 scFv to the mTCR β-
chain.  The binding of the anti-CD3 scFv component to immobilised CD3εγ protein was 
similar for all the ImmTAC reagents (Liddy et al., 2012). 
 
To evaluate the biological activity and specificity of the four different ImmTACs, IFN-γ 
ELISpot assays were conducted to measure the activation of unstimulated purified 
CD8
+
 T cells (Figure 4-1a-d).  In concentration-response experiments, all four 
ImmTACs produce EC50 values in the range of 100 pM or lower which is consistent 
with the KD values for the corresponding ImmTAC/pMHCI interactions.  Responses are 
only seen to the antigen relevant targets.   
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Figure 4-1 The biological activity and specificity of different ImmTAC molecules. 
 
IFN-γ ELISpot assay showing the activation of unstimulated purified CD8+ T cells 
mediated by increasing concentrations of ImmTAC molecules in the presence of tumour 
cells expressing endogenous levels of cognate antigen (closed circles).  Antigen-
negative tumour cells matched for expression of the relevant HLA class I molecules 
(closed triangles) were used in parallel titrations under identical conditions as specificity 
controls.  The shaped-matched open symbols represent the corresponding ImmTAC-
negative controls.  Tumour cell line target cells were as follows: (a) For ImmTAC-
NYE, IM9 EBV-transformed B-lymphoblastoid cells (NY-ESO
+
) and Mel526 
melanoma cells (NY-ESO
-
). (b) For ImmTAC-gp100, Mel526 melanoma cells (gp100
+
) 
and A375 melanoma cells (gp100
-
) were used. (c) For ImmTAC-MAGE, A375 
melanoma cells (MAGE-A3
+
) and Colo205 (MAGE-A3
-
). (d) For ImmTAC-MEL, 
Mel624 melanoma cells (Melan-A/MART-1
+
) and A375 melanoma cells (Melan-
A/MART-1
-
).  The equilibrium binding (KD) and half-life (T½) values determined by 
SPR are indicated for each ImmTAC-pMHCI interactions (Table 4-1).  Data are means 
± s.e.m.  The data shown are representative of three experiments. 
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Table 4-1 Binding kinetics of ImmTAC molecules with different specificities 
 
†
 SPR was carried out using soluble HLA complexed to heteroclitic peptide because 
these were more stable than the wild-type peptide in these soluble formats. 
 
 
 
 
 
 
 
 
 
ImmTAC 
Target 
Protein/Peptide 
HLA 
Peptide 
used for 
SPR
†
 
TCR binding to HLA-peptide 
complex 
Ka 
(M
-1
s
-1
) 
Kd 
(s
-1
) 
T ½ 
(h) 
KD 
(pM) 
ImmTAC-NYE 
NY-ESO-1157-165 
SLLMWITQC 
HLA*0201 SLLMWITQV 6.25x10
5
 1.13x10
-5
 17.0 18 
ImmTAC-
gp100 
gp100280-288 
YLEPGPVTA 
HLA*0201 YLEPGPVTV 5.38x10
5
 7.61x10
-6
 14.1 25 
ImmTAC-
MAGE 
Mage-A3168-176 
EVDPIGHLY 
HLA*0101 EVDPIGHLY 14.5x10
5
 1.92x10
-5
 12.3 44.5 
ImmTAC-MEL Melan-A/MART-126-
35 EAAGIGILTV 
HLA*0201 ELAGIGILTV 1.33x10
5
 5.20x10
-6
 37.0 39 
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4.2.2 The relationship between mTCR affinity and the capacity to detect low levels 
of peptide-MHC class I 
Down-regulation of MHC class I antigen expression is a common mechanism by which 
tumour cells evade immune detection (Cabrera et al., 2003; Seliger et al., 2001).  
Therefore, in order to be able to eliminate tumours, ImmTACs need to be effective in 
the presence of low levels of peptide-MHC class I (pMHCI).  To investigate further the 
relationship between the ImmTAC-pMHCI affinity and sensitivity to peptide, a panel of 
seven variants of ImmTAC-gp100 with KD values spanning over six orders of 
magnitude (Table 3-1) were evaluated.  T2 cells pulsed with titrating amounts of the 
heteroclitic gp100280-288 YLEPGPVTV peptide (10
-7
-10
-12 
M) in the context of HLA-
A*0201, were used as targets.  IFN-γ activity was measured from redirected 
unstimulated purified CD8
+
 T cells in the presence of each of the seven ImmTAC-
gp100 variants (Figure 4-2).  The data shows that there is a clear correlation between 
the KD of the ImmTAC reagent and the sensitivity to peptide.  For the ImmTAC 
variants with the higher KD values, a progressive reduction in peptide sensitivity is 
observed.  This is a strictly hierarchical relationship so that, the higher the KD, the 
further the concentration-response curves shift to the right, i.e., higher levels of peptide 
are required to elicit a T cell response.  Indeed, the wild-type ImmTAC-gp100 (KD = 30 
μM) and minimally modified ImmTAC-gp100 (KD = 8 μM) fail to activate CD8
+
 T 
cells at any of the tested peptide concentrations whereas the highest affinity ImmTACs 
(KD values of 0.32 nM and 0.03 nM) show the greatest peptide sensitivity and can 
activate CD8
+
 T cells at as low as 10
-10 
M peptide which equates to 2-10 pMHCI 
epitopes per cell.  This data highlights the importance of affinity engineering for the 
capability of mTCR ImmTACs to detect low levels of pMHCI.  
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Figure 4-2 The peptide sensitivity of a panel of ImmTAC-gp100 affinity variants. 
 
IFN-γ ELISpot assay showing the activation of unstimulated purified CD8+ T cells in 
the presence of T2 cells pulsed with titrated amounts of the gp100280-288 heteroclitic 
peptide YLEPGPVTV and different ImmTAC-gp100 variants, colour coded by affinity 
according to the inset key, each at a concentration of 100 pM.  The epitope numbers 
were determined by single-cell three-dimensional fluorescence microscopy at different 
concentrations of exogenous peptide and were 0-3 at 10
-11 
M, 2-10 at 10
-10 
M and 15-45 
at 10
-9 
M; the latter corresponds to the number of antigens typically detected on tumour 
cells (indicated with an asterisk).  At higher concentrations of peptide, the number 
presented could not be determined accurately as the large number of fluorescent 
molecules meant that these could not be individually differentiated under the 
microscope.  Data are means ± s.e.m.  The data shown are representative of three 
experiments. 
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4.2.3 ImmTAC redirected activation of different T cell populations 
The data presented thus far has examined the biological activity of ImmTAC molecules 
to activate purified unstimulated CD8
+
 T cells.  Next, the capacity of ImmTAC 
molecules to recruit T cells from the more physiologically relevant mixed population of 
peripheral blood mononuclear cells (PBMC) was examined.  Furthermore, as the 
activation of T cells by ImmTAC is not dependent on co-receptor binding, ImmTAC 
molecules should be capable of recruiting CD4
+
 T cells as well as CD8
+
 T cells and this 
was also investigated. 
 
4.2.3.1 Redirection of peripheral blood mononuclear cells (PBMC) 
In order to make the in vitro assays as physiological as possible, the ability of ImmTAC 
molecules to activate PBMC, i.e, ex vivo unselected effector cells, was assessed.  The 
melanoma cell line, Mel526, expressing natural levels of wild-type gp100280-288 
complexed to HLA-A*0201, was used as targets.  IFN-γ activity was measured from 
redirected unstimulated PBMC in the presence of increasing concentrations of the 
ImmTAC-gp100 (Figure 4-3).  The data shows concentration-dependent release of IFN-
γ from the redirected PBMC producing an EC50 value of 27 pM.  The potency seen is 
comparable to that achieved using purified unstimulated CD8
+
 T cells confirming that a 
mixed population of PBMC are equally responsive to ImmTAC stimulation.  No 
activation of PBMC is seen in the presence of ImmTAC without targets.  Furthermore, 
no response is seen against the HLA-A*0201
+
, antigen negative control cell line.  
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Figure 4-3 ImmTAC-gp100 redirected activity of healthy donor ex vivo PBMC. 
 
IFN-γ ELISpot assay showing activation of unstimulated PBMC mediated by increasing 
concentrations of ImmTAC-gp100 in the presence of the HLA-A*0201
+
/gp100
+
 
melanoma cell line Mel526 (red circles).  The HLA-A*0201
+
/gp100
-
 melanoma cell line 
A375 (grey squares) was included as a specificity control. The shape-matched open 
symbols represent the corresponding ImmTAC-gp100-negative controls.  Controls also 
include PBMC in the presence of 10 nM ImmTAC-gp100, without targets (open 
triangle).  Data are means ± s.e.m.  The data shown are representative of three 
experiments. 
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4.2.3.2 Redirection of CD4
+
 T cells 
PBMC contain a mixture of T cells which includes both CD8
+
 and CD4
+
 T cells.  CD4
+
 
T cells play a crucial role in anti-tumour immune responses, particularly the CD4
+
 T 
helper (Th) lymphocyte subset.  CD4
+
 Th lymphocytes mediate their anti-tumour effects 
in multiple ways including the release of cytokines such as IFN-γ and TNF-α, and 
through the recruitment of cells of the innate immune system to the tumour site such as 
macrophages and NK cells.  However, their major contribution for anti-tumour effects 
is thought to be by providing the required T cell help for generating and augmenting 
tumour-specific CTL responses, mainly by the secretion of the cytokine interleukin-2 
(IL-2).  IL-2 is an important growth factor for CTLs and its secretion by CD4
+
 Th cells 
can function to recruit and retain CTLs at the tumour site (Kennedy & Celis, 2008).  
Furthermore, the presence of IL-2 during priming has been shown to be necessary for 
the secondary expansion of memory CD8
+
 T cells (Williams et al., 2006).  Therefore, 
the recruitment by ImmTACs of CD4
+
 T cells, in addition to CD8
+
 T cells, is highly 
desirable. 
 
The ability of ImmTACs to activate CD4
+
 T cells was investigated as follows.  The 
melanoma cell line, Mel526, expressing natural levels of wild-type gp100280-288 
complexed to HLA-A*0201, was used as targets.  IFN-γ activity was measured from 
redirected unstimulated purified CD4
+
 T cells in the presence of increasing 
concentrations of ImmTAC-gp100 (Figure 4-4).  The data shows concentration-
dependent release of IFN-γ from the redirected CD4+ T cells.  The potency observed 
with ImmTAC-gp100 redirected CD4
+
 T cells (EC50 value = 58 pM) is similiar to that 
achieved using purified unstimulated CD8
+
 T cells (EC50 value = 62 pM) (Figure 4-1b) 
or PBMC (EC50 value = 27 pM) (Figure 4-3).  The data suggests that the recruitment by 
Chapter 4 
 137 
ImmTACs of CD4
+
 T cells could be beneficial in augmenting the anti-tumour response 
in vivo. 
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Figure 4-4 ImmTAC-gp100 redirected activity of CD4
+
 T cells. 
 
IFN-γ ELISpot assay showing activation of unstimulated purified CD4+ T cells 
mediated by increasing concentrations of ImmTAC-gp100 in the presence of the HLA-
A*0201
+
/gp100
+
 melanoma cell line Mel526 (red circles).  The HLA-A*0201
+
/gp100
-
.melanoma cell line A375 (grey squares) was included as a specificity control.  The 
shape-matched open symbols represent the corresponding ImmTAC-gp100-negative 
controls.  Controls also include CD4
+
 T cells in the presence of 10 nM ImmTAC-gp100, 
without targets (open triangle).  Data are means ± s.e.m.  The data shown are 
representative of two experiments. 
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4.2.4 The CD8
+
 T cell subsets and polyfunctional responses activated by ImmTAC 
redirection 
To further determine the effects of ImmTACs under physiological conditions and to 
examine in more detail the subsets of CD8
+
 T cells that are activated by ImmTAC, 
polychromatic flow cytometry experiments were conducted on PBMC directly ex vivo.  
The following flow cytometry data sets are courtesy of Dr. David Price and Dr. Kristin 
Ladell at Cardiff University (Liddy et al., 2012). 
 
A titration experiment with ImmTAC-gp100 against PBMC pulsed with the gp100280-288 
heteroclitic peptide YLEPGPVTV showed that CD8
+
 T cells are activated in a 
concentration-dependent manner to elicit multiple effector functions.  This includes 
degranulation, as indicated by the surface mobilisation of lysosomal-associated 
membrane protein-1 (CD107a), and production of the cytokines IFN-γ, tumour necrosis 
factor (TNF) and interleukin-2 (IL-2) (Figure 4-5a).  At the same time, the use of 
standard phenotypic parameters revealed which subsets of CD8
+
 T cells are being 
activated by ImmTAC-gp100 (Figure 4-5b).  The data indicates that the activated CD8
+
 
T cells are mainly distributed in the central memory (CD45RO
+
, CD27
+
) and effector 
memory (CD45RO
+
, CD27
-
) compartments.  A similar pattern of responses, although 
weaker, are also elicited when using the melanoma cell line, Mel526, expressing natural 
levels of antigen as targets (Figure 4-5c).  In addition, most of the activated CD8
+
 T 
cells showed a terminally differentiated phenotype characterised by the expression of 
the senescence marker CD57 (Liddy et al., 2012); CD57 identifies CD8
+
 T cells with 
maximal lytic capacity (Chattopadhyay et al., 2009).  Activation of the CD4
+
 T cell 
compartment is also detected and the response is characterised by the production of 
substantial amounts of TNF and IL-2 (Figure 4-5d-f). 
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Figure 4-5 Activation of multiple CD8
+
 T cell effector functions by ImmTAC-
gp100. 
 
Polychromatic flow cytometry experiments showing the activation of fresh PBMC 
mediated by ImmTAC-gp100 at the indicated concentrations in the presence of target 
PBMC pulsed with the gp100280-288 heteroclitic peptide YLEPGPVTV (10
-6
 M) or mock 
pulsed with medium alone, or target Mel526 melanoma cells expressing endogenous 
wild-type gp100280-288 complexed to HLA-A*0201.  Degranulation marker, CD107a 
(green) and the intracellular production of the cytokines IFN--γ (yellow), TNF (red) and 
IL-2 (turquoise) are shown. (a) The dose-response relationship between the 
concentration of ImmTAC-gp100 and the percentage of CD8
+
 T cells activated to 
express each individual function in the presence of peptide-pulsed PBMC. (b,c) The 
phenotypic profile of CD8
+
 T cells activated with ImmTAC-gp100 at a concentration of 
10
-11
 M in the presence of peptide-pulsed PBMC (b) or Mel526 cells (c).  The coloured 
dots depict individual cells that elicited a distinct function, as indicated in a, 
superimposed on cloud plots showing the phenotypic profile of the overall CD8
+
 T cell 
population; events shown in b correspond to those shown in a at a concentration of 10
-11
 
M and are colour coded to match. (d-f) CD4
+
 T cell activation data from the same 
experiments and with the same details described in a-c.  Courtesy of D. Price and K. 
Ladell. 
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4.2.5 Granzyme B release by T cells activated by ImmTAC 
Granzyme B is a member of the granzyme family of serine proteases which are located 
in the cytotoxic granules of CTLs and NK cells.  Granzyme B induces the apoptosis of 
target cells by cleaving and activating members of the caspase family.  Conventionally, 
killing assays such as 
51
Cr-release assay have been used for the detection of activated 
CTLs.  However, assays that measure the secretion of cytolytic granule contents provide 
an alternative functional readout of specifically activated and degranulating T cells.  
The granzyme B ELISpot assay has been validated as a non-radioactive alternative to 
51
Cr–release assays; results in the ELISpot assay have been shown to correlate with 
cytolytic responses measured by the classic radioactive 
51
Cr-release assay (Rininsland et 
al., 2000) and may even be superior because of its high sensitivity (Malyguine et al., 
2007).   
 
Using the ELISpot assay, the ability of ImmTACs to stimulate granzyme B release from 
unstimulated purified CD8
+
 T cells was investigated.  The Mel526 melanoma cell line 
expressing natural levels of wild-type gp100280-288 complexed to HLA-A*0201 was used 
as targets in the presence of increasing concentrations of ImmTAC-gp100 (Figure 4-6).  
A concentration-dependent release of granzyme B from the redirected CD8
+
 T cells is 
observed suggesting that ImmTAC-gp100 is specifically activating CTL mediated 
apoptosis of the Mel526 melanoma targets via the granule exocytosis pathway.  No 
activity is seen against the HLA-A*0201
+
, antigen-negative cell line A375, or in the 
absence of targets. 
 
 
 
Chapter 4 
 142 
-13 -12 -11 -10 -9 -8
0
10,000
20,000
30,000
40,000 Mel526
A375
C
o
n
tr
o
ls
EC50 = 59 pM
Log10[ImmTAC-gp100](M)
G
ra
n
z
y
m
e
 B
 S
F
C
p
e
r 
1
0
6
C
D
8
+
c
e
ll
s
 
Figure 4-6 Granzyme B release by CD8
+
 T cells redirected by ImmTAC-gp100. 
 
Granzyme B ELISpot assay showing activation of unstimulated purified CD8
+
 T cells 
mediated by increasing concentrations of ImmTAC-gp100 in the presence of the HLA-
A*0201
+
/gp100
+
 melanoma cell line Mel526 (red circles).  The HLA-A*0201
+
/gp100
-
 
melanoma cell line A375 (grey squares) was included as a specificity control.  The 
shape-matched open symbols represent the corresponding ImmTAC-gp100-negative 
controls.  Controls also include CD8
+
 T cells in the presence of 10 nM ImmTAC-gp100, 
without targets (open triangle).  Data are means ± s.e.m.  The data shown are 
representative of three experiments. 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 143 
Next, to test that ImmTACs could stimulate granzyme B release from a more 
physiologically relevant population of T cells, assays were performed using PBMC as 
effectors.  In this example, EJM, a multiple myeloma cell line expressing natural levels 
of wild-type MAGE-A3168-176 complexed to HLA-A*0101 was used as targets in the 
presence of increasing concentrations of the ImmTAC-MAGE (Figure 4-7).  As seen for 
purified CD8
+
 T cells, concentration-dependent release of granzyme B from the 
redirected PBMC is also observed producing an EC50 value of 30 pM. 
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Figure 4-7 Granzyme B release by PBMC redirected by ImmTAC-MAGE. 
 
Granzyme B ELISpot assay showing the activation of unstimulated PBMC mediated by 
increasing concentrations of ImmTAC-MAGE in the presence of the HLA-
A*0101
+
/MAGE-A3
+
 multiple myeloma cell line EJM (green circles).  The HLA-
A*0101
+
/MAGE-A3
-
 cell line Colo205 (grey squares) was included as a specificity 
control.  The shape-matched open symbols represent the corresponding ImmTAC-
MAGE-negative controls.  Controls also include PBMC in the presence of 6.4 nM 
ImmTAC-MAGE, without targets (open triangle).  Data are means ± s.e.m.  The data 
shown are representative of six experiments. 
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4.2.6 Testing the capacity of cancer patient derived T cells for ImmTAC redirected 
activation 
There is some evidence to suggest that global T cell dysfunction is a common feature in 
cancer patients (Finke et al., 1993; Nakagomi et al., 1993).  It has also been reported 
that tumour associated antigen (TAA)-specific T cells generated de novo in patients 
with metastatic melanoma are rendered functionally unresponsive, fail to kill melanoma 
target cells or produce cytokines in response to mitogens (Lee et al., 1999).  
Furthermore, cancer patients that have received intensive chemotherapy could be 
immunosuppressed (Mackall, 2000).  Therefore, T cells from late stage cancer patients 
could be less responsive to ImmTAC redirected activation compared to those from 
healthy donors.  To approach this question, the ability of ImmTAC-gp100 to redirect 
and enhance the biological activity of late stage melanoma patient T cells was 
investigated.  The Mel526 melanoma cell line, expressing natural levels of wild-type 
gp100280-288 complexed to HLA-A*0201, was used as targets.  IFN-γ and granzyme B 
activity was measured from redirected unstimulated PBMC derived from two different 
stage IV HLA-A*0201
+
 melanoma patients (Fig 4-8a,b and Fig 4-9a,b).  The data shows 
that these cancer patient T cells are not functionally impaired in the presence of 
ImmTAC-gp100, and respond in a similar concentration-dependant manner to T cells 
derived from healthy donors.  Interestingly, the PBMC of one patient already appears 
reactive to melanoma cells without stimulation by ImmTAC-gp100 as evidenced by the 
presence of raised IFN-γ baseline activity (indicated by the open circle in Figure 4-8a).  
This data further shows that ImmTAC-gp100 is capable of amplifying an already 
present anti-tumoural IFN-γ response in patient blood.  However, no raised baseline 
activity is evident for granzyme B release (Figure 4-8b) despite the same patient PBMC 
being used.   
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Figure 4-8 ImmTAC-gp100 redirected activity of stage IV melanoma patient 
PBMC (sample ID: IC/9/18). 
 
ELISpot assays showing the activation of advanced melanoma patient PBMC mediated 
by increasing concentrations of ImmTAC-gp100 in the presence of the HLA-
A*0201
+
/gp100
+
 melanoma cell line Mel526 (red circles) and the control HLA-
A*0201
+
/gp100
-
 melanoma cell line A375 (grey squares).  The shape-matched open 
symbols represent the corresponding ImmTAC-gp100-negative controls.  Controls also 
include PBMC in the presence of 10 nM ImmTAC-gp100, without targets (open 
triangles).  (a) IFN-γ release by redirected melanoma patient PBMC; data shown are 
representative of three experiments (b) Granzyme B release by redirected melanoma 
patient PBMC; data shown are representative of two experiments.  Data are means ± 
s.e.m. 
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Figure 4-9 ImmTAC-gp100 redirected activity of stage IV melanoma patient 
PBMC (sample ID: IC/12/20). 
 
ELISpot assays showing the activation of advanced melanoma patient PBMC mediated 
by increasing concentrations of ImmTAC-gp100 in the presence of the HLA-
A*0201
+
/gp100
+
 melanoma cell line Mel526 (red circles) and the control HLA-
A*0201
+
/gp100
-
 melanoma cell line A375 (grey squares).  The shape-matched open 
symbols represent the corresponding ImmTAC-gp100-negative controls.  Controls also 
include PBMC in the presence of 10 nM ImmTAC-gp100, without targets (open 
triangles).  (a) IFN-γ release by redirected melanoma patient PBMC; data shown are 
representative of three experiments (b) Granzyme B release by redirected melanoma 
patient PBMC; data shown are representative of two experiments.  Data are means ± 
s.e.m. 
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4.2.7 Ex vivo ImmTAC redirected activation of marrow infiltrating lymphocytes 
(MILs) 
Multiple myeloma is a disease that occurs in the bone marrow. It is characterised by the 
malignant outgrowth of clonal plasma cells that secrete a monoclonal immunoglobulin, 
and the eventual development of osteolytic bone lesions (Mahindra et al., 2010).  The 
bone marrow tumour microenvironment is known to play an important role in disease 
progression.  Complex interactions of the myeloma tumour cells with various cell types 
within the bone marrow such as bone marrow stroma, osteoclasts (bone resorbing cells), 
osteoblasts (bone forming cells), T cells, dendritic cells (DCs) and myeloid-derived 
suppressor cells (MDSCs) promote cancer cell survival and evasion of immune 
recognition (Noonan & Borrello, 2011). 
A study has shown that activated marrow-infiltrating lymphocytes (MILs) from 
multiple myeloma patients show significant tumour specificity compared to activated 
peripheral blood lymphocytes (PBL) from the same patient.  Furthermore, activated 
MILs were shown to target both the terminally differentiated CD138
+
 plasma cells and 
their clonogenic precursors (Noonan et al., 2005).  However, the immune suppressive 
microenvironment in myeloma usually prevents the generation of effective anti-tumour 
responses by MILs.  This is supported by evidence that tumour-specific T cells from the 
myeloma microenvironment are not reactive against autologous tumour cells ex vivo, 
but that this reactivity is restored after stimulation ex vivo with DCs that have processed 
autologous tumour cells (Dhodapkar et al., 2002). 
 
The ability of ImmTAC-MAGE to redirect and enhance the biological of activity of ex 
vivo MILs was investigated.  It was not technically feasible to isolate and purify MILs 
directly from the multiple myeloma patient bone marrow aspirate biopsy samples due to 
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the low cell numbers.  Therefore, the CD138
-
 population, which contains MILs, was 
isolated and used in the following in vitro cellular assays.  The percentage of CD4
+
 and 
CD8
+
 MILs present in the CD138
-
 fraction was determined by flow cytometry antibody 
staining experiments in order to calculate the appropriate number of MILs to use.  Thus, 
in the following experiment, IFN-γ release was measured from redirected MILs present 
in the CD138
-
 population isolated from bone marrow aspirate samples of two stage III 
myeloma patients.  EJM, a multiple myeloma cell line expressing natural levels of wild-
type MAGE-A3168-176 complexed to HLA-A*0101, was used as targets (Figure 4-10a,b).  
The data shows that ex vivo MILs from bone marrow aspirate samples of myeloma 
patients can be activated by ImmTAC-MAGE in a concentration-dependent manner.  
The potency seen with sample #26 MILs (Figure 4-10b) is similar to that observed with 
healthy donor T cells using the MAGE-specific ImmTAC (Figure 4-1c) (EC50 values of 
23 pM and 31 pM, respectively).  However, for sample #22, the EC50 value is ~ 5-fold 
higher at 125 pM.  It should be noted that due to limited cell numbers that the data are 
representative of one experiment only for each sample.  Further investigations on 
sample #26 by a colleague, Dr. Giovanna Bossi, demonstrated that redirection by 
ImmTAC-MAGE resulted in an up-regulation of the activation marker CD25 on both 
the CD4
+
 and CD8
+
 MIL populations and that the MILs were able to lyse EJM target 
cells in a FACS-based killing assay.  As a control, PBMC from a healthy donor were 
tested in parallel with the MILs, under identical conditions, and no significant 
differences were observed (data not shown).  Therefore, ImmTAC-MAGE can 
effectively redirect T cells extracted from the myeloma microenvironment.   
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Figure 4-10 ImmTAC-MAGE redirected activity of MILs isolated from the bone 
aspirate samples of two stage III myeloma patients. 
 
ELISpot assays showing the activation of late stage myeloma patient MILs mediated by 
titrated amounts of ImmTAC-MAGE in the presence of the HLA-A*0101
+
/MAGE-A3
+
 
myeloma cell line EJM (green).  The controls are represented by EJM and MILs, in the 
absence of ImmTAC-MAGE (open circles), HLA-A*0101
+
/MAGE-A3
-
 cell line 
Colo205 with MILs in the presence of 300 pM ImmTAC-MAGE (open squares) and, 
MILs in the presence of 0.3 nM ImmTAC-MAGE, without targets (open triangles) (a) 
MILs isolated from myeloma bone marrow aspirate sample #22 (b) MILs isolated from 
myeloma bone marrow aspirate sample #26.  Data are means ± s.e.m.  The data shown 
are representative of one experiment only. 
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4.2.8 ImmTAC redirected activation against ex vivo primary tumour cells 
Established, continuously growing tumour cell lines have been employed extensively to 
investigate ImmTAC redirected activity.  However, despite representing a convenient 
and reproducible tool for characterising the ImmTAC reagents, it is possible that the 
biological properties of tumour cell lines have been altered during the culturing process, 
and as such, may not completely reflect the characteristics of a clinical tumour (Tveit & 
Pihl, 1981).  Therefore, ImmTACs were also evaluated against fresh tumour samples 
taken directly from patients. 
Working with fresh tumour samples poses three main challenges:  first, 
obtaining fresh tumour sample to begin with; second, the difficultly of processing the 
samples; and third, the low cell number and poor viability of the tumour cells after 
processing which involves concerns about their ultimate quality when ready to use in 
assays.  Clinical tumour samples can be obtained from a commercial supplier or in some 
circumstances directly from the clinic.  The limitations that have been experienced with 
commercial suppliers are that they cannot necessarily supply the tumour of interest.  
The tumour sample also needs to be of the correct HLA type which reduces the number 
of suitable samples further.  Another issue with commercial tumour samples is the poor 
quality and/or viability of the samples.  Ideally, fresh patient tumour samples are 
obtained directly from a local oncology clinic so that samples remain fresh during 
transportation.   
For a tumour sample to be suitable for use in cell assays, a single-cell suspension 
is a prerequisite.  Furthermore, tumour tissues often contain many normal cells such as 
lymphocytes and fibroblasts and therefore need to be purified to obtain an enriched 
population of tumour cells.  For non-solid cancers, such as multiple myeloma, the 
cancer cells are already in suspension making them relatively easy isolate and purify.  
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However, for solid tumours such as melanoma, mechanical separation and/or enzymatic 
treatment of the tumour tissue is performed to make a single-cell suspension but this 
process can damage the tumour so as to limit the downstream applications.  ImmTAC 
redirected activity is dependent on the targeted epitope being present on the surface of 
the tumour cells but the use of the enzyme trypsin, for example, which is an effective 
treatment for the disaggregation of solid tumours, can destroy cell surface molecules 
such as pMHC.  On the other hand, gentler methods are usually not sufficient to 
produce a single-cell suspension.  However, the biggest challenge faced with using 
fresh tumour samples is the low cell number and poor viability after processing.  
Although bone marrow aspirate samples from multiple myeloma patients are relatively 
easy to process, the viability of CD138
+
 cells, which contain the malignant plasma cells, 
decreases rapidly, minutes after isolation.  To use the CD138
+
 cells in the cell assays 
described in section 4.2.8.2 required careful planning and efficient execution of the 
experiment to ensure the tumour cells were of good quality. 
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4.2.8.1 ImmTAC-NYE activation of T cells in the presence of freshly isolated lung 
tumour cells 
A clinical lung cancer sample, NSCLC#29, which is known to express high levels of 
LAGE-1, as determined by quantitative RT-PCR, and is HLA-A*0201 positive 
(McCormack et al., 2012), was used to test the ability of the NY-ESO-1/LAGE-1-
specific ImmTAC, ImmTAC-NYE, to redirect T cell activity against freshly isolated 
tumour cells.  IFN-γ activity was measured from redirected unstimulated PBMC (Fig 4-
11).  The data shows that IFN-γ is released from the PBMC in the presence of 
NSCLC#29 and ImmTAC-NYE in a concentration-dependent manner, similar to that 
observed against tumour cell lines.  However, the EC50 value at 1.3 nM is considerably 
higher than that seen against tumour cell lines.  The proportion of tumour cells within 
the sample was not known, and the quality of the material was quite low which may 
explain the discrepancy in EC50 values.  Limited tumour cell numbers meant that 
redirected killing by ImmTAC-NYE could not be evaluated, and it should be noted that 
the data is representative of one experiment only. 
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Figure 4-11 ImmTAC-NYE redirected activity against HLA-A*0201
+
/LAGE-1
+
 
freshly isolated lung cancer sample. 
 
IFN-γ ELISpot assay showing activation of unstimulated PBMC mediated by increasing 
concentrations of ImmTAC-NYE in the presence of freshly isolated HLA-
A*0201
+
/LAGE-1
+
 lung cancer sample, NSCLC#29 (blue squares).  The HLA-
A*0201
+
/LAGE-1
-
/NY-ESO
-
 cell line Colo205 (grey triangles) was used as a specificity 
control.  The shape-matched open symbols represent the corresponding ImmTAC-NYE-
negative controls.  Data are means ± s.e.m. 
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4.2.8.2 ImmTAC-MAGE activation of T cells in the presence of myeloma targets 
derived from fresh primary myeloma tumour sample 
CD138 (syndecan-1) is a trans-membrane heparin sulphate proteoglycan that is 
typically expressed on plasma cells but not on T or B cells.  Therefore, CD138 is 
considered the most specific marker for plasma cells and is expressed on normal and 
malignant plasma cells (P. Lin et al., 2004). 
 
To investigate the activity of ImmTAC-MAGE against cells from a primary myeloma 
tumour sample, CD138
+
 plasma cells isolated from the bone marrow aspirate sample of 
a stage II multiple myeloma patient (sample #20), which is known to express MAGE-
A3, as determined by quantitative RT-PCR, and is HLA-A*0101 positive, were used as 
targets.  IFN-γ activity was measured from redirected unstimulated PBMC isolated from 
a healthy donor (Fig 4-12).  The data shows that IFN-γ is released from the PBMC upon 
redirection with ImmTAC-MAGE in the presence of CD138
+
 cells, which contain the 
malignant plasma cells, whereas activity against the CD138
-
 cells is minimal.  Attempts 
were made to isolate CD138
+
 from four other myeloma patient bone marrow aspirate 
samples but data could not be obtained from these experiments due to the poor viability 
of the purified CD138
+
 cells.  This serves to highlight the challenges of handling fresh 
tumour samples. 
 
Furthermore, concomitant FACS-based killing experiments conducted by Dr. Giovanna 
Bossi, showed that ImmTAC-MAGE used at 0.1 nM redirect T cells to kill 52% of the 
CD138
+
 targets.  By using an additional phenotypic marker, CD38, which is expressed 
at higher frequency by myeloma cells (P. Lin et al., 2004), Dr. Bossi found that the 
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CD38
+
 sub-population within the CD138
+
 target cells were preferentially killed (data 
not shown). 
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Figure 4-12 ImmTAC-MAGE redirected activity against CD138
+
 cells isolated 
from multiple myeloma bone marrow aspirate sample.  
 
IFN-γ ELISpot assay showing activation of unstimulated PBMC mediated by 0.1 nM of 
ImmTAC-MAGE in the presence of CD138
+
 cells (green bar) or CD138
-
 cells (grey 
bar) isolated from bone marrow aspirate sample of a HLA-A*0101
+
 stage II multiple 
myeloma patient (sample #20).  Controls are represented by targets and PBMC in the 
absence of ImmTAC-MAGE, and 0.1 nM ImmTAC-MAGE and PBMC in the absence 
of targets.  Data are means ± s.e.m.  The data shown are representative of one 
experiment only. 
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4.3 Summary 
The experiments described in this chapter show that ImmTAC reagents can potently 
redirect and activate T cells in the presence of tumour cell lines presenting naturally 
processed cognate peptide-HLA complex. All 4 ImmTACs elicit cellular EC50 values in 
the range of 100 pM or lower.  In peptide-titration experiments I show that the antigen-
sensitivity of the ImmTAC reagents is critically dependent on the affinity of the mTCR 
for its cognate pHLA.  The highest affinity mTCR ImmTAC-gp100 was capable of 
activating CD8
+
 T cells in the presence of target cells with pHLA densities as low as 2-
10 copies per cell.  Subsequently, I demonstrated that ImmTACs can redirect T cell 
activity against ex vivo primary tumour in addition to tumour cell lines.  From these 
experiments I conclude that ImmTACs are effective against tumour cells expressing low 
surface epitope densities, as may be encountered on tumour cells in patients.  I also 
show that ImmTAC redirected responses are specific and limited to cells that express 
cognate pHLA. 
T cell activation assays, measuring IFN-γ release by ELISpot assay and the 
initiation of the granule-exocytosis pathway of cell cytotoxicity as measured by 
granzyme B ELISpot, were used for demonstrating ImmTAC redirection of healthy 
donor unstimulated CD8
+
 T cells and CD4
+
 T cells, as well as unselected T cells i.e. 
PBMC.  Furthermore, I was able to show that ImmTACs can potently redirect PBMC 
from late stage melanoma patients and marrow infiltrating lymphocytes (MILs) from 
late stage multiple myeloma patients.  These results provide the first demonstration that 
a soluble reagent, based on human T cell receptors, can redirect the activity of non-
tumour specific T cells, and enhance the activity of tumour specific T cells, against 
naturally presenting cancer cells.  
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Other markers of T cell activation were also investigated such as the 
degranulation marker CD107a, and cytokines TNF and IL-2, indicating that ImmTACs 
can induce polyfunctional T cell responses.  Furthermore, it was demonstrated that the 
responding CD8
+
 T cells are mainly distributed in the central memory (CD45RO
+
, 
CD27
+
) and effector memory (CD45RO
+
, CD27
-
) compartments, and the activation of 
naïve T cells (CD45RO
-
, CD27
+
) is minimal. 
For the therapeutic ImmTAC candidate, ImmTAC-gp100, the potency data I have 
presented in this chapter has also been used in the pre-clinical data package, including 
regulatory documentation for the Food and Drug Administration (FDA) and the 
Medicine and Healthcare products Regulatory Agency (MHRA), to support its 
admission into a first-in-human clinical trial.  The therapeutic ImmTAC-gp100 
candidate is described in more detail in Chapter 6. 
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CHAPTER 5 TARGET CELL KILLING BY IMMTAC REDIRECTED T CELLS 
 
5.1 Introduction 
In the previous chapter, T cell activation assays were performed to assess the early 
events leading to target cell lysis by ImmTAC redirected T cells.  In these assays, the 
secretion of the cytokine IFN-γ has been analysed as has initiation of the granule-
exocytosis pathway of cytotoxicity through the detection of the release of granzyme B.  
However, for cancer treatment, the most desirable effector function is target cell lysis.  
Critical to the therapeutic potential of the ImmTAC molecule is that it is capable of 
redirecting CTLs to lyse tumour cells.  In this chapter I have attempted to perform a 
range of cellular assays to examine target cell fate.  As described in section 1.5.7.1, 
killing by CTL is based, at least in part, on the induction of apoptosis within the target 
cell.  During CTL-induced apoptosis, caspases become activated via the action of death 
receptors, cytochrome c/ Apaf-1, or through direct cleavage by granzyme B.  A caspase 
cascade is triggered which in turn acts upon substrates to begin the final phase of 
apoptosis whereby the cell is eventually destroyed.  Killing assays such as 
51
Cr-release 
and other non-radioactive ‘release’ assays are the main techniques for measuring CTL-
induced target cell damage during the final phase of apoptosis.  However, in addition to 
‘release’ assays I have investigated other methodologies to examine the short-term 
manifestations of ImmTAC redirected target cell killing by measuring the activation of 
caspases.  Furthermore, I describe the use of a novel technique to directly visualise 
ImmTAC redirected target cell killing over longer time intervals.  Finally, I attempted to 
assess the redirected lytic capability of different T cell populations from healthy donors 
including CD8
+
 T cell clones, polyclonal CD8
+
 T cells, and PBMC.  As potential cancer 
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therapeutics, ImmTACs must be able to redirect cancer patient T cells; therefore, the 
lytic activity of redirected cancer patient PBMC was also assessed. 
 
5.2 Results 
5.2.1 Short-term manifestations of ImmTAC redirected target cell killing 
In order to assess the earliest manifestations of ImmTAC redirected killing, the 
activation of caspases in target cells, an event which occurs downstream of granzyme B 
release, was investigated.  Caspases are a family of intracellular cysteine proteases that 
are responsible for the breakdown of the cytoskeleton and the nuclear membrane, as 
well as fragmentation of DNA, during apoptotic cell death (Russell & Ley, 2002).  
Caspases are synthesised in the cytoplasm as inactive, pro-caspase zymogens which 
comprise several domains including an N-terminal pro-domain, a large subunit and a 
small subunit.  The pro-caspases can be classified into two main groups based on the 
length of their N-terminal pro-domain.  A short pro-domain characterises pro-caspase-3, 
-6 and -7 which exist as dimers that require proteolysis at internal aspartate residues to 
generate two large and two small subunits.  Fully active enzymes result from 
heterodimerisation of these subunits to form a caspase tetramer.  Caspases 3, 6 and 7 are 
the main effectors of apoptotic cell death by cleaving cellular substrates, either a down-
stream pro-caspase or other cellular proteins, on the C-terminal side of an aspartate 
residue.  Furthermore, activation of these ‘so-called’ effector or executioner caspases 
typically results in the irreversible commitment of a cell to apoptosis.  Other pro-
caspases such as pro-caspase-8, -9 and -10 are characterised by their long pro-domain.  
These caspases typically exist as monomers and require dimerisation or oligomerisation 
for activation that can occur in the absence of proteolytic cleavage.  Pro-caspase-8, -9 
and -10 are known as initiator caspases and can activate effector caspases, such as 
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caspase-3, thereby triggering a caspase cascade (I. Chowdhury et al., 2008; Launay et 
al., 2005).  
 
Activation caspase-3 and -7 are reliable markers for the detection of cells undergoing 
apoptosis, therefore, activation of these particular caspases by ImmTAC redirected T 
cells was evaluated.  The melanoma cell line, Mel526, expressing natural levels of wild-
type gp100280-288 complexed to HLA-A*0201 was used as targets, and incubated with 
CD8
+
 T cells in the presence of increasing concentrations of ImmTAC-gp100 (Figure 5-
1).  A concentration-dependent increase in the level of caspase-3/7 activity was 
observed after 4 hours.  ImmTAC-gp100 did not stimulate caspase-3/7 activity in the 
presence of the HLA*0201-positive, antigen-negative cell line, A375. 
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Figure 5-1 Activation of caspases by ImmTAC-gp100 redirected CD8
+
 T cells.  
 
A 4 hour caspase activation assay (Promega Apo-ONE® Homogeneous Caspase-3/7) 
showing caspase-3/7 activation in response to unstimulated purified CD8+ T cells 
mediated by increasing concentrations of ImmTAC-gp100 in the presence of the HLA-
A*0201
+
/gp100
+
 melanoma cell line Mel526 (red circles) at an E:T ratio of 5:1.  The 
HLA-A*0201
+
/gp100
-
.melanoma cell line A375 (grey square) was included as a 
specificity control at a single concentration of ImmTAC-gp100 (1 nM).  The shape-
matched open symbols represent the corresponding ImmTAC-gp100-negative controls.  
Data are means ± s.e.m.  The data shown are representative of three experiments. 
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5.2.2 Short-term target cell killing by ImmTAC redirected T cells 
Once the caspase cascade has been activated, the final stage in the process is lysis of the 
target cell.  To measure short-term target cell lysis by ImmTAC redirected T cells, a 
non-radioactive Lactate dehydrogenase (LDH) release assay (Promega CytoTox96®) 
was used.  LDH is a stable cytosolic enzyme that is released upon cell lysis.  The 
CytoTox96® assay quantitatively measures the amount of LDH released into the cell 
culture supernatant when a substrate mix is added that converts a tetrazolium salt (INT) 
into a red formazan product.  The amount of colour formed is proportional to the 
number of lysed cells, the absorbance of which can be measured.  LDH release killing 
assays have been well validated for measuring natural cytotoxicity and have been 
shown to give identical (within experimental error) values as those determined in 
parallel 
51
Cr-release assays (Decker & Lohmann-Matthes, 1988; Korzeniewski & 
Callewaert, 1983). 
 
5.2.2.1 ImmTAC enhancement of cancer-specific T cell potency 
The ability of ImmTAC-gp100 to enhance the killing of melanoma cells by a CD8
+
 T 
cell clone specific for Melan-A/MART-1 (MEL187.c5) was investigated in a LDH-
release killing assay.  The melanoma cell line, Mel624, which expresses natural levels 
of both gp100 and Melan-A/MART-1 antigen in the context of HLA-A*0201 are killed 
by MEL187.c5 without the presence of ImmTAC-gp100 with levels of specific lysis 
below 50% after 4 hours at an effector-to-target ratio of 5:1 (Figure 5-2).  However, in 
the presence of ImmTAC-gp100, which binds a different epitope on the same tumour 
cells, substantially more target cells are lysed by MEL187.c5 under otherwise identical 
conditions with specific lysis of 80% observed at an E:T ratio of 5:1.  Furthermore, the 
addition of a 100-fold excess of the high affinity gp100-specific mTCR as a competitor 
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for epitope binding effectively abrogates the enhanced killing effect, reducing the levels 
of lysis to that seen in the presence of MEL187.c5 alone.  The data shows that the 
enhancement of lytic function mediated by ImmTAC-gp100 is the direct result of 
binding to the cognate pMHCI epitopes expressed on the cell surface of the target cell 
and does not occur as a non-specific effect. 
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Figure 5-2 Enhanced redirected lysis of tumour cells by cancer-specific T cell clone 
in the presence of ImmTAC-gp100. 
 
LDH-release killing assay showing lysis of Mel624 melanoma cells over a 4 hour time 
course by a CD8
+
 T cell clone (MEL187.c5) specific for Melan-A/MART-126-35 epitope 
at different E:T ratios (grey squares).  Also shown is lysis by redirection in the presence 
of 1 nM ImmTAC-gp100 (red triangles) and inhibition of redirected lysis mediated by 
ImmTAC-gp100 with 100 nM cold high affinity mTCR-gp100 (orange inverted 
triangles).  Data are means ± s.e.m.  The data shown are representative of one 
experiment only.  
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5.2.2.2 Evaluation of 
51
Cr-release assay and its limitations in measuring ImmTAC 
redirected killing 
Conventionally, target cell lysis by CTL is measured using the four hour 
51
Cr-release 
assay, first described by Brunner et al. (1968), and is considered to be the gold standard 
despite the requirement for potentially hazardous and difficult-to-dispose-of radioactive 
labels.  When used as sodium chromate (Na2
51
CrO4), the 
51
Cr-isotope is taken up by live 
cells in the hexavalent form and is released from lysed cells in the trivalent form, which 
is not re-utilised.  The applicability of 
51
Cr-release to measure redirected lysis of 
Mel526 melanoma target cells by CD8
+ 
T cell clone (176.c4.1) specific for a BRLF1 
epitope derived from Epstein-Barr virus (EBV) and unstimulated purified (polyclonal) 
CD8
+
 T cells in the presence of ImmTAC-gp100 was assessed (Figure 5.3a,b).  The data 
shows that a concentration-dependent lysis of the Mel526 melanoma cell targets is 
detected, albeit at a low level, when redirecting a CD8
+
 T cell clone with ImmTAC-
gp100 (Figure 5.3a), which essentially represents a population of pre-activated T cells.  
Note that the Mel526 melanoma cells are not killed by this clone, unless redirected by 
ImmTAC, because they do not present the cognate antigen.  In contrast, redirected lysis 
by unstimulated, polyclonal CD8
+
 T cells is not detected (Figure 5.3b).  Attempts were 
made to increase the duration of the 
51
Cr-release assay beyond four hours to allow more 
time for the unstimulated CD8
+
 T cells to become activated and kill.  However, with 
extended assay times very high spontaneous release prevented the measurement of 
specific lysis. 
 
 
Chapter 5 
 168 
-13 -12 -11 -10 -9 -8 -7
0
2
4
6
8
Mel526
a
Log10[ImmTAC-gp100](M)
S
p
e
c
if
ic
 l
y
s
is
 (
%
)
-13 -12 -11 -10 -9 -8 -7
0
2
4
6
8
Mel526
b
Log10[ImmTAC-gp100](M)
S
p
e
c
if
ic
 l
y
s
is
 (
%
)
 
Figure 5-3 Applicability of 
51
Cr-release to measure redirected lysis of melanoma 
tumour cells by CD8
+ 
T cell clone and unstimulated purified CD8
+
 T cells in the 
presence of ImmTAC-gp100.  
 
51
Cr-release killing assay showing redirected lysis of HLA-A*0201
+
/gp100
+
 Mel526 
melanoma cells by CD8
+
 T cells in the presence of titrating amounts of ImmTAC-gp100 
over 4 hours. (a) CD8
+
 T cell clone (176.c4.1) specific for EBV BRLF1259-267 epitope at 
an E:T ratio of 5:1. (b) Unstimulated purified CD8
+
 T cells at an E:T ratio of 10:1.  Data 
are means ± s.e.m.  The data shown are representative of one experiment only. 
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5.2.3 An extended time course LDH-assay  
The non-radioactive Promega CytoTox96® LDH-release assay has been demonstrated 
to be a suitable alternative to the more traditional 
51
Cr-release assay.  Figure 5-2 shows 
an example of redirected target cell lysis as measured by LDH-release after 4 hours 
when redirecting a CD8
+
 T clone.  However, as was the case for the 
51
Cr-release assay, 
redirected target cell lysis was not observed in the same time frame when using 
unstimulated, polyclonal CD8
+
 T cells.  In contrast to the 
51
Cr-release assay, the LDH-
release assay could be run for a longer time course, up to 24 hours, without the 
spontaneous release becoming a limiting factor.  However, beyond 24 hours the 
spontaneous LDH release became too high to allow accurate calculation of the percent 
specific lysis.  The potency and specificity of ImmTAC redirected target cell killing was 
subsequently assessed in 24 hour LDH-release assays, as described below. 
 
5.2.4 ImmTAC redirected killing of tumour cells by polyclonal CD8
+
 T cells 
5.2.4.1 ImmTAC-NYE redirected killing 
To extend the LDH-release killing experiments to polyclonal systems, the ability of 
ImmTAC-NYE to redirect the lytic activity of unstimulated purified CD8
+
 T cells was 
evaluated over a 24 hour time period.  Various HLA-A*0201 positive tumour cell lines 
expressing natural levels of NY-ESO-1/LAGE-1157-165 epitope were used as targets 
(Figure 5-4).  With the exception of the SK-Mel-37 cells, after 24 hours concentration-
dependent lysis against all the target cell lines is observed although the concentration-
response curves and level of killing varied according to the tumour cell lines used.  
Approximately 100% killing of IM9, A375 and U266 targets is observed whereas only 
40% lysis is evident for Mel624 over the time period.  No lysis is observed in the 
absence of ImmTAC-NYE, with the exception of A375 where 30% lysis is evident.  
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A375 cells appear to be particularly sensitive to lysis and some background lysis of 
A375 is occasionally observed in the absence of ImmTAC. 
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Figure 5-4 Redirected lysis of various tumour cell lines by polyclonal CD8
+
 T cells 
in the presence of ImmTAC-NYE.  
 
LDH-release killing assay showing lysis of HLA-A*0201
+
, NY-ESO-1
+
/LAGE-1
+
 
tumour cell lines by unstimulated purified CD8
+
 T cells at an E:T ratio of 10:1 in the 
presence of increasing concentrations of ImmTAC-NYE over 24 hours.  Mel624 
melanoma cells (blue squares); IM9 Epstein-Barr virus (EBV)-transformed B-cells 
(orange triangles); A375 melanoma cells (green inverted triangles); U266 myeloma 
cells (red diamonds); SK-Mel-37 melanoma cells (pink circles).  The shape-matched 
open symbols represent the corresponding ImmTAC-NYE-negative controls Data are 
means ± s.e.m.  The data shown are representative of two experiments. 
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5.2.4.2 ImmTAC-gp100 redirected killing 
To demonstrate that an ImmTAC of a different specificity could also redirect the lytic 
activity of polyclonal CD8
+
 T cells, ImmTAC-gp100 was tested against four melanoma 
cell lines expressing <70 copies of the HLA-A*0201-restricted gp100280-288 epitope per 
cell (Figure 5-5).  After 24 hours concentration-dependent lysis against all the target cell 
lines is observed although the concentration-response curves and level of killing varied 
according to the tumour cell lines used.  However, the EC50 values in the experiments 
with Mel526 and Mel624 are 30 pM and 51 pM, respectively.  The control A375 cells, 
which express HLA-A*0201 but not gp100, are not lysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 173 
-13 -12 -11 -10 -9 -8
0
10
20
30
40
50
Mel624
Mel526
MeWo
SK-MEL-5
A375
Log10[ImmTAC-gp100](M)
S
p
e
c
if
ic
 l
y
s
is
 (
%
)
 
Figure 5-5 Redirected lysis of various melanoma cell lines by polyclonal CD8
+
 T 
cells in the presence of ImmTAC-gp100.  
 
LDH-release killing assay showing lysis of four gp100
+
, HLA-A*0201
+
 melanoma cell 
lines by unstimulated purified CD8
+
 T cells at an E:T ratio of 10:1 in the presence of 
increasing concentrations of ImmTAC-gp100 over 24 hours.  Mel526 cells (black 
triangles), Mel624 (purple squares), SK-Mel-5 (blue diamonds), and MeWo (green 
inverted triangles).  A375 (gp100
-
, HLA-A*0201
+
) melanoma cells (grey circles) were 
included as a specificity control.  Data are means ± s.e.m.  The data shown are 
representative of three experiments. 
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5.2.5 ImmTAC redirected killing of tumour cells by PBMC 
Next, in order to make the in vitro killing experiments as physiological as possible, the 
ability of ImmTAC molecules to redirect PBMC, i.e. unselected effector cells, to lyse 
tumour cells was assessed.  ImmTAC-MAGE was used to redirect the lytic activity of 
unstimulated PBMC against various HLA-A*0101 positive tumour cell lines expressing 
natural levels of MAGE-A3168-176 epitope (Figure 5-6).  After 24 hours concentration-
dependent lysis against all the target cell lines is observed.  The resulting concentration-
response curves varied according to the tumour cell lines used, but potent killing of the 
tumour cell lines A375 and EJM is seen with EC50 values below 50 pM.  The control 
Colo205 cells, which express HLA-A*0101 but are negative for MAGE-A3, are not 
lysed. 
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Figure 5-6 Redirected lysis of various tumour cell lines by PBMC in the presence 
of ImmTAC-MAGE.  
 
LDH-release killing assay showing lysis of HLA-A*0101
+
, MAGE-A3
+
 tumour cell 
lines by unstimulated PBMC at an E:T ratio of 50:1 in the presence of increasing 
concentrations of ImmTAC-MAGE over 24 hours.  A375 melanoma cells (blue circles); 
EJM multiple myeloma cells (green squares); HCT116 colorectal carcinoma cells 
(purple triangles).  The HLA-A*0101
+
/MAGE-A3
-
 cell line Colo205 (grey inverted 
triangles) was included as a specificity control. The shape-matched open symbols 
represent the corresponding ImmTAC-MAGE-negative controls.  Data are means ± 
s.e.m.  The data shown are representative of three experiments. 
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5.2.6 ImmTAC redirected killing of tumour cells by PBMC derived from cancer 
patients 
In the experiments described above, ImmTAC redirected killing has been evaluated 
using T cells derived from healthy donors.  As potential cancer therapeutics, ImmTACs 
must be able to redirect cancer patient T cells which could be compromised either 
through the damaging effects of previous treatment regimes, such as chemotherapy, or 
through progression to a fatigued state caused by the disease. 
 
To investigate whether cancer patient T cells could be redirected by ImmTAC to lyse 
cancer cell targets, ImmTAC-MAGE was used to redirect ex vivo PBMC from a 
relapse/refractory multiple myeloma patient against EJM targets which are HLA-
A*0101 positive and express natural levels of MAGE-A3168-176 epitope (Figure 5-7).  
EJM cells are a myeloma plasma cell line originally established from a patient with 
terminal refractory myeloma disease.  Importantly, EJM’s still retain the markers and 
growth characteristics of the primary tumour (Hamilton et al., 1990) and therefore 
represent a valuable model to investigate the potential therapeutic utility of ImmTAC-
MAGE in myeloma. The data in Figure 5-7 shows concentration-dependent lysis of the 
EJM target cells after 24 hours.  Notably, the potency seen with the cancer patient 
PBMC is similar to that achieved with healthy donor PBMC (Figure 5-6).  This data is 
representative of a total of six multiple myeloma patient PBMC that were tested.  All 
six donors produced EC50 values below 20 pM suggesting that the lytic capability of 
multiple myeloma patient PBMC is not defective.  The control Colo205 cells, which 
express HLA-A*0101 but are negative for MAGE-A3, are not lysed. 
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Figure 5-7 ImmTAC-MAGE redirected lysis of multiple myeloma tumour cells by 
multiple myeloma patient PBMC (sample ID: DV-PB0018).  
 
LDH-release killing assay showing lysis of HLA-A*0101
+
, MAGE-A3
+
 multiple 
myeloma cell line EJM by ex vivo PBMC from a relapse/refractory multiple myeloma 
patient at an E:T ratio of 30:1 in the presence of increasing concentrations of ImmTAC-
MAGE over 24 hours.  The HLA-A*0101
+
/MAGE-A3
-
 cell line Colo205 (grey square) 
was included as a specificity control at a single concentration of ImmTAC-MAGE (0.2 
nM). The shape-matched open symbols represent the corresponding ImmTAC-MAGE-
negative controls.  Data are means ± s.e.m.  The data shown are representative of six 
experiments. 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 178 
5.2.7 Specificity of ImmTAC redirected killing 
Thus far, the potency of ImmTAC redirected killing against antigen positive tumour cell 
lines presenting the relevant HLA molecule has been the main focus of attention.  Here, 
the specificity of ImmTAC-NYE was investigated using HLA-A*0201
+
, NY-ESO-
1/LAGE-1-negative primary human cells derived from normal tissues.  The data in 
Figure 5-8 shows that hepatocytes, astrocytes, cardiac myocytes, and melanocytes are 
not lysed by redirected ImmTAC-NYE up to a concentration of 1 nM; at 10 nM, a low 
level of lysis is observed.  This slight loss of epitope specificity at high concentrations 
(10 nM and above) has also been observed with other ImmTAC reagents. 
 
The specificity of the therapeutic ImmTAC candidate, ImmTAC-gp100, is investigated 
in Chapter 6.  
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Figure 5-8 Specificity of ImmTAC-NYE redirected killing against a panel of HLA-
A*0201
+
/ NY-ESO-1-/LAGE-1-negative human primary cells 
 
LDH-release killing assay showing lysis of HLA-A*0201
+
,NY-ESO-1
-
/LAGE-1
-
 
hepatocytes (HEP2), astrocytes (HA2), melanocytes (NHEM10), and cardiac myocytes 
(CM12) co-incubated with purified unstimulated CD8
+
 T cells at an E:T ratio of 10:1 in 
the presence of 0.1, 1, and 10 nM ImmTAC-NYE over 24 hours.  Antigen positive 
U266 cells were included as a positive control.  Data are means ± s.e.m.  The data 
shown are representative of three experiments. 
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5.2.8 Long-term target cell killing kinetics using IncuCyte FLR technology 
5.2.8.1 Target cell killing kinetics beyond 24 hours 
In some instances one hundred percent killing of target cells by ImmTAC redirected T 
cells is not achieved over a period of 24 hours which could be a result of very low 
epitope number or that the targets are particularly resistant to lysis by CD8
+
 T cells.  
The LDH assay is not suitable for assessing target cell killing for longer than 24 hours 
because the spontaneous release becomes too high thereby decreasing the signal to 
noise ratio. 
 
IncuCyte™ FLR technology enables direct visualisation of caspase-3/7 dependent 
apoptosis by microscopy at 37°C in real time.  This technology is relatively new and in 
our laboratory it has been specifically adapted and optimised to monitor the long-term 
killing kinetics of ImmTAC redirected T cells in vitro.  In the LDH-release killing 
assay, the melanoma cell lines SK-Mel-37 and Mel624, which are both HLA-A*0201-
positive and NY-ESO-1/LAGE-1-positive, are relatively resistant to ImmTAC-NYE 
redirected lysis at 24 hours (Figure 5-4).  To investigate the long-term killing kinetics of 
the tumour cell lines SK-Mel-37 and Mel624 by IncuCyte™ FLR, they were co-
incubated with unstimulated, purifed CD8
+
 T cells in the presence or absence of 
ImmTAC-NYE.  The level of caspase-3/7 activation was visualised from images taken 
at intervals of 10 minutes (Figure 5-9a-h).  In agreement with the LDH-release assay, no 
significant killing of the SK-Mel-37 (Figure 5-9a) or the Mel624 (Figure 5-9e) is 
observed at 24 hours.  However, for Mel624, most of the cells have been killed by 48 
hours; the images taken at 48 hours confirm that close to 100% of the cells have been 
killed at this time point (Figure 5-9h).  In the case of SK-Mel-37, significant killing is 
not evident until 72 hours and is illustrated by the end-point image (Figure 5-9d).  Thus, 
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redirected killing by ImmTACs can be missed in short-term killing assays as such as 
51
Cr-release and even the extended LDH-release assay.  The adaptation and use of the 
IncuCyte™ technology is therefore of critical importance for assessing ImmTAC 
potency and specificity under the strictest possible conditions. 
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Figure 5-9 Long-term direct visualisation of redirected tumour cell killing 
mediated by ImmTAC-NYE. 
 
IncuCyte™ FLR technology showing caspase-3/7 dependent apoptosis of target cells in 
real time.  (a) SK-Mel-37 or (e) Mel624 melanoma cells were incubated with CD8
+
 T 
cells (5:1 E:T) in the presence of ImmTAC-NYE at 1 nM (red circles), 0.1 nM (blue 
circles), or no ImmTAC-NYE (black circles).  Images were taken at intervals of 10 
minutes.  The number of objects/mm
2
, a measure of target cells undergoing apoptosis, 
was determined for each image and plotted against time.  Representative endpoint 
images are shown for SK-Mel-37 at 72 hours (b,c,d) and Mel624 at 48 hours (f,g,h) in 
the presence or absence of ImmTAC-NYE at the indicated concentrations.  White 
flashes marked with red-crosses represent cells undergoing apoptosis and are recorded 
as objects.  A size exclusion gate of >100 μm2 was set to eliminate dead effector cells 
from the object count and are shown in blue.  The data are courtesy of Dr. Namir 
Hassan at Immunocore Ltd. 
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5.2.8.2 The influence of effector cell variability on redirected killing mediated by 
ImmTAC 
In a study by Baeuerle and colleagues (Dreier et al., 2002) investigating the in vitro 
efficacy of bispecific T cell engager (BiTE) molecules, they describe the considerable 
variation observed in the half maximal concentration values (ED50) and the percent cell 
lysis between different PBMC donors.  Using a 4 hour fluorescence-based cytotoxicity 
assay, they tested unstimulated CD8
+
 T cells purified from the PBMC of six healthy 
donors in the presence of targets and titrated amounts of BiTE reagent.  The resulting 
concentration-response curves produced median half maximal concentrations ranging 
from 500 pg/ml (9.1 x 10
-12
 M) to as low a 7 pg/ml (1.3 x 10
-13
 M) and the percent of 
cell lysis from 25% to 95%.  Furthermore, they showed a correlation between the half 
maximal concentration values and the level of cell lysis seen; the lower the ED50, the 
higher the level of cell lysis (Dreier et al., 2002). 
 
The phenomenon of effector T cell variation was also apparent in the experiments 
conducted for this thesis.  To investigate donor T cell variability in more detail CD8
+
 T 
cells purified from the PBMC of four healthy donors were co-incubated with the 
multiple myeloma cell line, EJM, which is HLA-A*0101 positive and express natural 
levels of MAGE-A3168-176 epitope, in the presence of ImmTAC-MAGE.  The time to 
reach maximal killing for each of the donors was assessed by the direct visualisation of 
caspase-3/7 dependent apoptosis in real time using IncuCyte™ FLR technology.  Figure 
5-10a-d shows two example data sets to illustrate the variability in redirected killing 
kinetics between different donor effector T cells where maximal killing (plateau of 
apoptotic events) is seen at 24 hours for donor FB681 (Figure 5-10a) and at 54 hours for 
donor FB682 (Figure 5-10c).  The respective end-point images, Figure 5-10b for donor 
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FB681 and Figure 5-10d for donor FB682, show that in both cases nearly 100% of the 
targets are dead.  In 3 out of the 4 donors tested, a 48 hour exposure to ImmTAC-
MAGE was sufficient to achieve maximal target cell killing.  The control Colo205 cells, 
which express HLA-A*0101 but are negative for MAGE-A3, are not killed. 
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Figure 5-10 The influence of donor T cell variability on redirected target cell 
killing. 
 
IncuCyte FLR technology showing caspase-3/7 dependent apoptosis of HLA-A*0101
+
, 
MAGE-A3
+
 multiple myeloma cell line EJM (closed green circles) by unstimulated 
purified CD8
+
 T cells at an E:T ratio of 5:1 in the presence of 0.1 nM ImmTAC-MAGE.  
The HLA-A*0101
+
/MAGE-A3
-
 cell line Colo205 (closed grey squares) was included as 
a specificity control.  The shape-matched open symbols represent the corresponding 
ImmTAC-MAGE-negative controls.  Images taken at intervals of 2 hours.  The number 
of objects/mm
2
, a measure of target cells undergoing apoptosis, was determined for 
each image and plotted against time. (a) Donor FB681 CD8
+
 T cells. (c) Donor FB682 
CD8
+
 T cells.  Images are shown for donor FB681 (b) and donor FB682 (d) at the 
indicated time points.  White flashes marked with red-crosses represent cells 
undergoing apoptosis and are recorded as objects.  A size exclusion gate of >100 μm2 
was set to eliminate dead effector cells from the object count and are shown in blue.  
White arrows showing target cell (A) and T cell (B).  Data are means ± s.e.m. 
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5.3 Summary 
In this chapter I have evaluated redirected killing by ImmTAC reagents specific for two 
different HLA A*0201-restricted epitopes, NY-ESO-1 and gp100, and one HLA-
A*0101-restricted epitope, MAGE-A3.  ImmTAC mediated activation, after 4 hours, of 
the ‘effector’ caspases 3 and 7 in the presence of target cells presenting cognate pMHC, 
indicates that programmed cell death (apoptosis) has been triggered in the target cell.  
Despite the early manifestations of target cell killing as evidenced by caspase activation, 
my experiments show that conventional 
51
Cr-release assays are not suitable for 
assessing ImmTAC redirected target cell killing when using unstimulated polyclonal 
CD8
+
 T cell populations, although low level redirected killing was observed when using 
a pre-activated CD8
+
 T cell clone.  Likewise, in a 4 hour LDH release assay redirected 
killing was only detected when using a CD8
+
 T cell clone.  However, unlike the 
51
Cr-
release assay, the LDH assay could be extended to 24 hours.  In the extended LDH-
release assays all 3 ImmTACs showed significant lysis of the majority of the relevant 
tumour cell lines during the first 24 hours.  However, the IncuCyte real-time imaging 
system demonstrated that some cell lines require longer periods for caspase-3/7-
dependent apoptosis to occur.  It was also evident in the IncuCyte experiments that there 
is considerable variability in redirected killing kinetics between different donor effector 
T cells and the time taken to reach maximum target cell lysis.  Importantly, I was able to 
demonstrate that the lytic capability of PBMC derived from cancer patients is not 
defective; I observed no significant difference in the potency of redirected killing by 
cancer patient PBMC and that of healthy donor PBMC. 
The peptide specificity of ImmTAC redirected target cell killing was also 
investigated.  No redirected killing was observed against cell lines presenting the 
relevant HLA molecule but negative for the cognate peptide.  To investigate specificity 
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more thoroughly ImmTAC-NYE was tested against a range of HLA-A*0201+/LAGE-
1-/NY-ESO-1-negative primary human cells derived from normal tissue.  No redirected 
lysis was observed up to a concentration of 1 nM; at 10 nM, a low level of lysis was 
observed. 
Overall, I conclude that ImmTAC redirected T cells can potently kill tumour cell 
targets presenting cognate pHLA.  Furthermore, target cell killing by ImmTAC 
redirected T cells is specific and limited to cells that express cognate pHLA. 
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CHAPTER 6 T CELL ASSAYS TO DETERMINE SAFE STARTING AND 
MAXIMUM DOSES OF THE THERAPEUTIC IMMTAC CANDIDATE 
IMCGP100 IN PATIENTS 
 
6.1 Introduction 
Of the four ImmTAC reagents evaluated in this thesis, ImmTAC-gp100 was selected as 
the lead therapeutic ImmTAC candidate to take forward into pre-clinical development, 
and, subsequently, for testing in a first-in-human clinical trial. In order to distinguish 
Good Manufacturing Practice (GMP) manufactured, i.e., clinical grade, ImmTAC-
gp100 protein from research grade material, the GMP manufactured reagent is referred 
to as IMCgp100 (the ‘new drug’ name used for regulatory and clinical trial 
documentation purposes).   
 
The selection of ImmTAC-gp100 as the first candidate with which to test the ImmTAC 
concept in humans was based both on potency and specificity data.  The results 
presented in Chapters 4 and 5 demonstrated that ImmTAC-gp100 can induce the full 
repertoire of CTL activation events in a concentration-dependent manner when 
combined with target positive melanoma cells in vitro.  ImmTAC-gp100 is extremely 
potent and is able to activate unstimulated T cells from unselected populations i.e., 
PBMC, including those derived from melanoma patients, at concentrations as low as 1 
pM, with maximal activity at a concentration of 1 nM.  ImmTAC-gp100 is also highly 
specific for its target and no off-target activity has been observed against target negative 
cell lines.  In addition, gp100 is an attractive target for immunotherapy as up to 95% of 
all melanoma tissues express the gp100 protein (Barrow et al., 2006; Hofbauer et al., 
2004; Mocellin et al., 2001; Spagnoli et al., 1995; Wagner et al., 1997).  Furthermore, 
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the gp100 derived peptide that is the target of ImmTAC-gp100 is presented by the MHC 
class I molecule variant HLA-A*0201, which is one of the most prevalent HLA types 
carried by approximately 50% of the North American and Western European 
populations (New Allele Frequency Database: http://www.allelefrequencies.net/ 
(Gonzalez-Galarza et al., 2011).  Therefore, ImmTAC-g100 could cover approximately 
47% of malignant melanoma patients.  As described in section 1.2.2.1, there is a clear 
unmet medical need for new treatment options for malignant melanoma as current 
treatment options provide only a modest improvement in overall survival and rarely 
offer a cure.  Thus, the intended use of the ImmTAC-gp100 development candidate, 
IMCgp100, is for the treatment of patients with advanced melanoma at disease Stage IV 
or unresectable Stage III who are refractory or resistant to standard treatment regimens 
or for which no standard treatments exist.   
The planned Phase I clinical study to assess the safety and tolerability as well as 
the preliminary efficacy of IMCgp100 in the treatment of patients with malignant 
melanoma is the first clinical study to use IMCgp100.  In order to proceed with clinical 
testing of IMCgp100, it was necessary to receive approval from the regulatory 
authorities.  To be granted approval, a detailed study plan had to be designed with 
precise indications of duration of treatment, concentration of IMCgp100, and 
predictions of possible adverse effects.  Therefore, extensive pre-clinical studies have 
been carried out on IMCgp100 to obtain a full safety and efficacy profile in preparation 
for the first-in-human Phase I clinical trial.  Key to these investigations is establishing a 
safe starting dose of IMCgp100, with the intention of dose escalating until a maximum 
tolerated dose (MTD), i.e., when unacceptable toxicity becomes an issue, or the target 
limiting dose (TLD), i.e., the set top dose is reached.  Finding the starting dose of a new 
drug is subject to strict rules, as summarised briefly in the following: 
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For first-in-human (FIH) studies, a safe clinical starting dose needs to be established.  
Conventionally, the no observed adverse effect level (NOAEL) is determined in pre-
clinical studies involving one or more relevant animal species.  The NOAEL represents 
the highest dose of a compound that yields no measurable toxicologic effects or adverse 
events.  For calculation of FIH starting doses, the NOAEL is converted to a human 
equivalent dose (HED) which is generally normalised to the body surface area for low 
molecular weight new chemical entities, or mg per kg bodyweight normalisation for 
proteins >100 kDa.  A safety factor is then applied, generally a dose reduction of at least 
10-fold, to give the maximum recommended starting dose (MRSD).  However, the well-
publicised life-threatening cytokine-release syndrome suffered by volunteers in a Phase 
I clinical trial following administration of the anti-CD28 superagonist monoclonal 
antibody, TGN1412 (TeGenero AG), in March 2006 (Suntharalingam et al., 2006), 
highlighted the potential pit-falls in interpreting and extrapolating non-clinical findings 
to the clinical setting.  
After the severe adverse events of the TeGenero TGN1412 case, a broader 
spectrum of investigations for the calculation of starting dose in man was recommended 
by the Expert Scientific Group on Phase One Clinical Trials for investigational 
medicinal products (IMP) deemed to be associated with a high risk of toxicity 
(EMEA/CHMP/SWP/28367/2007).  According to the Expert Scientific Group 
recommendations, all relevant pre-clinical in vivo and in vitro information available is 
to be considered, resulting in definition of the minimal anticipated biological effect level 
(MABEL).  Relevant information includes (1) receptor binding and occupancy data 
from in vitro and in vivo studies, (2) concentration response curves determined in vitro 
and in vivo, and (3) exposures at pharmacological doses in relevant species.  In the 
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MABEL approach, dose calculations rely on any pharmacologic/biologic effect that 
typically can be observed at considerably lower concentrations than those required for 
pathologic responses (i.e., toxicity) as in the NOAEL approach.  The starting dose for 
FIH clinical trials is usually set 10-fold below the MABEL value as safety factors are 
also applied to this approach for determining a clinical starting dose. 
IMCgp100 was considered a high risk IMP because it is an immunomodulator 
and the mechanism of action is activation of T cells.  Furthermore, owing to the entirely 
human specific nature of IMCgp100, both with respect to the TCR-pHLA and the scFv-
CD3 interactions, no relevant species exists in which to test the potential toxicity of 
IMCgp100.  Therefore, in vitro cellular assays were used for determining clinical 
dosage and predicting toxicity.  It is anticipated that these studies with IMCgp100 will 
function as a ‘pathfinder’ for all future ImmTAC pre-clinical development, and in 
understanding the predictability of the effects in humans of soluble TCR therapeutics 
based on in vitro assays.   
 
In this chapter I describe the in vitro efficacy (potency) experiments that determined the 
MABEL and hence the starting dose for IMCgp100 in the Phase I clinical trial.  The in 
vitro functional cross-reactivity and whole blood assays used to investigate potential 
sources of IMCgp100 toxicity are also described, as well as the key data sets used to set 
the top dose, known as the target limiting dose (TLD).   
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6.2 Results 
6.2.1 Specificity testing of IMCgp100 redirected T cell activity 
Toxicology studies in animals are typically conducted to provide guidance on what may 
be a safe starting dose for an IMP in humans, what may constitute a toxic dose, and 
what kind of adverse events (AEs) may be expected in a clinical trial.  However, both 
subunits, and thereby both functionalities, of IMCgp100 are based on completely human 
specific molecules and as such, no relevant toxicology species exists in which it can be 
tested.  Instead, a series of in vitro functional cross-reactivity studies on human primary 
tissue have been conducted to assess the potential toxicological profile of IMCgp100 by 
measuring the activation of T cells.  Although IMCgp100 has been highly engineered 
for the specific recognition of its cognate antigen in the context of HLA-A*0201 there 
is the possibility that it could react unexpectedly to other antigens on normal tissue.  In 
the case of gp100, two kinds of reactivity mechanisms are feasible: on-target reactivity 
and off-target reactivity (cross-reactivity).  For the following experiments, a minimum 
of three repeats using PBMC from three different healthy donors were conducted. 
 
6.2.1.1 On-target reactivity 
Expression of gp100 is not restricted to melanoma; normal tissues that have been shown 
directly to express gp100 include the retina, melanocytes, the substantia nigra and the 
thymus (Takase et al., 2005; Wagner et al., 1997).  Other tissues are known to contain 
melanocytes such as the iris, the inner ear and the choroid plexis of the brain but so far 
no evidence has been reported of gp100 expression in these tissues.  Sourcing primary 
cells from the eye and ear was not possible; therefore, cells cultured from the skin and 
brain such as melanocytes and astrocytes were some of the most important cell types 
used to evaluate on-target reactivity. 
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To investigate on-target reactivity against epidermal skin derived melanocytes, IFN-γ 
activity was measured from unstimulated PBMC, and granzyme B activity measured 
from unstimulated purified CD8
+
 T cells, when co-incubated with the melanocytes in 
the presence of increasing concentrations of IMCgp100 (Figure 6-1a,b).  The data 
shows IMCgp100 concentration-dependent release of IFN-γ (Figure 6-1a) and 
granzyme B (Figure 6-1b) from the redirected T cells in response to the melanocytes.  
The potency measured in the IFN-γ ELISpot shows that the response to the melanocytes 
is 2.5-fold less than that observed against the HLA-A*0201
+
/gp100
+
 melanoma cell 
line, Mel526, which was included as a positive control and comparator (EC50 values are 
51 pM and 20 pM, respectively).  No activity is seen against the HLA-A*0201
+
/, gp100
-
 
cell line A375, apart from at the highest dose of IMCgp100 tested, 10 nM, where there 
is some non-specific reactivity occurring.  In all cases (in total, melanocyte lots derived 
from six HLA-A*0201
+
 donors were tested), the potency of redirection is weaker 
against the melanocyte lots than that observed for the melanoma cell line, Mel526.  This 
suggests that there is a therapeutic window between organ specific toxicity and 
melanoma reactivity.   
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Figure 6-1 IMCgp100 on-target reactivity against epidermal skin derived 
melanocytes. 
 
ELISpot assays (a) IFN-γ activity (line graph) of unstimulated PBMC mediated by 
increasing concentrations of IMCgp100 in the presence of melanocytes (lot N1, blue 
circles), positive control HLA-A*0201
+
/gp100
+
 melanoma cell line Mel526 (red 
squares) and the negative control HLA-A*0201
+
/gp100
- 
melanoma cell line A375 (grey 
triangles). The shape-matched open symbols represent the corresponding IMCgp100-
negative controls. (b) Granzyme B activity (bar graph) of unstimulated, purified CD8
+
 T 
cells mediated by increasing concentrations of IMCgp100 in the presence of 
melanocytes (lot N1, blue bar), Mel526 (red bar), A375 (grey bar).  Data are means ± 
s.e.m.  The data is representative of epidermal skin derived melanocytes from a total of 
six HLA-A*02 positive donors.  The data shown are courtesy of Dr. Jane Harper at 
Immunocore Ltd. 
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The brain is an immune privileged organ, meaning that there is little or no expression of 
MHC class I on brain tissue cells (Lampson & Hickey, 1986).  In addition, the blood 
brain barrier (BBB) prevents access of immune cells as well as proteins and the 
majority of drugs to the brain.  However, inflammatory conditions such as mulitiple 
sclerosis, glioblastoma multiform (GBM) tumours or brain metastases can result in a 
breakdown of the BBB barrier allowing entry of immune cells.  Furthermore, the 
secretion of cytokines by the immune cells, specifically, IFN-γ, can upregulate MHC 
class I expression in brain tissue (Deeken & Loscher, 2007; Jarosinski & Massa, 2002; 
Schneider et al., 2004; Simka, 2009).  Astrocytes are a sub-type of glial cells and they 
are the most abundant cell type in the human brain.  Astrocytes can form GBM tumours 
which have been shown to express gp100 (Saikali et al., 2007).  Therefore, the use of 
astrocytes could represent a valid model to investigate IMCgp100 on-target reactivity 
against brain tissue. 
 
IFN-γ was measured from unstimulated PBMC, and granzyme B activity measured 
from unstimulated purified CD8
+
 T cells, when co-incubated with astrocytes in the 
presence of increasing concentrations of IMCgp100 (Figure 6-2a,b).  Astrocyte samples 
from a total of five HLA-A*02 positive donors were evaluated.  No IMCgp100 
reactivity was observed against 4 out of the 5 astrocyte samples.  However, the data set 
presented in Figure 6-2a,b shows that one astrocyte lot (HA2) did induce some 
IMCgp100 reactivity.  The potency of the response observed against this lot of 
astrocytes is approximately 80-fold less than that observed against the HLA-
A*0201
+
/gp100
+
 melanoma cell line, Mel526, which was included as a positive control 
(EC50 values are 2 nM and 24 pM, respectively) (Figure 6-2a).  In blocking experiments 
using cold high affinity gp100-specific mTCR as a competitor for epitope binding, the 
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response against the astrocytes is effectively abrogated (Figure 6-2b).  This suggests 
that the reactivity seen against lot HA2 astrocytes is gp100 specific and, thus, that this 
particular sample of astrocytes may have a low level of gp100 presentation. 
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Figure 6-2 IMCgp100 on-target reactivity against astrocytes. 
 
ELISpot assays (a) IFN-γ activity (line graph) of unstimulated PBMC mediated by 
increasing concentrations of IMCgp100 in the presence of astrocytes (lot HA2, blue 
circles), positive control HLA-A*0201
+
/gp100
+
 melanoma cell line Mel526 (red 
squares) and the negative control HLA-A*0201
+
/gp100
- 
melanoma cell line A375 (grey 
triangles). The shape-matched open symbols represent the corresponding IMCgp100-
negative controls. (b) Granzyme B activity (bar graph) of unstimulated, purified CD8
+
 T 
cells mediated by either 1 nM or 10 nM of IMCgp100 in the presence of astrocytes (lot 
HA2, dark blue bar), Mel526 (dark red bar), A375 (dark grey bar).  The pale coloured 
bars represent the inhibition of IMCgp100 redirected activity with 1 µM cold high 
affinity mTCR-gp100.  Data are means ± s.e.m.  The data shown are courtesy of Dr. 
Sandrine Buisson and Dr. Jane Harper at Immunocore Ltd, respectively. 
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6.2.1.2 The use of steroids to control the potential on-target activity of IMCgp100 
Some on-target reactivity has been observed for IMCgp100 against primary 
melanocytes (Figure 6-1).  Therefore, adverse events as a result of reactivity of 
IMCgp100 to tissues expressing both gp100 and HLA-A*0201 cannot be precluded.  
Studies investigating T cell adoptive therapy for the treatment of patients with 
melanoma have reported cases of vitiligo (de-pigmentation of sections of skin), uveitis 
(eye inflammation), and hearing loss caused by the attack of normal melanocytes.  In 
these studies the adverse events were treated and controlled with steroids (Dudley et al., 
2005; Palmer et al., 2008; Yeh et al., 2009).  As similar toxicities could be exhibited in 
patients treated with IMCgp100, the effect of the steroid hydrocortisone on IMCgp100 
redirected T cell activation was examined (Figure 6-3).  The data shows concentration-
dependent inhibition by hydrocortisone of IMCgp100 redirected activity.  The use of 25 
μM hydrocortisone, which is a clinically relevant concentration, almost completely 
abrogates the activation of T cells even at a high test concentration of IMCgp100 (1 
nM) and suggests that this agent could be effective at controlling on-target toxicity.   
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Figure 6-3 The effect of hydrocortisone on IMCgp100 redirected activity.  
 
IFN-γ ELISpot assay showing activation of unstimulated purified CD8+ T cells 
mediated by 1 nM of IMCgp100 in the presence of HLA-A*0201
+
/gp100
+
 melanoma 
cell line, Mel526, with titrated amounts hydrocortisone or no hydrocortisone (positive 
control).  Data are means ± s.e.m.  The data shown are representative of four 
experiments. 
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6.2.1.3 Off-target reactivity (cross-reactivity) 
To investigate IMCg100 reactivity to other antigens on normal tissues, a panel of 
primary cells, representative of a broad range of human organs, were used in functional 
cross-reactivity studies.  The data from these studies are summarised in Table 6-1 and 
are courtesy of Dr. Jane Harper.  Figure 6-4 shows example data sets using cardiac 
myocytes as targets.  No off-target cross-reactivity was observed for any of the tested 
primary cell types, except at high concentrations (10 nM and above) where a slight loss 
of specificity is observed against HLA-A*0201
+
 primary cells (as illustrated by the 
example data set in Figure 6-4a). This non-specific activity is absent in the presence of 
HLA-A*0201
-
 primary cells (as illustrated by the example data set in Figure 6-4b).  
These data suggests that at concentrations of approximately 10 nM, IMCgp100 elicits 
some loss of specificity by recognising and activating T cells in response to HLA-
A*0201
+
, but not to HLA-A*0201
-
, cells presenting other, unknown peptides than 
gp100. However, at concentrations up to 1 nM, IMCgp100 is highly specific for its 
HLA-A*0201
+
/gp100
+ 
target. 
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Figure 6-4 IMCgp100 off-target reactivity (cross-reactivity) against cardiac 
myocytes. 
 
IFN-γ ELISpot assays showing activity of unstimulated PBMC mediated by increasing 
concentrations of IMCgp100 in the presence of cardiac myocytes (blue circles), positive 
control HLA-A*0201
+
/gp100
+
 melanoma cell line Mel526 (red squares) and the 
negative control HLA-A*0201
+
/gp100
- 
melanoma cell line A375 (grey triangles).  The 
shape-matched open symbols represent the corresponding IMCgp100-negative controls. 
(a) HLA-A*0201
+
 cardiac myocytes (lot CM5).  (b) HLA-A*0201
-
 cardiac myocytes 
(lot CM1).  The data shown are courtesy of Dr. Jane Harper at Immunocore Ltd. 
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Table 6-1 Summary of in vitro specificity studies with IMCgp100 
HLA-A*02+ human tissue cells 
Cellular origin 
Assay 
gp100 Summary 
IFN GrB N 
Hepatocytes X X 2 ND No reactivity 
Colonic smooth muscle cells X X 1 NT No reactivity 
Dermal fibroblasts X X 3 NT No reactivity 
Pulmonary fibroblasts X X 2 NT No reactivity 
Bronchial epithelial cells X X 1 ND No reactivity 
Bronchial smooth muscle cells X X 1 NT No reactivity 
Renal epithelial cells X X 1 ND No reactivity 
Astrocytes  X X 5 ND Observed in 1/5 lots 
Dermal MVECs X X 3 ND No reactivity 
Cardiac myocytes X X 1 ND No reactivity 
Skeletal muscle cells X X 2 ND No reactivity 
Prostate epithelial cells X X 2 NT No reactivity 
HLA-A*02- human tissue cells 
Colonic smooth muscle cells X X 1 NT No reactivity 
Pulmonary fibroblasts X NT 1 NT No reactivity 
Astrocytes  X X 1 NT No reactivity 
Cardiac myocytes X NT 2 NT No reactivity 
 
HLA-A*02
+
 and HLA-A*02
-
 primary human cell lines (Sciencell, Lonza and 
PromoCell) were used as targets in IFN and granzyme B (grB) ELISpot assays as 
indicated. Expression of gp100 was assessed at the transcriptional and translational 
levels. For RT-PCR, the following gp100-specific primers were used: 5'-
TCAGGCGCCAACTGCAGAGC-3' (forward) and 5'-
CCCGCCTTGGCAGGACACAG-3' (reverse). For flow cytometry, the anti-gp100 mAb 
NK1/beteb (HyCult Biotechnology) was used in standard intracellular staining 
protocols. Each sample was tested in triplicate using unstimulated purified CD8
+
 T cells 
from 3 separate donors. IMCgp100 was used at a final assay concentration of 1 nM. 
MVECs, microvascular endothelial cells; N, number of different donors for each tissue 
tested; ND, not detected; NT, not tested; X, no reactivity (Liddy et al., 2012) 
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6.2.3 Testing of IMCgp100 in whole blood assays 
The superagonist anti-CD28 monoclonal antibody, TGN1412 (TeGenero AG), triggered 
multiple cytokine release syndrome (CRS, also, in extreme cases such as this, 
sometimes referred to as ‘cytokine storm’) in the healthy volunteers enrolled on the 
phase I trial (Suntharalingam et al., 2006).  CRS is an acute immune reaction to the first 
infusion of a drug, characterised by the systemic release of several inflammatory 
mediators which trigger a cascade of cytokines, predominantly TNF-α and IFN-γ, 
followed by IL-6, IL-1β and in some cases IL-2 and IL-8.  All therapeutic monoclonal 
antibodies (mAb) have the potential to mediate CRS, particularly those directed against 
targets on the surface of lymphocytes (M. R. Walker et al., 2011).  As the mode of 
action of ImmTAC is to activate T cells via anti-CD3 it was important to determine in 
the pre-clinical studies the potential for ImmTAC mediated CRS. 
The majority of immune effector cells are found in systemic circulation 
including those that express the protein CD3 on their surface such as CD4
+
 and CD8
+
 T 
cells.  Bulk activation of these cells in circulation could potentially initiate CRS.  
Studies on whole blood were carried out to determine the potential for IMCgp100 
mediated activation of haematological cells.  These investigations were performed ex 
vivo to allow examination of the drug in close to physiological conditions.  The blood 
from healthy HLA*0201
+
 donors was incubated with increasing concentrations of 
IMCgp100.  Positive controls for activation included anti-CD28, which activates T cells 
via the costimulatory pathway, and UCHT1 which is the mAb from which the scFv of 
ImmTAC is derived.  It is important to note that, whilst the UCHT1 mAb is bivalent 
and can cross link and activate T cells via CD3, the scFv is monovalent and is therefore 
incapable of cross-linking in the absence of target.  The Luminex® assay was used to 
measure the release of the cytokines IL-1β, TNF-α, IL-6, IFN-γ, and IL-2 (Figure 6-5).  
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The data shows that IMCgp100 does not induce cytokine release when incubated with 
ex vivo whole blood except at the two highest test concentrations, 10 nM and 100 nM, 
where some cytokine release is observed for IFN-γ, TNF-α and IL-6.  Given that non-
specific activation above 1 nM has been observed in the in vitro functional assays with 
control cell lines that do not express gp100, the responses seen in the whole blood assay 
are not unexpected.  Furthermore, the magnitude of the cytokine response in the 
presence of 10 nM and 100 nM IMCgp100 is considerably less than that observed for 
the immune stimulatory antibody UCHT1 alone or in combination with anti-CD28 
antibody.  It should also be noted that these responses did not occur in all the donors 
tested.  In total, four healthy donors were tested. 
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Figure 6-5 Whole blood cross-reactivity assays. 
 
Luminex® assays showing cytokine release mediated by increasing concentrations of 
IMCgp100 in the presence of whole blood from a healthy donor (FB375) over a period 
of 4 hours at 37ºC and 5% CO2. (a) IL-1β (b) IL-2 (c) IL-6 (d) IFN-γ (e) TNF-α.  
Controls included anti-CD3 (UCHT1) mAb alone; anti-CD3 (UCHT1) mAb and anti-
CD28 mAb; and, IMCgp100 (10nM) and anti-CD28 mAb.  Data are means ± s.e.m.  
The data shown are courtesy of Dr. Sandrine Buisson at Immunocore Ltd. 
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6.2.4 Applying cellular data for the determination of the MABEL and TLD for 
IMCgp100 
6.2.4.1 Minimal anticipated biological effect level (MABEL) for IMCgp100 
In the absence of a relevant toxicology species in which to determine a safe clinical 
starting dose for IMCgp100 using the conventional no observed adverse effect level 
(NOAEL) method, the minimal anticipated biological effect level (MABEL), as derived 
from the in vitro data, was applied.  This approach assumes that the in vitro data can be 
used as guidance for what may occur in patients in the clinic.  This assumption has been 
supported by another class of anti-CD3 fusion proteins, the Micromet bispecific T cell 
engager (BiTE) molecules.  BiTE molecules are conceptually similar to IMCgp100 in 
that they are comprised of a targeting entity (antibody) fused to an anti-CD3 scFv 
effector function.  An anti-CD19/CD3 BiTE molecule was tested in patients with B cell 
non-Hodgkin’s lymphoma as part of a phase I clinical trial; the doses of drug that were 
efficacious in the in vitro assays are the same drug doses that have proven efficacious in 
plasma.  Supporting the predictive value for clinical application of the in vitro 
experimentation, a BiTE dose of 0.06 mg/m
2
/24h resulted in 2 complete responses and 5 
partial responses in a total of 7 patients (Bargou et al., 2008).  
 
In vitro LDH-release killing assays demonstrating the efficacy of IMCgp100 have been 
used to determine the MABEL.  The MABEL has been defined as the dose of drug to be 
administered by intravenous (i.v) injection such that the predicted Cmax (peak 
concentration) in the plasma will be lower than a concentration of drug known to have a 
minimal biological effect in these assays.  The assay has been reproduced with four 
donor effector T cells and the most sensitive target cell line to IMCgp100 redirected 
lysis, Mel526, has been used.  A high effector-to-target ratio of 10:1 and a long 
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incubation period of 24 h were used to allow for the most sensitive analysis.  Figure 6-6 
shows an example data set using Mel526 as targets; the MABEL is calculated as a dose 
of drug to give a plasma concentration lower than 1 pM or 10
-12
 M (as indicated).  The 
molecular weight of IMCgp100 is 76 kDa, hence the concentration of IMCgp100 in the 
plasma at which a minimal biological effect is expected is < 76 pg/ml. 
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Figure 6-6 In vitro efficacy assay used to determine the MABEL. 
 
LDH-release killing assay (Promega CytoTox96®) showing lysis of HLA-A*0201
+
, 
gp100
+
 melanoma cell line Mel526 by unstimulated, purified CD8
+
 T cells at an E:T 
ratio of 10:1 in the presence of titrated doses of IMCgp100 over 24 hours.  The open 
symbol represents the corresponding IMCgp100-negative control.  The MABEL is 
represented by the black arrow.  Data are means ± s.e.m.  The data shown are 
representative of four experiments. 
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6.2.4.2 Setting the target limiting dose (TLD) for IMCgp100 
The target limiting dose (TLD) is defined as the concentration of drug beyond which a 
loss of specificity is observed.  To determine the TLD of IMCgp100, the HLA-A*0201 
positive, gp100 negative melanoma cell line, A375, was co-incubated with 
unstimulated, purified CD8
+
 T cells in the presence of increasing concentrations of 
IMCgp100 (Figure 6-7).  The killing data shows that there is no IMCgp100 redirected 
lysis of the gp100 negative cell line A375 until a concentration of 10
-8 
M (10 nM) is 
reached.  The loss of specificity of IMCgp100 at 10 nM and above has also been 
observed for a panel of HLA-A*0201 positive primary cells in T cell activation assays 
(described in section 6.2.1.3).  Based on the in vitro killing and the functional cross-
reactivity assay data, the TLD for IMCgp100 has been set at 1 nM i.e., the maximum 
plasma concentration will not be allowed to exceed 1 nM until more is known about the 
safety profile of IMCgp100 in patients. 
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Figure 6-7 In vitro killing assay used to determine the TLD. 
 
LDH-release killing assay (Promega CytoTox96®) showing the non-specific lysis of 
HLA-A*0201
+
, gp100
-
 melanoma cell line A375 by unstimulated, purified CD8
+
 T cells 
at an E:T ratio of 10:1 in the presence of titrated doses of IMCgp100 over 24 hours.  
The open symbol represents the corresponding IMCgp100-negative control.  The TLD 
is represented by the black arrow.  Data are means ± s.e.m.  The data shown are 
representative of four experiments. 
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6.3 Summary 
This chapter describes the key data sets used to support the entry of IMCgp100 into a 
Phase I clinical trial.  In the absence of a relevant toxicology species, IMCgp100 was 
investigated for potential reactivity to tissues other than target melanoma tissue in vitro.  
In functional cross-reactivity assays, that measure T cell activation in the presence of 
IMCgp100, on-target reactivity is observed against primary tissue that is HLA-A*0201
+
 
and known to express gp100, such as epidermal skin derived melanocytes.  However, in 
all cases the reactivity seen against the melanocyte lots was weaker than that observed 
for the melanoma cell line Mel526, suggesting that there is a therapeutic window 
between melanoma reactivity and organ specific toxicity.  Nevertheless, on-target 
reactivity of T cells in response to IMCgp100 could possibly result in toxicities in some 
organs.  Therefore, I investigated the use of the steroid, hydrocortisone, as a possible 
option for controlling on-target toxicity.  I was able to demonstrate that hydrocortisone, 
used at a clinically relevant dose, prevents the activation of T cells even at the highest 
concentration of IMCgp100 (1 nM) in vitro.  
No cross-reactivity is observed against HLA-A*0201
+
, gp100-negative primary 
cells, suggesting that IMCgp100 is highly specific for its target.  However, at high 
concentrations (10 nM and above), IMCgp100 elicits some loss of specificity by 
recognising and activating T cells in response to HLA-A*0201
+
, but not to HLA-
A*0201
-
, gp100-negative cells.  The concentration of IMCgp100 beyond which a loss 
of specificity is observed was used to set the target limiting dose (TLD).  Based on the 
in vitro killing and the functional cross-reactivity assay data, the TLD for IMCgp100 
has been set at 1 nM.  Ex vivo whole blood assays indicate that IMCgp100 does not 
cross-react with haematological cells in systemic circulation which could lead to 
cytokine release syndrome. 
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Finally, I produced the in vitro efficacy data that was used to determine a safe 
starting dose for the first administration of IMCgp100 in humans, which was set by 
establishing the minimal anticipated biological effect level (MABEL).  Based on the in 
vitro data presented in this thesis, IMCgp100 has received phase I clinical trial 
regulatory approval in the UK. 
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CHAPTER 7 DISCUSSION 
 
ImmTACs are a novel class of bispecific reagents intended for therapeutic use against 
cancer.  These reagents are comprised of a humanised CD3-specific scFv fused to a 
high affinity mTCR specific for a tumour-associated pMHCI antigen.  In this PhD 
thesis, the potency, sensitivity, and specificity of ImmTACs is investigated for pMHCI 
epitopes derived from four tumour-associated antigens: (1) gp100, a melanocyte 
differentiation antigen, (2) MAGE-A3, a cancer/testis antigen expressed by a wide 
variety of tumours, (3) Melan-A/MART-1, a lineage-specific antigen expressed by a 
large proportion of primary and metastatic melanomas, and (4) NY-ESO, a cancer/testis 
antigen expressed in multiple myeloma, lung cancer, melanoma and several other 
cancers.  The data presented describes the evolution of the ImmTAC molecules, from 
selecting a suitable effector function providing functional potency, to the modifications 
investigated to improve the potency, including those which are important for the 
manufacture of ImmTACs and their potential use in the clinic.  A comprehensive range 
of assays and methodologies have been established to characterise the ImmTAC 
reagents including functional T activation assays and cytotoxicity assays.  However, the 
main focus of the work was on the developmental pathway of the lead therapeutic 
candidate ImmTAC molecule from early pre-clinical testing, to the studies required for 
admission to clinical trials. 
 
CD8
+
 T cells have evolved to seek out and eliminate abnormal cells in the body.  They 
are guided by T cell receptors (TCRs) which recognise endogenously processed 
peptides derived from cellular proteins and presented on cell surfaces by MHC 
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molecules.  A highly diverse TCR repertoire is generated to recognise this array of 
peptides; each one unique to a particular T cell clone.  The human TCR repertoire is 
shaped at an early age in a process called thymic selection; a trade-off between the 
dangers of failing to recognise abnormal cells and that of potentially devastating auto-
reactivity results in a TCR repertoire of approximately 25 million distinct TCRs (Arstila 
et al., 1999; Robins et al., 2009) which have very low affinities for their relevant 
pMHC.  Given that the majority of tumour-associated peptide antigens (TAPAs) are 
derived from non-mutated self proteins, T cells often fail to detect and eradicate 
malignant cells.  Even so, the T cell system, through the capacity of TCRs to recognise 
virtually all pMHC antigens, has a unique, if largely untapped potential for addressing 
cancer, because MHC presenting TAPAs constitute by far the largest class of 
therapeutic targets in malignant diseases. 
Notwithstanding the failure of the natural T cell repertoire to effectively recognise 
malignant cells, TCRs do exist that have specificity for TAPAs.  However, the affinities 
of such TCRs are usually too low to instigate a T cell response against tumour cells, and 
immune escape mechanisms employed by the tumour, such as the down-regulation of 
MHC and the ability to induce inhibitory signals in T cells, increase the hurdles to an 
effective immune response.  Immunocore Ltd has developed a technology based on the 
capacity of TCRs to recognise TAPAs to potentially overcome the limitations of the 
immune system to respond adequately to cancer.  To achieve this, TCRs have been 
engineered in three key ways to turn the natural TCR complex into a potential drug 
candidate;  
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(1) A soluble version of the TCR has been generated by deleting the 
transmembrane regions and introducing a disulphide bond between the Cα and 
Cβ chains to stabilise the protein 
(2) The affinity (KD) of the TCR for its pMHC has been increased from the 
micromolar level of naturally selected TCRs to picomolar level 
(3) The TCR has been fused to an effector function to replace the natural effector 
function, the T cell.  An anti-CD3 single chain variable fragment (anti-CD3 
scFv) has been selected which is capable of activating non-cancer specific T 
cells when cross-linked to an antigen positive cancer cell via the mTCR  
 
Thus, the ImmTAC functions as a transient linker between the cancer cell and the T 
cell, forcing an immune response where the natural immune system has failed. 
 
7.1 The testing of TCR-effector function fusions capable of redirecting T cells 
against cancer cells with an extremely low HLA-peptide antigen target number per 
cell 
Levels of tumour-associated pMHC can be as low as 10-50 epitopes per cell; this has 
been observed both on cell lines and, much more importantly, on fresh tumour samples 
(Purbhoo et al., 2006).  Therefore, the effector function fused to the mTCR must be 
highly potent.  The use of anti-CD3 monoclonal antibodies to recruit and activate T 
cells has been employed by a number of bispecific T cell activating antibody 
therapeutics, most notably, the potent bispecific T cell engager (BiTE) antibodies.  The 
observation that the mTCR is not internalised to any substantial degree when bound to 
its target cell (Purbhoo et al., 2007; Purbhoo et al., 2006) ruled out the use of toxin 
payloads that require cellular internalisation.  Instead, strategies that worked from the 
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cell surface were investigated.  Anti-CD3 was particularly attractive as it is capable of 
unleashing the cytotoxic potential of CD8
+
 CTLs.  To find the most applicable anti-CD3 
antibody to fuse to the mTCR, three humanised anti-CD3 scFv antibodies were tested; 
OKT3 (Xu et al., 2000), 12F6 (B. Li et al., 2005) and UCHT1 (Shalaby et al., 1992).  
As described in Chapter 3, UCHT1 was shown to be at >1000-fold more effective at 
triggering CD8
+
 T cell activation than 12F6 and OKT3 when fused to a Melan-
A/MART-1-specific mTCR (Figure 3-1).  ImmTAC-MEL/UCHT1 when used at 10 pM 
concentration in cellular assays, was able to activate CD8
+
 T cells in the presence of 
target cells loaded with 10
-9
 M peptide, giving a level of peptide presentation close to 
that found on cancer cells. 
One of the main concerns associated with using an anti-CD3 antibody as an 
effector function is the risk of potentially activating T cells without the simultaneous 
binding of the mTCR to its target.  Whilst the mTCR arm of the fusion binds to an 
antigenic pMHC on the target cell, the anti-CD3 scFv arm of the molecule, by engaging 
the invariant ε-chain of the CD3 glycoprotein complex associated with T cell receptors, 
is capable of activating any CD8
+
 T cell independently of the intrinsic antigen 
specificity of its own TCR.  The experiments presented with the UCHT1-mTCR 
fusions, called ImmTACs, show that no activation of CTLs by ImmTAC was observed 
in the absence of target cells (see, for example, Figure 3-1c).  Furthermore, no 
activation of CTLs by ImmTAC was observed in the presence of antigen-negative target 
cells containing the correct HLA type (see, for example, Figure 4-1).  This illustrates 
that the biological activity of ImmTAC is highly specific, requiring not only the correct 
HLA type but also the correct peptide for recognition, and that the ImmTAC only 
activates when a multivalent contact, i.e. cross-linking, is established between the target 
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cell and the T cell.  This last feature is essential for avoiding systemic toxicity when 
applied as a therapeutic.   
Another important aspect of the anti-CD3 effector function is that it binds CD3 
with an affinity that is considerably lower than the mTCR-pMHC interaction.  For 
IMCgp100 (the selected development candidate for ImmTAC-gp100), for example, the 
TCR affinity for pMHCI is approximately 24 pM whereas the UCHT1 scFv affinity for 
CD3 has been measured at 38 nM.  This difference in affinity should permit the 
preferential decoration of the tumour target cells with ImmTAC thereby signalling them 
for destruction by T cells present in the vicinity of the tumour.  However, when 
ImmTACs are administered to patients it is likely that binding to both tumour cells and 
T cells will occur to a greater or lesser extent with some sequestering of ImmTAC by T 
cells in the blood before it has bound the tumour cell target.  In the Phase I clinical trial 
with IMCgp100 it has been observed that CD3, CD4 and CD8 staining of T cells 
transiently reduces after 24 hours following drug dosing, to then gradually reappear 
after 3 days (Figure 6-1).  This could suggest that the CD3, CD4 and CD8 are down-
regulated or, perhaps more likely, that T cells migrate from the blood into tissues.  
Whatever the explanation, which has not been ascertained yet, it appears likely that the 
changes observed in T cell staining are caused by some kind of contact with the 
ImmTAC anti-CD3 scFv component.  Transient T cell disappearance (lymphopenia) is 
also consistent with clinical observations made with T cell-engaging BiTE antibody, 
blinatumomab (Nagorsen & Baeuerle, 2011).   
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Figure 6-1 Example of T cell staining time course in blood of a melanoma patient 
treated with a single 4 hour infusion of 405 ng/Kg of IMCgp100.   
 
DX refers to the day after infusion was initiated.  Data courtesy of Dr. Stephen Megit at 
Immunocore Ltd. 
 
The affinity of the binding to CD3 by bispecific T cell activators is considered to be 
optimal for triggering T cell activation and cytotoxicity (Bortoletto et al., 2002).  
Studies have also shown that T cells are stimulated best by low affinity ligands of the 
TCR/CD3 complex (Goldrath & Bevan, 1999).  This observation is supported by the 
experiments described in Chapter 3 comparing single- and tandem anti-CD3 scFv TCR 
fusions which indicate that the high avidity binding of the tandem anti-CD3 scFv fusion 
is less efficient at activating T cells than the single anti-CD3 scFv fusion (Figure 3-6 
and Figure 3-7).  Indeed, the low efficiency of some bispecific antibodies could possibly 
be attributed to sub-optimal CD3 engagement whereby the affinity of the interaction is 
too high (Shalaby et al., 1992).  This could be because experimental observations 
indicate that T cell activation requires serial triggering (Valitutti & Lanzavecchia, 
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1997), which depends on receptor-ligand interactions being of low affinity, and, in 
particular, having short engagement times (M. M. Davis et al., 1998; Matsui et al., 
1991; Weber et al., 1992; Willcox et al., 1999). 
 
While for ImmTACs, the functionally optimal anti-CD3 interaction is not achieved with 
the highest affinity, the mTCR affinity for the target pMHC appears to be almost 
directly proportional to potency (Figure 3-8).  Here, seven different affinity variants of 
the gp100-specific ImmTAC (ImmTAC-gp100) were tested with KD values ranging 
from 30 pM for the highest affinity variant to the lowest at 30 μM.  All the variants 
were able to activate and redirect unstimulated CD8
+
 T cells in a concentration-
dependent manner when in the presence of HLA-A*0201
+
/gp100
+
 targets.  However, 
the degree of the response varied considerably with the higher affinity variants 
progressively more potent, activating CD8
+
 T cells at concentrations as low as 10
-11
 M.  
This shows that the engineering of high affinity mTCRs is critical for the targeting and 
CD8
+
 T cell activating capability of the ImmTAC molecules.  Furthermore, the high on-
target potency of ImmTACs, which correlates with mTCR-pMHC affinity, means that 
very small doses should be applicable in the clinic.  This is likely to have the significant 
advantage of minimising any systemic activation of T cells that could occur as a result 
of scFv-mediated ImmTAC binding to CD3 on T cells. 
 
TCR affinity is also pertinent when considering that down-regulation of MHC 
expression is a well-documented mechanism by which tumour cells evade immune 
surveillance (Cabrera et al., 2003; Dunn et al., 2004).  Therefore, in order for ImmTACs 
to be effective immunotherapeutics, they must be able to eradicate tumours expressing 
particularly low levels of peptide-MHC.  The relationship between the peptide-
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sensitivity of the ImmTACs and the ImmTAC-pMHCI affinity was investigated using 
the same set of ImmTAC-gp100 affinity variants described above.  As predicted, the 
highest affinity variants were the most peptide sensitive and were able to activate CD8
+
 
T cells in the presence of T2 cells loaded with 10
-10
 M peptide (Figure 4-2).  Epitope 
counting studies using single-cell three-dimensional fluorescence microscopy have 
shown that T2 cells pulsed with different concentrations of exogenous the gp100280-288 
heteroclitic (YLEPGPVTV) peptide produced the following epitope numbers: 0-3 at 10
-
11
 M, 2-10 at 10
-10
 M and 15-45 at 10
-9
 M peptide (Liddy et al., 2012).  At pulsing 
concentrations at or above 10
-8
 M peptide it is no longer possible to distinguish the 
individual epitopes and quantification becomes less accurate.  Based on this 
information, the peptide sensitivity of the highest affinity variants (KD value = 0.03 and 
0.32 nM) equates to 2-10 pMHCI epitopes per cell.  Notably, the TCR wild-type affinity 
ImmTAC (KD value = 30 μM) and the minimally modified variant (KD value = 8 μM), 
were not able to activate CD8
+
 T cells at any of the tested peptide concentrations, 
further illustrating the significance of TCR affinity for ImmTAC function.   
However, the ultimate test of the capability of ImmTACs at redirecting T cells 
against targets expressing extremely low levels of peptide-MHCI is to use tumour cells.  
Studies using high affinity mTCRs to quantify the number of cognate antigens 
expressed on the surfaces of tumour cells have shown that individual melanoma and 
myeloma cells present an average of 10-50 copies of the NY-ESO157-165 epitope per cell 
(Purbhoo et al., 2006).  It has also been reported that other tumour associated peptide 
antigens are similarly presented at extremely low levels on the surfaces of melanoma 
cells, averaging 20-70 copies per cell for the HLA-A*0201 restricted epitopes gp100280-
288 and MAGE-A3168-176, and 60-150 copies per cells for Melan-A/MART-126-35 (Liddy 
et al., 2012).   
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The ability of ImmTACs to potently redirect CD8
+
 T cell activity against tumour 
cell lines was demonstrated for all four ImmTAC molecules (see, for example, Figure 4-
1).  The most valid data sets are those where it was possible to obtain freshly isolated 
clinical tumour samples to use as targets.  The data presented shows that ImmTAC-
NYE is able to activate and redirect unstimulated PBMC to freshly isolated HLA-
A*0201
+
/LAGE-1
+
 lung cancer cells (Figure 4-11).  However, the potency of the 
ImmTAC-NYE redirected activity against the lung cancer cells was considerably lower 
than that seen against tumour cell lines.  There are two possible reasons for this; first, 
the lung tumour sample was composed of a heterogeneous population of cells, probably 
containing normal lung tissue cells and other normal cells as well as tumour cells; the 
percentage of tumour cells within the sample could not be established.  Second, the 
viability and quality of the tumour sample cells was poor prior to use in the assay.  The 
data presented also shows that ImmTAC-MAGE is able to activate and redirect 
unstimulated PBMC to CD138
+
 cells, which contain the malignant plasma cells, 
isolated from the bone marrow aspirate sample of a multiple myeloma patient (Figure 4-
12). 
Taken together the in vitro cellular data presented suggests that ImmTACs are 
able to redirect T cell activity to both tumour cell lines that are known to express low 
levels of cognate antigen per cell and most significantly, to fresh tumour samples.  The 
down-regulation of MHC by tumours may prevent recognition by naturally occurring 
tumour specific T cells which require higher levels of epitope to become activated.  
However, the ability of ImmTAC to detect a low density of pMHC means that 
ImmTACs have the potential to establish immune recognition of tumours that might 
normally evade detection. 
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7.2 ImmTAC redirected T cell responses 
The potency of ImmTAC-mediated CD8
+
 T cell activation is closely correlated to the 
mTCR-pMHCI affinity.  The data presented in Chapter 4 shows that all four ImmTACs 
activate CD8
+
 T cells in a concentration-dependent manner, producing cellular EC50 
values below 100 pM (Figure 4-1); these closely match the KD values of the 
corresponding monomeric mTCR-pMHCI interactions as determined by surface 
plasmon resonance (SPR) equilibrium-binding measurements.  However, the potency of 
the ImmTAC reagents is not only a function of the mTCR binding affinity; the physical 
length of the ImmTAC molecule also seems to be important. 
As described in Chapter 3, in the first generation ImmTAC constructs the anti-
CD3 scFv was fused to the C-terminus of the TCR beta chain via an inter-linker.  The 
reasoning for this design was that molecular modelling studies indicated that fusing the 
effector function to the N-terminus of the TCR beta chain would obstruct the binding of 
the TCR to its target.  However, while the fusion of anti-CD3 scFv to the C-terminus 
increased the overall length of the construct, its fusion to the N-terminus would produce 
a more compact molecule which would impose closer proximity between the redirected 
T cell and the target cell possibly facilitating maximal T cell activation.  Surprisingly, 
the cellular data revealed that the N-terminus ImmTAC construct, i.e. N-UCHT1-TCR-
C (Figure 3-3a)  is functional and able to redirect CD8
+
 T cell activity in response to 
targets presenting the correct HLA with the relevant peptide and does not induce a 
response in the presence of targets presenting the correct HLA with an irrelevant 
peptide (Figure 3-2).  This suggests that, notwithstanding the molecular modelling 
predictions, the binding of the mTCR to its pMHCI has not been impeded by the anti-
CD3 scFv.  Furthermore, the N-terminus ImmTAC redirected activity is 4-fold more 
potent than that mediated by the C-terminus ImmTAC. 
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In order for CD8
+
 T cells to kill their targets, the formation of a cytolytic 
synapse is critical (Stinchcombe et al., 2001).  This structure enables T cells to tightly 
adhere to targets for the controlled release of granzymes and perforin, the protein 
mediators of target cell apoptosis.  BiTE antibodies have been shown to induce cytolytic 
synapses that are indistinguishable in structure and composition from naturally formed 
cytolytic synapses between TCR and pMHC (Offner et al., 2006).  Key to this is the 
length of the inter-cellular bridge formed by the tumour-associated antigen on the target 
cell, the BiTE antibody, and the CD3ε subunit of the TCR complex.  This distance has 
been estimated to be 12-14 nm for BiTE antibodies (Bluemel et al., 2010), which is very 
similar to the length of a natural TCR/peptide/MHC complex of ~14 nm (Garboczi et 
al., 1996; Garcia et al., 1998).  At the time of writing this thesis the length of the inter-
cellular bridge formed by ImmTACs was not known; indeed the length of the ImmTAC 
molecule could be difficult to establish by biophysical methods because it is not known 
how the TCR and scFv portions are organised in relation to each other in the tertiary 
structure.  Nevertheless, the increased potency observed with the N-terminus ImmTAC 
suggests that synapse formation and function may be more efficient with the more 
compact N-terminus design as a result of the closer proximity between the target cell 
and T cell.  The potency of target cell lysis by BiTE-redirected cytotoxic T cells has 
been shown to be optimal when the epitope is positioned close to the plasma membrane 
of the target cell (Bluemel et al., 2010).  Similarly, the antigen sensitivity of an 
engineered chimeric TCR was found to be modulated by target epitope distance from 
the cell membrane (James et al., 2008).  Indeed, it is a general feature of T cell 
activation that higher potency is achieved when the T cell and target membranes are in 
closer proximity to each other, as illustrated by experiments with super-agonistic 
antibodies to various T cell co-receptors (S. J. Davis & van der Merwe, 2006)  The 
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greater redirected T cell activity observed for the more compact N-terminus ImmTAC 
fusion lends support to this notion, and indirectly provides evidence in favour of the 
kinetic-segregation (K-S) model of TCR triggering whereby T cell activation is a result 
of net phosphorylation.  This model proposes that TCR triggering is the result of the 
exclusion of bulky negative regulators, such as the tyrosine phosphatase CD45, when 
multiple zones of close contact (~ 15 nm apart) form at the target cell-T cell interface 
(S. J. Davis & van der Merwe, 2006). 
 
ImmTACs are capable of polyclonal activation of unstimulated CD8
+
 T cells that 
includes cytokine production and lytic activity when in the presence of relevant target 
cells.  The cellular assay data sets presented in Chapter 4 shows concentration-
dependent release of IFN-γ and granzyme B from ImmTAC-redirected purified CD8+ T 
cells as well as from unselected T cells present in the more physiologically relevant 
peripheral blood mononuclear cells (PBMC).  Furthermore, ImmTACs have also been 
shown to elicit concentration-dependent release of the degranulation marker CD107a 
and the cytokines TNF-α and IL-2 (Figure 4-5).  These data demonstrate that multiple 
effector functions are induced in the ImmTAC redirected CD8
+
 T cells, comprising both 
lytic activity and the production of soluble factors.  Moreover, the polyfunctional 
responses induced by ImmTAC redirected activity could help to broaden an immune 
reaction against tumour cells in vivo by recruiting other types of immune cells to the 
tumour microenvironment.   
ImmTACs mainly activate terminally differentiated CD8
+
 effector memory 
(Tem) cells (characterised by the standard phenotypic markers, CD45RO
+
 and CD27
-
), 
and central memory (Tcm) cells (CD45RO
+
 and CD27
+
) whereas activation of naïve T 
cells (CD45RO
-
 and CD27
+
) is minimal (Liddy et al., 2012).  Comprehensive activation 
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of naïve T cells could potentially be dangerous as became evident in the Phase I clinical 
trial of the superagonist anti-CD28 monoclonal antibody, TGN1412 (TeGenero AG) 
(Suntharalingam et al., 2006) (discussed in more detail in section 7.5).  The activation 
of T cells predominantly from the memory compartments, rather than naïve T cells, 
suggests that ImmTACs do not provide costimulation via CD28.  Naïve T cells require 
CD28 costimulation to become activated whereas memory T cells are less dependent.  
The apparent lack of T cell costimulation by ImmTAC via CD28 could be important in 
avoiding differentiation of potentially autoreactive naïve T cell clones.  Although 
ImmTACs do not appear to activate naïve T cells during the relatively short time frame 
of the assay, it does not rule out the possibility that long-term exposure to ImmTACs in 
vivo could potentially lead to the activation of naïve T cells.  However, as naïve T cells 
are not usually present within the vicinity of tumours, prolonged contact between 
ImmTAC and naïve T cells that might result their activation, is unlikely. 
The primary function of ImmTAC is to recruit CD8
+
 cytotoxic T cells (CTLs); a 
subset of T cells recognised as the major effector cell type involved in the potent killing 
of malignant cells.  However, data presented in Chapter 4 shows that ImmTACs can 
also redirect and activate polyclonal CD4
+
 T cells (Figure 4-4).  Concentration-
dependent release of IFN-γ by CD4+ T cells mediated by ImmTAC produced similar 
cellular EC50 values to that observed for CD8
+
 T cells and PBMC.  The recruitment of 
CD4
+
 T helper (Th) cells by ImmTACs could have a beneficial role in augmenting anti-
tumour immune response in vivo.  It is well established that CD4
+
 Th cells play an 
important part in enhancing and sustaining CD8
+
 T cell responses (Antony et al., 2005; 
Pardoll & Topalian, 1998).  Moreover, there is increasing evidence that CD4
+
 Th cells 
have a more direct role in orchestrating host anti-tumour responses than previously 
thought.  For example, a recent study demonstrated that adoptively transferred tumour-
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reactive CD4
+
 T cells acquire cytotoxic activity and eradicate large established tumours 
in lymphopenic mouse model hosts (Quezada et al., 2010).  
Overall, the data presented in Chapter 4 indicates that the initial redirection 
event induced by ImmTACs could serve as a catalyst to precipitate the recruitment of 
additional immune effectors to the tumour site.  Furthermore, in addition to ImmTAC-
mediated activation of CD4
+
 T cells, there is evidence that antigen cross-presentation by 
dendritic cells and epitope spreading may amplify ImmTAC-redirected T cell responses 
(manuscript in preparation), all of which could contribute to generating a self-sustaining 
tumour-specific immune response, potentially minimising the necessity for prolonged 
dosing schedules.  Most importantly, it could induce anti-tumour responses that also 
address antigen-negative cells. 
 
7.3 ImmTAC redirected target cell killing 
To be effective in vivo ImmTACs must be able to redirect CTLs, irrespective of their 
native specificity, to lyse tumour cells.  CTL induce target cell lysis by two main 
mechanisms: either by releasing the contents of cytolytic granules in the granule-
exocytosis pathway of cytotoxicity, or by engaging cell-surface death receptors, such as 
members of the tumour-necrosis factor receptor (TNFR) family, which includes Fas 
(CD95).  Both mechanisms trigger the inherent apoptotic response within the target cell.  
However, the dominant mechanism by which CTLs destroy target cells is through 
granule-exocytosis pathway.  The granules of CTLs contain various proteins; the lytic 
granules involved in the induction of apoptosis include the pore-forming protein 
perforin and a family of serine proteases that are known as granzymes.  Lysis by CTL 
involves the formation of a cytolytic synapse with a specifically recognised target cell 
and the release of the granule contents into the synaptic cleft.  The granzymes are then 
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delivered into the target cell, where they initiate programmed cell death via proteolytic 
activation of pro-caspases and direct cleavage of caspase substrates. 
The mechanism by which ImmTAC-redirected target cell killing is achieved was 
not specifically investigated but the data presented indicates that granule-exocytosis 
mediated apoptosis is the primary mode-of-action.  Furthermore, the perforin-dependent 
granule exocytosis pathway has been shown to be important in BiTE antibody-mediated 
cytotoxicity whereas death receptor-mediated lysis does not appear to play a role 
(Gruen et al., 2004).  One of the earliest markers of granule-exocytosis mediated 
apoptosis is the release of granzyme B, which is one of the most abundant and best-
studied granzymes.  In ELISpot assays, concentration-dependent release of granzyme B 
from ImmTAC-redirected purified CD8
+
 T cells and PBMC was observed (Figures 4-6 
& 4-7).  Only recently activated CD8
+
 T cells are capable of exerting perforin/granzyme 
B-mediated cytolytic functions (Kaech & Ahmed, 2001).  Resting CD8
+
 T cells (naïve 
and central memory cells) do not have cytolytic granules containing granzyme B but 
can express granzyme several days later following antigen encounter – provided they 
also receive the correct cytokine stimuli (Curtsinger et al., 2005; Trapani & Sutton, 
2003).  At any one time, up to 20% of all CD8
+
 T cells in the PBMC of healthy 
individuals are granzyme B positive due to on-going stimulation with various 
environmental antigens (Rock et al., 2005).  Therefore, the ImmTAC-redirected T cell 
responses observed in the granzyme B ELISpot are most likely to be those of recently 
activated CD8
+
 effector T cells. 
Once inside the target cell, granzyme B induces programmed cell death by 
activating the key executioner (effector) caspases, caspase-3 and caspase-7.  ImmTAC-
mediated caspase-3/7 activity was detected after 4 hours and the level of activity was 
concentration-dependent (Figure 5-1).  Like the other consequences of ImmTAC 
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redirected T cell activity, caspase activation was induced in an antigen-specific manner 
as no activity was observed in the presence of targets expressing the correct HLA 
molecule but negative for the relevant antigen.  Activation of caspase-3/7 by ImmTAC 
indicates the apoptotic pathway is being triggered in the target cells and that they are 
doomed to die. 
The extent of target cell lysis induced by ImmTAC redirected CD8
+
 T cells was 
investigated using the conventional 
51
Cr-release assay and a non-radioactive alternative, 
the LDH-release assay, to assess short-term killing kinetics.  The levels of ImmTAC-
redirected target cell lysis and the time required to reach maximum lysis varied 
considerably depending on the effector and target cells used.  Typically, 
51
Cr-release 
and alternative ‘release’ assays such as the LDH-release assay are conducted over 4 
hours.  The data presented in Chapter 5 shows that while ImmTAC redirected target cell 
lysis could be detected within this time frame, it was only possible when redirecting a 
CD8
+
 T cell clone but not when using polyclonal unstimulated and purified CD8
+
 T 
cells or unselected T cells present in PBMC (Figures 5-2 & 5-3).  A T cell clone 
represents a population of activated CD8
+
 T cells which are expected to have the same 
cytotoxic potential, whereas peripheral T cells are a mixture of T cells of varying 
cytotoxic potential and differentiation state.  Therefore, only a fraction of peripheral T 
cells is likely to have the phenotype of a cytotoxic CD8
+
 T cell clone.  To be effective in 
vivo, it is critical that ImmTACs have the capability to potently redirect unstimulated, 
peripheral T cells.  However, it was clear from the early ImmTAC-redirected target cell 
killing experiments that the duration of the cytotoxicity assay would need to be 
extended beyond 4 hours in order to evaluate redirected killing by peripheral T cells.  
While the 
51
Cr-release assay was not suited to a longer time course because of 
prohibitively high spontaneous release, the Promega Cytotox96® LDH-release assay 
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could be extended to a 24 hour time course without spontaneous release becoming an 
issue.  Thus, the LDH-release assay revealed that despite slow killing kinetics, 
ImmTACs can potently redirect unstimulated purified CD8
+
 T cells as well as 
unselected T cells present in PBMC to kill a range of different tumour cell lines 
(Figures 5-4, 5-5, 5-6 & 5-7).  ImmTAC-redirected killing is concentration-dependent 
and typically produces cellular EC50 values below 100 pM, similar to those observed in 
the IFN-γ and granzyme B activation assays described in Chapter 4.  Furthermore, it has 
been demonstrated that ImmTAC reagents can induce serial killing, a feature that is 
likely to contribute to their potency (Liddy et al., 2012). 
In contrast to the relatively slow killing kinetics of ImmTAC-mediated target 
cell lysis, the BiTE antibody, anti-CD19/anti-CD3 single-chain bispecific antibody 
(bscCD19xCD3), has been shown to potently redirect both T cell clones, and 
unstimulated polyclonal T cells purified from PBMC, to lyse target cells after 4 hours 
(Dreier et al., 2002).  The key reason for this difference in killing kinetics between 
BiTE antibodies and ImmTACs is probably due to the levels of target cell antigen being 
targeted.  The Micromet single chain bispecific antibody bscCD19xCD3 targets CD19, 
a B cell co-receptor expressed on a high percentage of human B-cell malignancies and 
on normal B cells.  The levels of expression of CD19 on chronic B cell leukaemias, and 
on normal B cells, has been found to number tens of thousands of molecules per cell 
(Ginaldi et al., 1998).  ImmTACs, on the other hand, are potentially targeting less than a 
hundred epitopes per cell (Liddy et al., 2012).  Therefore, it is likely that during 
ImmTAC-redirected killing there is a greater lag phase prior to synapse formation and 
target cell lysis.  For lysis to occur, a target and/or T cell occupied by ImmTAC must 
come into close contact.  The low epitope numbers on the target cells means that the 
number of ImmTAC molecules bound on each target cell will also be low.  Therefore, it 
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is speculated that it will take time for T cells to form a close contact zone within which 
there is a high enough density of bound ImmTAC molecules to generate the binding 
avidity necessary to trigger potent T cell activation. 
 
While significant lysis of the majority of the tested tumour cell lines occurred during the 
first 24 hours, the IncuCyte real time imaging system, which measures caspase-3/7 
activation, demonstrated that some cell lines require even longer periods for apoptosis 
to occur (Figure 5-9).  This variation in cell lysis could reflect the difference in density 
of target epitopes on the surface of each cell line.  Other factors which may influence 
the rate of target cell killing include the susceptibility of individual tumour cell lines to 
lysis and the presence of co-factors, for example, CD80 and CD86 on the tumour cells, 
which may enhance killing. 
The efficacy of ImmTAC redirected target cell killing also varied depending on 
the PBMC donor used.  The use of the IncuCyte real time imaging system to monitor 
long term redirected killing kinetics revealed that the time taken to reach maximal target 
cell lysis could vary considerably depending on the donor effector T cells used.  For 
instance, CD8
+
 T cells purified from the PBMC of two healthy donors were tested 
against the same target cell line, EJM, in the presence of ImmTAC-MAGE; while the 
CD8
+
 T cells from one donor achieved maximal target cell killing by 24 hours, 
redirected killing by another donor’s T cells took over 50 hours before most of the 
targets were lysed (Figure 5-10).  Possible explanations for the variability include 
various proportions of CD8 memory cells and differences in the cytokine (infectious) 
state of donors. 
Taken together, understanding ImmTAC redirected killing kinetics is hugely 
important when designing a dosing strategy for the lead therapeutic development 
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candidate in order to maximise the chances that the drug will be efficacious in the 
clinic. 
 
7.4 The rationale for the ability of ImmTACs to redirect T cell activation in cancer 
patients 
One of the main obstacles to effective tumour immunotherapy is the ability of tumours 
to foster a tolerant microenvironment in which they employ a diverse range of 
immunosuppressive mechanisms that may act in concert to thwart effective immune 
responses. 
Most tumour antigens are derived from ‘self’ proteins, which are also expressed 
in normal cells, as opposed to neo-antigens that are uniquely present in cancer cells 
(Boon et al., 2006; Rosenberg, 1999).  The immune system has evolved complex 
mechanisms for establishing T cell tolerance against self and, by extension, to the 
majority of tumour antigens.  So, ironically, it is the immune system itself that poses the 
greatest challenge for harnessing immune responses against tumours.  ‘Tumour-induced 
anergy’ is a well documented phenomenon which was initially demonstrated in two 
independent studies showing that antigen-specific CD4
+
 T cells were rendered tolerant 
during tumour growth in vivo (Bogen, 1996; Staveley-O'Carroll et al., 1998).  Several 
studies since have shown that this state of T cell unresponsiveness occurs during the 
growth of haematologic or solid tumours expressing model or true tumour antigens 
(Cuenca et al., 2003; D. J. Morgan et al., 1998; Overwijk et al., 2003).  T cell anergy is 
also observed during the progression of spontaneously arising tumours (Willimsky & 
Blankenstein, 2005) and most significantly, during the progression of human cancers 
(Lee et al., 1999; Noonan et al., 2005).  Therefore, induction of tolerance to tumour 
antigens, via regulatory mechanisms akin to those that prevent autoimmunity, represents 
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an important immunosuppressive strategy by which tumour cells might escape T cell 
mediated anti-tumour responses.  Crucially, in order for a cancer immunotherapeutic to 
be effective against tumours expressing mainly self-antigens, the barrier imposed by 
immune tolerance must be broken.  However, there could be ‘a price to be paid’ for 
breaking tolerance to self-antigens in that it involves a potential for inducing tissue-
specific autoimmunity.  For example, treatment of melanoma patients with anti-CTLA-
4 antibodies and peptide vaccination was associated with strong anti-tumour effects and 
development of vitiligo (de-pigmentation of areas of the skin) as a manifestation of 
tissue-specific autoimmune responses (Phan et al., 2003).   
 
There have been reports that peripheral blood T cells of patients with certain cancers 
have decreased expression of TCR-ζ chain, a protein tyrosine kinase that plays a critical 
role in proximal signalling events leading to T cell activation, implying that systemic T 
cells are dysfunctional in cancer patients (Gunji et al., 1994; Healy et al., 1998; Matsuda 
et al., 1995).  A marked decrease in the expression of TCR-ζ chain has been observed in 
the peripheral blood T cells of subsets of patients with malignant melanoma.  Cytokine 
production by T cells from melanoma patients with diminished TCR-ζ chain expression 
was also shown to be reduced, with lower IL-2 and IFN-γ production compared to 
levels observed in normal subjects.  Furthermore, the overall survival of TCR-ζ chain 
deficient melanoma patients was significantly shorter than that of patients with normal 
TCR-ζ.chain expression (Zea et al., 1995).  This data is one of several observations 
indicating that the T cell system can play a pivotal role in controlling malignant 
melanoma.  The corollary to this is that it appears to be generally assumed that many 
cancer patients, and particularly those affected by late stage disease, have reduced T cell 
immunity.  In this context, the data presented in Chapter 4 showing that fresh ex vivo 
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PBMC derived from late stage cancer patients can act as effector cells for ImmTAC-
mediated activity, is encouraging.  The lead therapeutic candidate, ImmTAC-gp100, 
which is intended for the treatment of patients with metastatic melanoma, has been 
shown to potently redirect PBMC isolated from two stage IV HLA-A*0201
+
 melanoma 
patients.  Notably, redirection of the cancer patients T cells produced similar cellular 
EC50 values to those of healthy donors of less than 40 pM (Figure 4-8 and Figure 4-9).  
The responses seen with melanoma patient PBMC comprised the production of soluble 
factors IFN-γ and granzyme B (Figure 4-8 and Figure 4-9), suggesting that the 
peripheral effector cells of these patients are not functionally defective, at least not to 
ImmTAC-induced activation, as a consequence of the cancer.  Interestingly, the one 
notable difference between the melanoma patients PBMC and those from healthy 
donors was the observation of a pre-existing melanoma response.  In the in vitro cellular 
assays, it was evident that the T cells from one of the two melanoma patients was 
already reactive to the Mel526 melanoma cells without stimulation as evidenced by the 
presence of raised baseline activity in the IFN-γ ELISpot assay (Figure 4-8a).  However, 
there was no raised baseline activity against the HLA-A*0201
+
, gp100
-
 cell line, A375, 
suggesting the response was antigen specific.  Therefore, ImmTAC-gp100 can 
potentially serve to significantly augment an already existing anti-tumoural response in 
patients.  Melanoma is unique among solid tumours in being relatively immunogenic, 
and the existence of tumour associated antigen (TAA)-specific CD8
+
 T cells exhibiting 
an antigen-experienced phenotype has been demonstrated in patients with malignant 
melanoma (Pittet et al., 1999; Romero et al., 1998; Valmori et al., 2000).  Furthermore, 
TAA-specific T cells have directly been implicated in spontaneous melanoma 
regression, occurring more frequently in melanoma than in any other cancer 
(Mackensen et al., 1994).  Functional and phenotypical analysis of circulating tumour-
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reactive CD8
+
 T cells from stage IV metastatic melanoma patients identified a subset of 
terminally differentiated effector T cells, characterised by the phenotype markers 
CD45RA
+
CCR7
-
, which produced IFN-γ and exhibited lytic activity ex vivo upon 
stimulation with autologous tumour (Valmori et al., 2002).  So despite the many 
mechanisms by which tumour cells may evade immune recognition such as down-
regulation of target antigens and/or HLA expression, absence of costimulatory molecule 
expression, or secretion of immunosuppressive cytokines, TAA-specific T cell 
responses can still develop.  Nevertheless, the presence of TAA-specific T cells in 
patients with metastatic melanoma indicate that these responses fail to contain tumour 
progression.  A study investigating Melan-A/MART-1-specific CD8
+
 T cell responses 
in patients with late stage melanoma, showed that while primed Melan-A/MART-1-
specific T cells that circulate in the peripheral blood display the full arsenal of effector 
functions, similar cells that reside within the melanoma lesions fail to secrete IFN-γ, an 
important cytokine in anti-tumour immunity.  However, the functional tolerance of the 
TAA-specific T cells was rapidly reversible in vitro upon non-specific PMA/Ionomycin 
stimulation (Zippelius et al., 2004).  The findings of this study suggest that the tumour 
microenvironment is suppressing T cell effector functions and may explain the failure 
of tumour-specific responses to effectively counter tumour progression.   
 
In this thesis, it was also found that PBMC from multiple myeloma patients, including 
those with relapse/refractory disease status, could act as effector cells for ImmTAC-
MAGE-induced lysis of target multiple myeloma cells.  Notably, there was no 
significant difference in the potency seen with the patient PBMC compared to those 
from healthy donors, with cells from all six patient donors producing cellular EC50 
values below 20 pM (Figure 5-7).  The anti-tumour effect of ImmTACs is dependent on 
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both the expression of tumour antigen and on the activity of CD3
+
 T cells in and around 
the tumour.  Given that tumour infiltrating lymphocytes (TILs) within the tumour 
environment may be functionally impaired this could severely hamper the effectiveness 
of ImmTAC-redirected activity.  Multiple myeloma is a malignancy in which it is 
possible to reliably investigate the effect of the tumour microenvironment on ImmTAC-
mediated activity.  This is because it is relatively easy to purify both the primary tumour 
and the immune cells from the tumour bed within the bone marrow.  In contrast, solid 
tumours, such as melanoma, require enzymatic treatment to isolate tumour cells.  
Alternatively, it maybe necessary to generate cell lines from tumour or TILs which may 
alter gene- expression profiles and other properties of tumours as well as T cells.  
Dhodapkar et al (Dhodapkar et al., 2002) reported that freshly isolated T cells from the 
tumour microenvironment of patients with progressive myeloma are unresponsive to 
autologous tumour ex vivo.  However, both cytolytic and IFN-γ-producing responses 
could be restored upon stimulation with DCs that had processed fresh autologous 
tumour cells.  In chapter 4, marrow infiltrating lymphocytes (MILs) from bone marrow 
aspirates derived from two stage III patients were potently redirected in a concentration-
dependent manner by ImmTAC-MAGE against a HLA-A*0101-restricted allogeneic 
myeloma tumour cell line, EJM (Figure 4-10).  The potency exhibited by the redirected 
MILs in an IFN-γ ELISpot assay was comparable to that achieved using peripheral T 
cells from healthy donors, producing EC50 values in the range of 100 pM or lower.  
Furthermore, ImmTAC-MAGE redirected MILs did not respond in the presence of 
targets presenting the correct HLA but negative for the relevant antigen.  Therefore, 
MILs from the myeloma microenvironment contain T cells which appear fully 
functional and can be effectively redirected by ImmTAC-MAGE.  This is a crucial 
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finding since these T cells are likely to be the initial pool of myeloma target proximal 
effectors engaged by ImmTAC if used in multiple myeloma patients.   
 
7.5 The relationship between ImmTAC in vitro cellular assays and clinical results 
IMCgp100 has received Clinical Trials Application (CTA) approval by the Medicines 
and Healthcare products Regulatory Agency (MHRA) in the UK, and regulatory and 
ethics approval by the Food and Drug Administration (FDA) in the US. 
In the UK, the MHRA has approved a Phase I dose finding study to assess safety 
and tolerability in HLA-A*0201
+
 patients with advanced malignant melanoma.  The 
primary aim of the trial is to establish the maximum tolerated dose (MTD).  ImmTACs 
are entirely human specific, that is both with respect to the TCR-pHLA and the scFv-
CD3 interactions, meaning that no suitable animal model exists in which to test the 
toxicity of IMCgp100.  The regulatory authorities endorsed that the clinical trial with 
IMCgp100 could proceed solely on the support of in vitro toxicity data.  A 
comprehensive pre-clinical toxicity data package was produced and was used to set the 
target limiting dose (TLD); the key data sets from these studies are presented in Chapter 
6.  The starting dose for the Phase I trial was set by establishing the minimal anticipated 
biological effect level (MABEL), predicted from the in vitro efficacy (potency) assays, 
and also described in Chapter 6. 
Gp100, the target antigen of IMCgp100, is not only expressed in melanoma 
tumours but also in some normal tissues.  Gp100 expression has been demonstrated in 
melanocytes, the retina, the substantia nigra (Wagner et al., 1997), and the thymus 
(Takase et al., 2005)  Also, the iris, the inner ear and the choroid plexus of the brain are 
known to contain melanocytes but currently no evidence has been reported of gp100 
expression in these tissues.  However, adverse events related to toxicity against normal 
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tissue have been reported in melanoma trials using other immune-based therapies.  For 
example, melanoma trials using infusions of melanoma/melanocyte-specific CD8
+
 T 
cells, ex vivo expanded from the patients’ own TILs (and of unknown specificity), have 
reported cases of eye inflammation and hearing loss in some patients (Dudley et al., 
2005; Palmer et al., 2008; Yeh et al., 2009), which are most likely caused by the attack 
of pigmented cells of the retina and melanocytes in the inner eye.  Vitiligo is also a 
common manifestation with many melanoma immunotherapies.  Therefore, the 
expression of gp100 on normal tissue was expected to be a potential source of 
IMCgp100 toxicity.  In the in vitro cellular activation assays there is evidence of 
IMCgp100 redirected activity against epidermal skin derived melanocytes which are 
HLA-A*0201
+
 and known to express gp100 (Figure 6-1).  However, in all cases the 
potency of the response against the melanocytes is weaker than that elicited against the 
melanoma tumour cell lines.  To activate T cells, ImmTACs must bind above a 
threshold number of cognate antigens.  In the case of IMCgp100 the threshold number 
is thought to be approximately 10 copies per cell (as described in section 7.1).  Below 
this threshold number of cognate antigens, activation of bystander T cells is not 
detectable.  Above this level, T cell activation increases proportionally with the level of 
antigen presentation on the target cell.  Thus, T cell activation via the anti-CD3 scFv 
arm of the ImmTAC reagent in all likelihood involves an avidity effect.  This 
mechanism of action has been demonstrated for IMCgp100 in experiments (conducted 
by Dr. Giovanna Bossi) using T2 cells loaded with varying concentrations of gp100 
peptide.  The level of antigen presentation was then quantified by incubating the loaded 
T2 cells with fluorescently labelled high affinity gp100 mTCR and counting the number 
of bound TCRs under the microscope.  T cell activation assays using T2 cells, peptide 
loaded with the same concentrations as used for epitope counting experiments, showed 
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that the level of IMCgp100 redirected activity was directly proportional to the level of 
antigen presentation.  Therefore, the lower potency observed for IMCgp100 redirected 
activity against normal melanocytes compared to the potency seen against melanoma 
cells implies that the number of epitopes on the surface of melanocytes is less than that 
on the surface of melanoma cells.  Importantly, lower expression of gp100 on normal 
melanocytes means that, all other conditions being equal, a higher concentration of 
IMCgp100 would be required to trigger T cell activation than would be needed to target 
and kill melanoma cells.  In clinical use, this may translate into a therapeutic window.  
However, the environment in and around the tumour sites are likely to be more 
suppressive for T cell activation. Thus, firm predictions about how IMCgp100 
redirected T cell reactivity against melanoma and normal melanocytes will compare are 
not possible purely based on in vitro data. 
Gp100 is also known to be expressed in certain areas of the brain, most 
prominently, in the substantia nigra (Wagner et al., 1997).  IMCgp100 is too large a 
molecule to cross the blood brain barrier passively.  Therefore, on-target brain toxicity 
is not expected in the majority of patients where the blood brain barrier has not been 
compromised.  Furthermore, the brain is considered to be an immune privileged organ 
with low levels or no expression of MHC class I molecules in neurons, glia, 
oligodendrocytes, microglia or astrocytes (Lampson & Hickey, 1986).  Primary cells 
derived from the substantia nigra or the choroid plexus could not be obtained for 
experimentation, so astrocytes were selected to investigate potential IMCgp100 on-
target activity against brain tissue.  Astrocytes are the most abundant cell type in the 
central nervous system (CNS).  They perform a variety of roles including regulating 
neuronal signalling, maintaining homeostasis at neuronal synapses, and regulating 
cerebral blood delivery (Figley & Stroman, 2011).  Furthermore, astrocytes can form 
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glioblastoma multiform (GBM) tumours which have been shown to express gp100 
(Saikali et al., 2007).  No IMCgp100 redirected activity was observed in four of the 
astrocyte lots tested.  However, in one out of the five lots of astrocytes IMCgp100 
reactivity was detected (Figure 6-2a).  Furthermore, IMCgp100 redirected activity could 
be abrogated using high affinity gp100-specific mTCR (Figure 6-2b) indicating that 
some gp100-specific reactivity is occurring.  However, as observed for normal 
melanocytes, reactivity to this particular lot of astrocytes was only seen in the presence 
of high concentrations of IMCgp100 (1 nM and above), suggesting that the cause of the 
activity is extremely low presentation of the HLA-A*0201 gp100 epitope.  An 
uncompromised blood brain barrier (BBB) will preclude the entry of IMCgp100 to 
brain tissue, and therefore the risk of toxicity is considered to be very low.  Even so, 
patients with an overtly compromised BBB, for example, patients that have developed 
brain metastases, are currently excluded from the trial.   
Adverse events due to on-target activity in melanoma trials have largely been 
tolerable and controllable with the use of steroids (Dudley et al., 2005; Palmer et al., 
2008; Yeh et al., 2009).  Here, it has been shown that the steroid hydrocortisone inhibits 
IMCgp100 redirected T cell activity at clinically relevant concentrations (Figure 6-3).  
The highest test concentration of hydrocortisone (25 μM) used in the in vitro assay is 
equivalent to the maximum plasma concentration (Cmax) that may be expected upon 
administration of a bolus IV injection of 100 mg of hydrocortisone.  Thus, the data 
indicates that, if toxicities associated with on-target activity are observed with 
IMCgp100, then they could be managed with the administration of steroids. 
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Cross-reactivity of IMCgp100 is defined as the binding of the drug to a non-target 
epitope and the simultaneous triggering of its effector function, i.e. the activation of T 
cells.  There is no toxicologically relevant animal species in which to test IMCgp100 
due to a lack of interspecies specificity.  Therefore, in vitro functional cross-reactivity 
studies were conducted on human primary tissue to assess the potential toxicological 
profile of IMCgp100.  The panel of human primary cells selected to screen for 
IMCgp100 cross-reactivity represented all the major organs of the body.  In total, eleven 
HLA-A2
+
/gp100
-
 and four HLA-A2
-
/gp100
-
 primary cell lots were evaluated (Table 6-
1).  No IMCgp100 redirected activity was observed against any of the primary cell lots, 
except at concentrations of 10 nM and above where a slight HLA-A*0201
+
 dependent 
loss of peptide specificity is observed.  These data suggest that at concentrations of 
approximately 10 nM, IMCgp100 elicits some loss of specificity by activating T cells in 
response to HLA-A*0201
+
cells, but not to HLA-A*0201
-
 cells, presenting other, 
unknown peptides.  Thus, at concentrations up to 1 nM, IMCgp100 is highly specific for 
its HLA-A*0201
+
/gp100
+ 
target which is 1,000-fold higher than the lowest 
concentration required for observing anti-tumour cell reactivity.  This suggests that 
organ specific cytotoxicity due to promiscuous cross-reactivity is unlikely to occur 
when IMCgp100 is administered to patients.  However, the study, inevitably, was not 
exhaustive and was limited by the availability of primary cells. 
Another potential source of IMCgp100 cross-reactivity is to cells in systemic 
circulation.  Cytokine release syndrome (CRS) or cytokine storm is an adverse event 
resulting in the systemic release of cytokines and is sometimes seen upon the first 
exposure to a therapeutic monoclonal antibody (mAb).  CRS can develop within 1-2 
hours after infusion and symptoms range from mild to severe, including fatigue, 
headache, bronchospasm, swelling of the throat, nausea, vomiting, fever, chills, 
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hypotension, tachycardia and asthenia (Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.03).  CRS is a prominent feature associated with therapeutic 
mAbs to CD2, CD3, CD20, CD40, CD52, IL-2R, and, by far most dramatically, 
superagonist (SA) CD28 (M. Walker et al., 2010).  The mechanism by which CRS 
occurs is not fully understood but three principal mechanisms have been proposed.  
First, the direct binding of mAb to its ligand on the target cell triggers signalling and 
causes cytokine release by the target cells.  Second, binding of the Fc region of the mAb 
to Fc receptors on non-target cells triggers signalling and causes cytokine release by 
non-target cells.  Third, binding to Fc receptor causes clustering and signalling through 
the target cell (Bugelski et al., 2009).  However, it is likely that some therapeutic mAbs 
elicit CRS through a combination of these mechanisms.  It is thought that anti-CD28 SA 
mAbs cause CRS primarily through the first mechanism.  
While most CRS reactions can be controlled by slowing the infusion rate or by 
the administration of anti-inflammatory drugs, reactions to an anti-CD28 mAb, 
TGN1412, constitute a warning of how severe toxicity reactions to immunotherapies 
can potentially be.  In 2006, life-threatening cytokine-release syndrome was triggered in 
all six healthy volunteers enrolled on a Phase I clinical trial following administration of 
the CD28 superagonist mAb TGN1412.  The clinical events that followed were rapid 
and severe and can be divided into four phases.  The first phase began within 90 
minutes of the volunteers receiving an intravenous infusion of the drug, provoking a 
systemic inflammatory response characterised by a rapid induction of pro-inflammatory 
cytokines.  High cytokine levels in the blood were accompanied by headache, myalgias, 
nausea, diarrhoea, erthema, vasodilation and hypotension.  In the second phase, which 
occurred within 12 to 16 hours after infusion, the volunteers became critically ill with 
pulmonary infiltrates and lung injury, renal failure and disseminated intra-vascular 
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coagulation.  The third phase was characterised by a severe depletion of lymphocytes 
and monocytes and occurred within 24 hours of the infusion.  In the fourth phase, the 
volunteers developed prolonged cardiovascular shock and acute respiratory distress 
syndrome (Suntharalingam et al., 2006).  Fortunately, despite the severity of the events, 
all six volunteers survived.  However, in light of the comprehensive pre-clinical testing 
which involved human whole blood assays and in vivo primate studies, the adverse 
events of the TGN1412 incident were unexpected.  This highlighted the differences that 
can be encountered in the effects of immunomodulatory agents when tested in in vitro 
and in in vivo model systems as opposed to when administered to humans.  The 
European Medicines Agency (EMA) responded immediately by changing the 
methodology for calculating the starting dose of first-in-human biologicals (discussed in 
more detail below).  However, it took six years to understand why the pre-clinical data, 
from three test systems (rodents, primates and human cells), used to support the 
TGN1412 Phase I trial had failed to predict the cytokine storm. 
CD28 is a costimulatory molecule present on the cell surface of T cells.  
Engagement of its ligands CD80 and CD86, on the surface of professional APCs, 
costimulates T cell responses during antigen recognition.  TGN1412 and other anti-
CD28 SA mAb trigger particularly strong CD28 signalling, allowing the activation of T 
cells without simultaneous engagement of the T cell receptor (TCR).  Even so, anti-
CD28 SA mAbs depend on sub-threshold or ‘tonic’ TCR signals, which they amplify 
(Dennehy et al., 2007; Levin et al., 2008).  In both rats and mice, anti-CD28 SA mAbs 
predominantly induce the activation of regulatory T (Treg) cells and have been used to 
treat experimental autoimmune disease (Beyersdorf et al., 2005; Hunig, 2007).  The 
adverse events, as seen in the human volunteers on the TGN1412 trial, were absent in 
the rodent model systems.  However, a recent study has shown that if mice are first 
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depleted of Tregs, high levels of circulating pro-inflammatory cytokines are observed 
upon administration of anti-CD28 SA mAb.  Thus, the Treg cell-mediated response 
appears to be crucial for preventing systemic inflammation in rodents (Gogishvili et al., 
2009).  So, why did this mechanism fail to protect the human volunteers receiving 
TGN1412?  CD4
+
 effector memory T (Tem) cells have been identified as the source of 
the cytokines interferon-γ (IFN-γ), tumour necrosis factor (TNF) and interleukin-2 (IL-
2) that mediated the CRS seen in the volunteers (Eastwood et al., 2010; Romer et al., 
2011).  Multiple exposures to infectious agents during the life of an individual lead to 
the accumulation of Tem cells.  However, this does not occur in laboratory rodents 
housed under clean conditions.  Thus, in the presence of TGN1412, the balance between 
Treg cell to Tem cell numbers is less favourable in humans compared with mice or rats.  
Moreover, it is likely that the very high dose of TGN1412 used in the trial exacerbated 
the problem further as studies in rats have shown that low doses of anti-CD28 SA mAb 
selectively expand Treg (CD4
+
/CD25
+
) cell populations and do not activate 
CD4
+
/CD25
-
 (‘conventional’) T cells (Beyersdorf et al., 2005). 
In pre-clinical studies in primates, TGN1412 had been administered to 
cynomolgus macaques at up to 500 times the dose administered to the human 
volunteers.  Cynomolgus macaques were thought to be an appropriate species for the 
pre-clinical safety testing of TGN1412 because the amino acid sequences of the 
extracellular and intracellular domains of cynomolgus macaque CD28 are 100% 
identical to the human molecule.  Furthermore, they both bind TGN1412 with the same 
affinity (Hanke, 2006).  So, why was there no TGN1412-induced CRS in macaques?  
Unfortunately, what had been overlooked, and has only recently come to light, is that 
macaque CD4
+
 T cells lose CD28 expression during their differentiation into Tem cells, 
whereas human CD4
+
 T cells do not (Eastwood et al., 2010). 
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Finally, pre-clinical studies using human peripheral blood mononuclear cells 
(PBMC) also failed to predict the TGN1412-mediated CRS.  When TGN1412 is added 
in soluble form to PBMC cultures, it does not trigger cytokine or proliferative 
responses.  However, based on a serendipitous discovery, it has since been 
demonstrated that if T cells are first cultured at high density, TGN1412 can then 
potently activate these T cells (Romer et al., 2011).  It has been proposed that cellular 
contacts during the high-density pre-culture of PBMC restores the sub-threshold or 
‘tonic’ TCR signal that TGN1412 requires as a ‘substrate’ for amplification.  In 
contrast, T cells in circulation lose this cell-cell contact dependent sub-threshold signal, 
and are therefore less responsive.  Furthermore, there is evidence to suggest that it was 
the tissue resident CD4
+
 Tem T cells that responded immediately to TGN1412 with 
cytokine release rather than circulating T cells.  Pre-culturing PBMC at high density 
mimics more closely tissue-like conditions and has allowed more detailed in vitro 
investigations of T cell responses to soluble TGN1412 (Romer et al., 2011).  An 
important finding from these studies was that a TGN1412 concentration of 1 μg per ml 
of blood – a level predicted to be equivalent to the 0.1 mg per kg of body weight dose of 
TGN1412 administered to the volunteers on the Phase I trial (Duff, 2006) - was not only 
close to saturation with regard to receptor occupancy but also exceeded the amount 
required for maximum cytokine release (Romer et al., 2011).   
All three pre-clinical test systems failed to provide evidence for the toxic 
potential of TGN1412 for the distinct and unrelated reasons described above.  Notably, 
it highlighted the limitations of no observed adverse effect level (NOAEL)-based 
calculation, which is the conventional approach for determining first-in-human (FIH) 
starting doses.  NOAEL represents the highest dose of a drug that yields no measurable 
toxicological effects or adverse events.  To calculate FIH starting dose, the NOAEL is 
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divided by a conversion factor taking into account the body surface area and an 
additional safety factor (usually ten) is also applied.  However, if the animal model 
failed to respond for some unforeseen reason (in the case of TGN1412, the lack of 
CD28 expression by macaque CD4
+
 Tem cells), the requested dose escalation leads to a 
very high tolerated level (for TGN1412, 50 mg per kg) from which the human starting 
dose was calculated. 
In response to the TGN1412 incident, a guideline was produced by the 
Committee For Medicinal Products (CHMP) of the European Medicines Agency 
(EMEA) (EMEA/CHMP/SWP/28367/2007) to identify and decrease the risk with new 
medicinal products being studied in FIH clinical trials.  The guideline highlights the 
importance of considering minimal anticipated biological effect level (MABEL) in 
deciding the initial dose of a biologic to be used in humans.  The MABEL approach 
selects the starting dose for a FIH study on the basis of the lowest animal dose or 
concentration required to produce pharmacological activity in vivo and/or in vitro data 
in animal/human systems.  If TGN1412 had been administered using MABEL-based 
calculations, the entry dose would have been at least 200-fold lower (Hunig, 2012). 
In this thesis, the potential for IMCgp100 to trigger CRS was examined in an ex 
vivo whole blood assay, under physiological conditions.  The release of five main 
cytokines associated with CRS (IL-1-β, TNF-α, IL-6, IFN-γ and IL-2) were measured in 
the presence of varying concentrations of IMCgp100 (Figure 6-5).  No cytokine release 
was observed up to and including 1 nM IMCgp100.  At concentrations above this level 
(10 and 100 nM) some cytokine release is observed, specifically TNF-α, IL-6 and IFN-
γ, although not from all the donors tested.  Furthermore, when IMCgp100-mediated 
cytokine release is seen it is of a much lower magnitude to that observed with the 
positive control immune stimulatory mAb UCHTI.  Although UCHT1 is the 
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monoclonal antibody from which the anti-CD3 scFv of IMCgp100 is derived, the 
important distinction between them is that like all antibodies UCHTI is bivalent 
whereas the scFv component of IMCgp100 is monovalent, and lacks a Fc region.  While 
mAb UCHT1 can cross-link and activate T cells by engaging CD3, the anti-CD3 scFv is 
incapable of cross-linking in the absence of target.  Monovalent binding by the anti-
CD3 scFv portion of IMCgp100 and the absence of Fc means that the risk of CRS upon 
first exposure to IMCgp100 is likely to be minimal.  The observation that IMCgp100 
used at concentrations above 1 nM can elicit some cytokine release in the whole blood 
assay is not unexpected.  Indeed, non-specific activity at concentrations above 1 nM 
IMCgp100 has been observed in in vitro cellular assays with control cell lines and 
primary cells that do not express gp100 (as described above).  The concentration of 
IMCgp100 beyond which a loss of specificity is observed defines the target limiting 
dose (TLD) i.e. the maximum dose of IMCgp100 to be administered to patients (Figure 
6-7).  Based on the in vitro killing and the functional cross-reactivity assay data, the 
TLD for IMCgp100 has been set at 1 nM.  As there is no pharmacokinetic data in 
humans, the Cmax of IMCgp100 in treated patients will be measured throughout the 
dose escalation and the PK modelled so that the dose of IMCgp100 will not exceed 1 
nM until more is known about its safety profile.  The primary aim of the Phase I trial is 
to establish the maximum tolerated dose of IMCgp100, therefore, dose escalation will 
continue until a maximum tolerated dose (MTD) or the TLD is reached. 
In the absence of a suitable toxicology species, it was not possible to set a 
starting dose for IMCgp100 using the conventional NOAEL method.  In light of new 
recommendations by the Expert Scientific Group on Phase One Clinical Trials 
(EMEA/CHMP/SWP/28367/2007), the MABEL was determined solely from in vitro 
cellular assays in order to set a safe starting dose for a first administration of IMCgp100 
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in humans.  This approach relies on the assumption that in vitro cellular data can predict 
what may occur in patients in the clinic.  In vitro efficacy assays were used to set the 
MABEL for IMCgp100 using a clinically representative melanoma target cell line.  The 
LDH-release killing assay was deemed to be the most sensitive assay in terms of 
cellular EC50 values compared to activation assays such as IFN-γ ELISpot.  The lowest 
concentration of IMCgp100 that caused measureable redirected lysis of the HLA-
A*0201
+
 melanoma target cell line, Mel526, was 1 pM or 76 pg/ml (Figure 6-6). 
Based on additional PK data generated in C57Black/6 mice and PK modelling 
studies, the starting dose of IMCgp100 for FIH clinical trial was proposed to be set at 5 
ng/Kg, administered as a 4 hour intravenous infusion, in order to generate a Cmax 
below the MABEL level of 1 pM.  The proposed starting dose and treatment duration 
was accepted by the regulatory authorities. 
Crucially, no adverse events were recorded for patients administered at the first 
two doses (5 ng/Kg and 15 ng/Kg) for IMCgp100.  Therefore, it can be concluded that 
for a bispecific mTCR-anti-CD3 scFv fusion protein which targets CD3, in vitro 
efficacy assay data can be used to set a safe starting dose for a FIH clinical trial.  
Furthermore, it appears that the same data sets can predict the dose at which in vivo 
biological responses may occur.  Gp100, the target antigen for IMCgp100, is a 
melanosomal antigen which is also expressed in the skin.  Notably, a generalised skin 
rash has been reported in patients treated with IMCgp100 which is probably the result 
of the drug targeting the skin.   
 
Concluding remarks 
ImmTACs represent a new class of bispecific therapeutics, for the first time enabling 
the targeting of cancer cells through pMHC, which constitutes a much larger and more 
Chapter 7 
 250 
diverse target pool than the cell surface proteins available to antibody targeting.  The 
work described in this thesis has demonstrated the in vitro potency of ImmTACs against 
tumour cells, showing that a full range of T cell responses, including cytokine release 
and cytotoxicity, can be induced by redirecting non-cancer specific T cells to cancer 
cells through ImmTAC cross-linking.  The work described has also formed the basis for 
determining a safe starting dose for a first-in-human clinical trial and has therefore 
contributed to establish a path to the clinic for further ImmTAC molecules in the future.  
Hopefully, these will become valuable tools in the fight against many forms of cancer, 
where immunotherapies appear to hold the best promise for more efficacious and safe 
treatments. 
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